CN111247138A - Ether compound and use thereof - Google Patents
Ether compound and use thereof Download PDFInfo
- Publication number
- CN111247138A CN111247138A CN201880067990.7A CN201880067990A CN111247138A CN 111247138 A CN111247138 A CN 111247138A CN 201880067990 A CN201880067990 A CN 201880067990A CN 111247138 A CN111247138 A CN 111247138A
- Authority
- CN
- China
- Prior art keywords
- unsubstituted
- compound
- substituted
- group
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 Ether compound Chemical class 0.000 title description 204
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 title description 65
- 150000001875 compounds Chemical class 0.000 claims abstract description 215
- 238000000034 method Methods 0.000 claims abstract description 66
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 44
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 38
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 34
- 102000004127 Cytokines Human genes 0.000 claims abstract description 31
- 108090000695 Cytokines Proteins 0.000 claims abstract description 31
- 201000010099 disease Diseases 0.000 claims abstract description 26
- 208000035475 disorder Diseases 0.000 claims abstract description 18
- 210000004027 cell Anatomy 0.000 claims description 145
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 81
- 150000003839 salts Chemical class 0.000 claims description 73
- 125000000623 heterocyclic group Chemical group 0.000 claims description 70
- 229910052739 hydrogen Inorganic materials 0.000 claims description 64
- 239000001257 hydrogen Substances 0.000 claims description 64
- 125000000217 alkyl group Chemical group 0.000 claims description 58
- 230000000694 effects Effects 0.000 claims description 43
- 229910052736 halogen Inorganic materials 0.000 claims description 38
- 150000002367 halogens Chemical class 0.000 claims description 38
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 37
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 36
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 33
- 229910052805 deuterium Inorganic materials 0.000 claims description 32
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 32
- 150000002431 hydrogen Chemical class 0.000 claims description 28
- 230000002401 inhibitory effect Effects 0.000 claims description 27
- 229910052731 fluorine Inorganic materials 0.000 claims description 26
- 239000011737 fluorine Substances 0.000 claims description 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 26
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 25
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 25
- 108010002350 Interleukin-2 Proteins 0.000 claims description 24
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 23
- 101000599042 Homo sapiens Zinc finger protein Aiolos Proteins 0.000 claims description 20
- 102100037798 Zinc finger protein Aiolos Human genes 0.000 claims description 20
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 20
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 20
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 19
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 19
- 108010013958 Ikaros Transcription Factor Proteins 0.000 claims description 19
- 102000017182 Ikaros Transcription Factor Human genes 0.000 claims description 19
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 19
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 18
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 18
- 229910052801 chlorine Inorganic materials 0.000 claims description 18
- 239000000460 chlorine Substances 0.000 claims description 18
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 15
- 125000002947 alkylene group Chemical group 0.000 claims description 15
- 125000002252 acyl group Chemical group 0.000 claims description 14
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 14
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 108090001005 Interleukin-6 Proteins 0.000 claims description 12
- 208000034578 Multiple myelomas Diseases 0.000 claims description 12
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 12
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 12
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 12
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 12
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 11
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- 208000011231 Crohn disease Diseases 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 7
- 206010038389 Renal cancer Diseases 0.000 claims description 7
- 201000010982 kidney cancer Diseases 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 7
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 206010014733 Endometrial cancer Diseases 0.000 claims description 6
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 6
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 6
- 208000001640 Fibromyalgia Diseases 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 206010029260 Neuroblastoma Diseases 0.000 claims description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 6
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 6
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 6
- 201000000582 Retinoblastoma Diseases 0.000 claims description 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 6
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 6
- 206010043276 Teratoma Diseases 0.000 claims description 6
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 6
- 206010057644 Testis cancer Diseases 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 201000004101 esophageal cancer Diseases 0.000 claims description 6
- 201000010536 head and neck cancer Diseases 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 206010024627 liposarcoma Diseases 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 201000008482 osteoarthritis Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 206010038038 rectal cancer Diseases 0.000 claims description 6
- 201000001275 rectum cancer Diseases 0.000 claims description 6
- 201000000849 skin cancer Diseases 0.000 claims description 6
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 6
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 6
- 201000003120 testicular cancer Diseases 0.000 claims description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
- 101000599037 Homo sapiens Zinc finger protein Helios Proteins 0.000 claims description 5
- 102100037796 Zinc finger protein Helios Human genes 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 206010018341 Gliosis Diseases 0.000 claims description 3
- 208000019693 Lung disease Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 208000037875 astrocytosis Diseases 0.000 claims description 3
- 230000007341 astrogliosis Effects 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 101710118321 Casein kinase I isoform alpha Proteins 0.000 claims 2
- 102100034356 Casein kinase I isoform alpha-like Human genes 0.000 claims 2
- 210000001130 astrocyte Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 164
- 230000004044 response Effects 0.000 abstract description 2
- 230000001404 mediated effect Effects 0.000 abstract 3
- 230000017455 cell-cell adhesion Effects 0.000 abstract 1
- 230000004853 protein function Effects 0.000 abstract 1
- 230000007111 proteostasis Effects 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 180
- 239000000243 solution Substances 0.000 description 155
- 239000007787 solid Substances 0.000 description 110
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 102
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 93
- 239000002904 solvent Substances 0.000 description 93
- 238000010898 silica gel chromatography Methods 0.000 description 59
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 52
- 235000019439 ethyl acetate Nutrition 0.000 description 51
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 50
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 48
- 239000012043 crude product Substances 0.000 description 44
- 238000000746 purification Methods 0.000 description 36
- 238000005160 1H NMR spectroscopy Methods 0.000 description 34
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 34
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 33
- 239000003208 petroleum Substances 0.000 description 31
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 30
- 239000000725 suspension Substances 0.000 description 29
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 28
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 28
- 229910052757 nitrogen Chemical group 0.000 description 27
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 26
- 125000003118 aryl group Chemical group 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 24
- 125000001072 heteroaryl group Chemical group 0.000 description 24
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 24
- 229910052760 oxygen Inorganic materials 0.000 description 24
- 239000001301 oxygen Substances 0.000 description 24
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 23
- 238000003756 stirring Methods 0.000 description 23
- 125000005842 heteroatom Chemical group 0.000 description 22
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 22
- 125000000753 cycloalkyl group Chemical group 0.000 description 21
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 21
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 21
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 21
- 102000000588 Interleukin-2 Human genes 0.000 description 20
- 125000004429 atom Chemical group 0.000 description 20
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 20
- 238000010626 work up procedure Methods 0.000 description 20
- 239000007832 Na2SO4 Substances 0.000 description 17
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 17
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 17
- 238000002953 preparative HPLC Methods 0.000 description 17
- 229910052938 sodium sulfate Inorganic materials 0.000 description 17
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 15
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 14
- 238000001704 evaporation Methods 0.000 description 14
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 14
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 14
- 229920006395 saturated elastomer Polymers 0.000 description 13
- 230000008020 evaporation Effects 0.000 description 12
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 12
- 238000012746 preparative thin layer chromatography Methods 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 11
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 11
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 11
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 150000003254 radicals Chemical class 0.000 description 11
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 9
- 125000003545 alkoxy group Chemical group 0.000 description 9
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 125000000304 alkynyl group Chemical group 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 8
- 229910052794 bromium Inorganic materials 0.000 description 8
- 125000006038 hexenyl group Chemical group 0.000 description 8
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 8
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 8
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 8
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 8
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 8
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 8
- 239000012453 solvate Substances 0.000 description 8
- 125000003003 spiro group Chemical group 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 125000002950 monocyclic group Chemical group 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 6
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 239000006196 drop Substances 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- PJSKJGYGIBLIAS-UHFFFAOYSA-N methyl 3-hydroxy-2-methylbenzoate Chemical compound COC(=O)C1=CC=CC(O)=C1C PJSKJGYGIBLIAS-UHFFFAOYSA-N 0.000 description 6
- 125000001624 naphthyl group Chemical group 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 235000019345 sodium thiosulphate Nutrition 0.000 description 6
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
- FHCLMXPLVSYZHZ-NSHDSACASA-N 4-hydroxy-2-[(3S)-2-oxoazepan-3-yl]-3H-isoindol-1-one Chemical compound OC1=C2CN(C(C2=CC=C1)=O)[C@@H]1C(NCCCC1)=O FHCLMXPLVSYZHZ-NSHDSACASA-N 0.000 description 5
- NPTGDIHRIHGDPG-UHFFFAOYSA-N BrCC1=C(C(=O)OC)C=C(C=C1O[Si](C)(C)C(C)(C)C)F Chemical compound BrCC1=C(C(=O)OC)C=C(C=C1O[Si](C)(C)C(C)(C)C)F NPTGDIHRIHGDPG-UHFFFAOYSA-N 0.000 description 5
- BOWUOGIPSRVRSJ-YFKPBYRVSA-N L-2-aminohexano-6-lactam Chemical compound N[C@H]1CCCCNC1=O BOWUOGIPSRVRSJ-YFKPBYRVSA-N 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 5
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 239000012230 colorless oil Substances 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- 125000001183 hydrocarbyl group Chemical group 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 125000006308 propyl amino group Chemical group 0.000 description 5
- 239000011734 sodium Chemical class 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 4
- XFEXKSRAWHFBGG-NSHDSACASA-N 6-fluoro-4-hydroxy-2-[(3S)-2-oxoazepan-3-yl]-3H-isoindol-1-one Chemical compound FC1=CC(=C2CN(C(C2=C1)=O)[C@@H]1C(NCCCC1)=O)O XFEXKSRAWHFBGG-NSHDSACASA-N 0.000 description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 4
- 239000005977 Ethylene Substances 0.000 description 4
- LQUKVJPOSNXBRZ-UHFFFAOYSA-N [Si](C)(C)(C(C)(C)C)OC=1C(=C(C(=O)OC)C=C(C=1)F)C Chemical compound [Si](C)(C)(C(C)(C)C)OC=1C(=C(C(=O)OC)C=C(C=1)F)C LQUKVJPOSNXBRZ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- YOPIDFXZGOIPLC-UHFFFAOYSA-N methyl 2-(bromomethyl)-3-[tert-butyl(dimethyl)silyl]oxybenzoate Chemical compound COC(=O)C1=CC=CC(O[Si](C)(C)C(C)(C)C)=C1CBr YOPIDFXZGOIPLC-UHFFFAOYSA-N 0.000 description 4
- STDLLKIYSCNAKL-UHFFFAOYSA-N methyl 3-[tert-butyl(dimethyl)silyl]oxy-2-methylbenzoate Chemical compound COC(=O)C1=CC=CC(O[Si](C)(C)C(C)(C)C)=C1C STDLLKIYSCNAKL-UHFFFAOYSA-N 0.000 description 4
- GGDSIQSMQPTJQF-UHFFFAOYSA-N methyl 5-fluoro-3-hydroxy-2-methylbenzoate Chemical compound FC=1C=C(C(=C(C(=O)OC)C=1)C)O GGDSIQSMQPTJQF-UHFFFAOYSA-N 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 4
- 230000004952 protein activity Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 4
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 3
- AETRBPKCETYASO-UHFFFAOYSA-N 2-[3-[4-[[4-[3-(tert-butylsulfamoyl)anilino]-5-methylpyrimidin-2-yl]amino]phenoxy]propylamino]acetic acid Chemical compound C(C)(C)(C)NS(=O)(=O)C=1C=C(C=CC=1)NC1=NC(=NC=C1C)NC1=CC=C(OCCCNCC(=O)O)C=C1 AETRBPKCETYASO-UHFFFAOYSA-N 0.000 description 3
- RIERSGULWXEJKL-UHFFFAOYSA-N 3-hydroxy-2-methylbenzoic acid Chemical compound CC1=C(O)C=CC=C1C(O)=O RIERSGULWXEJKL-UHFFFAOYSA-N 0.000 description 3
- XAASLEJRGFPHEV-UHFFFAOYSA-N 4-cyanobenzyl alcohol Chemical compound OCC1=CC=C(C#N)C=C1 XAASLEJRGFPHEV-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 108060000903 Beta-catenin Proteins 0.000 description 3
- 102000015735 Beta-catenin Human genes 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 3
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 3
- BWVAOONFBYYRHY-UHFFFAOYSA-N [4-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(CO)C=C1 BWVAOONFBYYRHY-UHFFFAOYSA-N 0.000 description 3
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- BBRKLPKNNGAWLA-UHFFFAOYSA-N azepane-2,3-dione Chemical class O=C1CCCCNC1=O BBRKLPKNNGAWLA-UHFFFAOYSA-N 0.000 description 3
- OSNDUYDDOHEKEE-UHFFFAOYSA-N azepane-2,7-dione Chemical compound O=C1CCCCC(=O)N1 OSNDUYDDOHEKEE-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 230000005754 cellular signaling Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 3
- FFUBXANSXRGVKW-UHFFFAOYSA-N n-tert-butylbenzenesulfonamide Chemical compound CC(C)(C)NS(=O)(=O)C1=CC=CC=C1 FFUBXANSXRGVKW-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- CCLDERBFQNOJDH-QMMMGPOBSA-N (2S)-4-amino-2-(7-hydroxy-3-oxo-1H-isoindol-2-yl)-4-oxobutanoic acid Chemical compound NC(C[C@@H](C(=O)O)N1C(C2=CC=CC(=C2C1)O)=O)=O CCLDERBFQNOJDH-QMMMGPOBSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- MVQWETIOECQWOJ-QFIPXVFZSA-N (3S)-3-[6-(aminomethyl)-7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound NCC=1C(=C2CN(C(C2=CC=1)=O)[C@@H]1C(NC(CC1)=O)=O)OCC1=CC=C(C=C1)CN1CCOCC1 MVQWETIOECQWOJ-QFIPXVFZSA-N 0.000 description 2
- ZNJQMVMWOXPAQW-KRWDZBQOSA-N (3S)-3-[7-[[4-(aminomethyl)phenyl]methoxy]-5-fluoro-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound NCC1=CC=C(COC2=C3CN(C(C3=CC(=C2)F)=O)[C@@H]2C(NC(CC2)=O)=O)C=C1 ZNJQMVMWOXPAQW-KRWDZBQOSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- PWKYXCYDYAVAMW-QFIPXVFZSA-N (4S)-5-amino-4-[6-cyano-7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1H-isoindol-2-yl]-5-oxopentanoic acid Chemical compound NC([C@H](CCC(=O)O)N1C(C2=CC=C(C(=C2C1)OCC1=CC=C(C=C1)CN1CCOCC1)C#N)=O)=O PWKYXCYDYAVAMW-QFIPXVFZSA-N 0.000 description 2
- NRXRZYABKNWDPC-KRWDZBQOSA-N (4S)-5-amino-4-[7-[(4-cyanophenyl)methoxy]-5-fluoro-3-oxo-1H-isoindol-2-yl]-5-oxopentanoic acid Chemical compound NC([C@H](CCC(=O)O)N1C(C2=CC(=CC(=C2C1)OCC1=CC=C(C=C1)C#N)F)=O)=O NRXRZYABKNWDPC-KRWDZBQOSA-N 0.000 description 2
- NCBGUSUJBVLYMX-JTQLQIEISA-N (6S)-6-(7-hydroxy-3-oxo-1H-isoindol-2-yl)-1,4-oxazepan-5-one Chemical compound OC1=C2CN(C(C2=CC=C1)=O)[C@@H]1C(NCCOC1)=O NCBGUSUJBVLYMX-JTQLQIEISA-N 0.000 description 2
- MOQATYJACDDVCV-SFHVURJKSA-N (6S)-6-[7-[[4-(hydroxymethyl)phenyl]methoxy]-3-oxo-1H-isoindol-2-yl]-1,4-oxazepan-5-one Chemical compound OCC1=CC=C(COC2=C3CN(C(C3=CC=C2)=O)[C@@H]2C(NCCOC2)=O)C=C1 MOQATYJACDDVCV-SFHVURJKSA-N 0.000 description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 2
- AEBWATHAIVJLTA-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropentalene Chemical compound C1CCC2CCCC21 AEBWATHAIVJLTA-UHFFFAOYSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 2
- WQADWIOXOXRPLN-UHFFFAOYSA-N 1,3-dithiane Chemical compound C1CSCSC1 WQADWIOXOXRPLN-UHFFFAOYSA-N 0.000 description 2
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- HMRUAWOGPPVELH-UHFFFAOYSA-N 2-(4-formylphenyl)ethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCC1=CC=C(C=O)C=C1 HMRUAWOGPPVELH-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WGVAXVOIMGJRPV-QFIPXVFZSA-N 2-[(3S)-2,6-dioxopiperidin-3-yl]-4-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-1-oxo-3H-isoindole-5-carbonitrile Chemical compound O=C1NC(CC[C@@H]1N1C(C2=CC=C(C(=C2C1)OCC1=CC=C(C=C1)CN1CCOCC1)C#N)=O)=O WGVAXVOIMGJRPV-QFIPXVFZSA-N 0.000 description 2
- UUKRSWFLAAWXGH-IBGZPJMESA-N 2-[(3S)-2,7-dioxoazepan-3-yl]-4-[(4-formylphenyl)methoxy]-1-oxo-3H-isoindole-5-carbonitrile Chemical compound O=C1NC(CCC[C@@H]1N1C(C2=CC=C(C(=C2C1)OCC1=CC=C(C=C1)C=O)C#N)=O)=O UUKRSWFLAAWXGH-IBGZPJMESA-N 0.000 description 2
- JNYDLFCWCDMSSG-UHFFFAOYSA-N 2-[4-(hydroxymethyl)phenyl]ethanol Chemical compound OCCC1=CC=C(CO)C=C1 JNYDLFCWCDMSSG-UHFFFAOYSA-N 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- VNVVFWYCFVNBMI-UHFFFAOYSA-N 4-(2-hydroxyethyl)benzaldehyde Chemical compound OCCC1=CC=C(C=O)C=C1 VNVVFWYCFVNBMI-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- HRRGDUQZMVTMLN-ZDUSSCGKSA-N 4-(hydroxymethyl)-2-[(3S)-2-oxoazepan-3-yl]-3H-isoindol-1-one Chemical compound OCC1=C2CN(C(C2=CC=C1)=O)[C@@H]1C(NCCCC1)=O HRRGDUQZMVTMLN-ZDUSSCGKSA-N 0.000 description 2
- AXOQDIMMGPFZEH-FQEVSTJZSA-N 4-[(4-formylphenyl)methoxy]-1-oxo-2-[(3S)-2-oxoazepan-3-yl]-3H-isoindole-5-carbonitrile Chemical compound C(=O)C1=CC=C(COC2=C3CN(C(C3=CC=C2C#N)=O)[C@@H]2C(NCCCC2)=O)C=C1 AXOQDIMMGPFZEH-FQEVSTJZSA-N 0.000 description 2
- URJRQWPVDYXXCK-FQEVSTJZSA-N 4-[2-[[1-oxo-2-[(3S)-2-oxoazepan-3-yl]-3H-isoindol-4-yl]oxy]ethyl]benzaldehyde Chemical compound O=C1N(CC2=C(C=CC=C12)OCCC1=CC=C(C=O)C=C1)[C@@H]1C(NCCCC1)=O URJRQWPVDYXXCK-FQEVSTJZSA-N 0.000 description 2
- IOUGNHJCTLTTHW-IBGZPJMESA-N 4-[2-[[2-[(3S)-2,7-dioxoazepan-3-yl]-1-oxo-3H-isoindol-4-yl]oxy]ethyl]benzaldehyde Chemical compound O=C1NC(CCC[C@@H]1N1C(C2=CC=CC(=C2C1)OCCC1=CC=C(C=O)C=C1)=O)=O IOUGNHJCTLTTHW-IBGZPJMESA-N 0.000 description 2
- FXDSZRXSSATGFO-FQEVSTJZSA-N 4-[[1-oxo-2-[(3S)-2-oxoazepan-3-yl]-3H-isoindol-4-yl]methoxy]benzaldehyde Chemical compound O=C1N(CC2=C(C=CC=C12)COC1=CC=C(C=O)C=C1)[C@@H]1C(NCCCC1)=O FXDSZRXSSATGFO-FQEVSTJZSA-N 0.000 description 2
- AVMCACOSVDDLMZ-UHFFFAOYSA-N 4-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3h-isoindol-4-yl]oxymethyl]benzonitrile Chemical compound O=C1N(C2C(NC(=O)CC2)=O)CC2=C1C=CC=C2OCC1=CC=C(C#N)C=C1 AVMCACOSVDDLMZ-UHFFFAOYSA-N 0.000 description 2
- HEOFGLJBCTWWBK-UHFFFAOYSA-N 4-[[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxo-3H-isoindol-4-yl]oxymethyl]benzonitrile Chemical compound O=C1NC(CCC1N1C(C2=CC(=CC(=C2C1)OCC1=CC=C(C#N)C=C1)F)=O)=O HEOFGLJBCTWWBK-UHFFFAOYSA-N 0.000 description 2
- HEOFGLJBCTWWBK-KRWDZBQOSA-N 4-[[2-[(3S)-2,6-dioxopiperidin-3-yl]-6-fluoro-1-oxo-3H-isoindol-4-yl]oxymethyl]benzonitrile Chemical compound O=C1NC(CC[C@@H]1N1C(C2=CC(=CC(=C2C1)OCC1=CC=C(C#N)C=C1)F)=O)=O HEOFGLJBCTWWBK-KRWDZBQOSA-N 0.000 description 2
- QJHRMEVTIXKQNI-IBGZPJMESA-N 4-[[2-[(3S)-2,7-dioxoazepan-3-yl]-1-oxo-3H-isoindol-4-yl]methoxy]benzaldehyde Chemical compound O=C1NC(CCC[C@@H]1N1C(C2=CC=CC(=C2C1)COC1=CC=C(C=O)C=C1)=O)=O QJHRMEVTIXKQNI-IBGZPJMESA-N 0.000 description 2
- JPTLBHGKKLRWGP-IBGZPJMESA-N 4-[[3-(hydroxymethyl)phenyl]methoxy]-2-[(3S)-2-oxoazepan-3-yl]-3H-isoindol-1-one Chemical compound OCC=1C=C(COC2=C3CN(C(C3=CC=C2)=O)[C@@H]2C(NCCCC2)=O)C=CC=1 JPTLBHGKKLRWGP-IBGZPJMESA-N 0.000 description 2
- AMUKPPJBCLULLP-QFIPXVFZSA-N 4-[[4-(diethoxymethyl)phenyl]methoxy]-6-fluoro-2-[(3S)-2-oxoazepan-3-yl]-3H-isoindol-1-one Chemical compound C(C)OC(C1=CC=C(COC2=C3CN(C(C3=CC(=C2)F)=O)[C@@H]2C(NCCCC2)=O)C=C1)OCC AMUKPPJBCLULLP-QFIPXVFZSA-N 0.000 description 2
- PXJSQBGMEZOUHB-LBPRGKRZSA-N 4-hydroxy-1-oxo-2-[(3S)-2-oxoazepan-3-yl]-3H-isoindole-5-carbonitrile Chemical compound OC1=C2CN(C(C2=CC=C1C#N)=O)[C@@H]1C(NCCCC1)=O PXJSQBGMEZOUHB-LBPRGKRZSA-N 0.000 description 2
- AEHPAXZTAFYEAM-VIFPVBQESA-N 4-hydroxy-2-[(3S)-2-oxoazepan-3-yl]isoindole-1,3-dione Chemical compound OC1=C2C(N(C(C2=CC=C1)=O)[C@@H]1C(NCCCC1)=O)=O AEHPAXZTAFYEAM-VIFPVBQESA-N 0.000 description 2
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- PWPQKMGPTYUPNZ-JTQLQIEISA-N 4-methoxy-2-[(3S)-2-oxoazepan-3-yl]isoindole-1,3-dione Chemical compound COC1=C2C(N(C(C2=CC=C1)=O)[C@@H]1C(NCCCC1)=O)=O PWPQKMGPTYUPNZ-JTQLQIEISA-N 0.000 description 2
- KRKJKLCCCGDNCY-UHFFFAOYSA-N 4-methoxy-2-benzofuran-1,3-dione Chemical compound COC1=CC=CC2=C1C(=O)OC2=O KRKJKLCCCGDNCY-UHFFFAOYSA-N 0.000 description 2
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
- IPEIYWOQIKKYAP-FQEVSTJZSA-N 5-[[4-(hydroxymethyl)phenyl]methoxy]-2-[(3S)-2-oxoazepan-3-yl]-3H-isoindol-1-one Chemical compound OCC1=CC=C(COC=2C=C3CN(C(C3=CC=2)=O)[C@@H]2C(NCCCC2)=O)C=C1 IPEIYWOQIKKYAP-FQEVSTJZSA-N 0.000 description 2
- NRXRZYABKNWDPC-UHFFFAOYSA-N 5-amino-4-[7-[(4-cyanophenyl)methoxy]-5-fluoro-3-oxo-1H-isoindol-2-yl]-5-oxopentanoic acid Chemical compound NC(C(CCC(=O)O)N1C(C2=CC(=CC(=C2C1)OCC1=CC=C(C=C1)C#N)F)=O)=O NRXRZYABKNWDPC-UHFFFAOYSA-N 0.000 description 2
- CMZCBPLTJBYJHZ-UHFFFAOYSA-N 5-fluoro-2-methyl-3-nitrobenzoic acid Chemical compound CC1=C(C(O)=O)C=C(F)C=C1[N+]([O-])=O CMZCBPLTJBYJHZ-UHFFFAOYSA-N 0.000 description 2
- OFSKSZKTIVZYOJ-LBPRGKRZSA-N 5-hydroxy-2-[(3S)-2-oxoazepan-3-yl]-3H-isoindol-1-one Chemical compound OC=1C=C2CN(C(C2=CC=1)=O)[C@@H]1C(NCCCC1)=O OFSKSZKTIVZYOJ-LBPRGKRZSA-N 0.000 description 2
- RWYDDCPKQMXIAC-ZDUSSCGKSA-N 5-methoxy-2-[(3S)-2-oxoazepan-3-yl]-3H-isoindol-1-one Chemical compound COC=1C=C2CN(C(C2=CC=1)=O)[C@@H]1C(NCCCC1)=O RWYDDCPKQMXIAC-ZDUSSCGKSA-N 0.000 description 2
- CFTZWKSEUATNTB-LBPRGKRZSA-N 6-fluoro-4-methoxy-2-[(3S)-2-oxoazepan-3-yl]-3H-isoindol-1-one Chemical compound FC1=CC(=C2CN(C(C2=C1)=O)[C@@H]1C(NCCCC1)=O)OC CFTZWKSEUATNTB-LBPRGKRZSA-N 0.000 description 2
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 102000008122 Casein Kinase I Human genes 0.000 description 2
- 108010049812 Casein Kinase I Proteins 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 102000013814 Wnt Human genes 0.000 description 2
- 108050003627 Wnt Proteins 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- JEIIGVJHNDJSPV-UHFFFAOYSA-N [4-(hydroxymethyl)phenyl]-morpholin-4-ylmethanone Chemical compound C1=CC(CO)=CC=C1C(=O)N1CCOCC1 JEIIGVJHNDJSPV-UHFFFAOYSA-N 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003140 astrocytic effect Effects 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- SHOMMGQAMRXRRK-UHFFFAOYSA-N bicyclo[3.1.1]heptane Chemical compound C1C2CC1CCC2 SHOMMGQAMRXRRK-UHFFFAOYSA-N 0.000 description 2
- RPZUBXWEQBPUJR-UHFFFAOYSA-N bicyclo[4.2.0]octane Chemical compound C1CCCC2CCC21 RPZUBXWEQBPUJR-UHFFFAOYSA-N 0.000 description 2
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000004965 chloroalkyl group Chemical group 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 2
- 150000004691 decahydrates Chemical class 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 125000003709 fluoroalkyl group Chemical group 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- 125000004969 haloethyl group Chemical group 0.000 description 2
- 125000004970 halomethyl group Chemical group 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- ZVWFTHCALCGSJC-VIFPVBQESA-N methyl (2S)-4-amino-2-(7-hydroxy-3-oxo-1H-isoindol-2-yl)-4-oxobutanoate Chemical compound NC(C[C@@H](C(=O)OC)N1C(C2=CC=CC(=C2C1)O)=O)=O ZVWFTHCALCGSJC-VIFPVBQESA-N 0.000 description 2
- OHJDCBMJCPEWQD-JTQLQIEISA-N methyl (2S)-4-amino-2-(7-methoxy-3-oxo-1H-isoindol-2-yl)-4-oxobutanoate Chemical compound NC(C[C@@H](C(=O)OC)N1C(C2=CC=CC(=C2C1)OC)=O)=O OHJDCBMJCPEWQD-JTQLQIEISA-N 0.000 description 2
- XWBUDPXCXXQEOU-VKHMYHEASA-N methyl (2s)-2,4-diamino-4-oxobutanoate Chemical compound COC(=O)[C@@H](N)CC(N)=O XWBUDPXCXXQEOU-VKHMYHEASA-N 0.000 description 2
- WBCWYEJCFYVRMG-LURJTMIESA-N methyl (2s)-4-amino-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxobutanoate Chemical compound COC(=O)[C@H](CC(N)=O)NC(=O)OC(C)(C)C WBCWYEJCFYVRMG-LURJTMIESA-N 0.000 description 2
- QIDNAKPQXIHABV-UHFFFAOYSA-N methyl 2-(bromomethyl)-3-[tert-butyl(dimethyl)silyl]oxy-4-cyanobenzoate Chemical compound BrCC1=C(C(=O)OC)C=CC(=C1O[Si](C)(C)C(C)(C)C)C#N QIDNAKPQXIHABV-UHFFFAOYSA-N 0.000 description 2
- KXENUXLNAPNGAC-UHFFFAOYSA-N methyl 2-(bromomethyl)-4-methoxybenzoate Chemical compound COC(=O)C1=CC=C(OC)C=C1CBr KXENUXLNAPNGAC-UHFFFAOYSA-N 0.000 description 2
- TXHWLJYJCICQQV-UHFFFAOYSA-N methyl 2-(bromomethyl)-5-fluoro-3-methoxybenzoate Chemical compound BrCC1=C(C(=O)OC)C=C(C=C1OC)F TXHWLJYJCICQQV-UHFFFAOYSA-N 0.000 description 2
- MURCWRKTMBFXKT-UHFFFAOYSA-N methyl 3-[tert-butyl(dimethyl)silyl]oxy-4-cyano-2-methylbenzoate Chemical compound [Si](C)(C)(C(C)(C)C)OC=1C(=C(C(=O)OC)C=CC=1C#N)C MURCWRKTMBFXKT-UHFFFAOYSA-N 0.000 description 2
- KKIKUUCOPAYYIW-UHFFFAOYSA-N methyl 3-amino-5-fluoro-2-methylbenzoate Chemical compound COC(=O)C1=CC(F)=CC(N)=C1C KKIKUUCOPAYYIW-UHFFFAOYSA-N 0.000 description 2
- FOXSTOFDDYPHTA-UHFFFAOYSA-N methyl 3-chloro-4-(dimethoxymethyl)benzoate Chemical compound ClC=1C=C(C(=O)OC)C=CC=1C(OC)OC FOXSTOFDDYPHTA-UHFFFAOYSA-N 0.000 description 2
- KJQPVKLURCKVPY-UHFFFAOYSA-N methyl 4-bromo-3-hydroxy-2-methylbenzoate Chemical compound COC(=O)C1=CC=C(Br)C(O)=C1C KJQPVKLURCKVPY-UHFFFAOYSA-N 0.000 description 2
- RIDBHWDRQHGXKN-UHFFFAOYSA-N methyl 4-cyano-3-hydroxy-2-methylbenzoate Chemical compound COC(=O)c1ccc(C#N)c(O)c1C RIDBHWDRQHGXKN-UHFFFAOYSA-N 0.000 description 2
- QOEAMLSLLJPIRF-UHFFFAOYSA-N methyl 5-fluoro-2-methyl-3-nitrobenzoate Chemical compound COC(=O)C1=CC(F)=CC([N+]([O-])=O)=C1C QOEAMLSLLJPIRF-UHFFFAOYSA-N 0.000 description 2
- UOBUPXWQYDLGGK-UHFFFAOYSA-N methyl 5-fluoro-3-methoxy-2-methylbenzoate Chemical compound FC=1C=C(C(=C(C(=O)OC)C=1)C)OC UOBUPXWQYDLGGK-UHFFFAOYSA-N 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 2
- VQSRKMNBWMHJKY-YTEVENLXSA-N n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide Chemical compound C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]23[C@@H](CN(C2)C=2N=CC(F)=CN=2)CSC(N)=N3)=C1 VQSRKMNBWMHJKY-YTEVENLXSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000028617 response to DNA damage stimulus Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- BGGAUBUWJOBQTL-LBPRGKRZSA-N tert-butyl (4S)-5-amino-4-(5-fluoro-7-hydroxy-3-oxo-1H-isoindol-2-yl)-5-oxopentanoate Chemical compound C(C[C@@H](C(=O)N)N1C(=O)C2=CC(=CC(=C2C1)O)F)C(=O)OC(C)(C)C BGGAUBUWJOBQTL-LBPRGKRZSA-N 0.000 description 2
- QOORTIXDUHEYHI-ZDUSSCGKSA-N tert-butyl (4S)-5-amino-4-(6-cyano-7-hydroxy-3-oxo-1H-isoindol-2-yl)-5-oxopentanoate Chemical compound NC([C@H](CCC(=O)OC(C)(C)C)N1C(C2=CC=C(C(=C2C1)O)C#N)=O)=O QOORTIXDUHEYHI-ZDUSSCGKSA-N 0.000 description 2
- BVNNUEQTBPSILK-VWLOTQADSA-N tert-butyl (4S)-5-amino-4-[6-cyano-7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1H-isoindol-2-yl]-5-oxopentanoate Chemical compound NC([C@H](CCC(=O)OC(C)(C)C)N1C(C2=CC=C(C(=C2C1)OCC1=CC=C(C=C1)CN1CCOCC1)C#N)=O)=O BVNNUEQTBPSILK-VWLOTQADSA-N 0.000 description 2
- SFCXBQOLCFTHRT-FQEVSTJZSA-N tert-butyl (4S)-5-amino-4-[7-[(4-cyanophenyl)methoxy]-5-fluoro-3-oxo-1H-isoindol-2-yl]-5-oxopentanoate Chemical compound NC([C@H](CCC(=O)OC(C)(C)C)N1C(C2=CC(=CC(=C2C1)OCC1=CC=C(C=C1)C#N)F)=O)=O SFCXBQOLCFTHRT-FQEVSTJZSA-N 0.000 description 2
- BRWIPGSUTYVUBF-LURJTMIESA-N tert-butyl (4s)-4,5-diamino-5-oxopentanoate Chemical compound CC(C)(C)OC(=O)CC[C@H](N)C(N)=O BRWIPGSUTYVUBF-LURJTMIESA-N 0.000 description 2
- YPAVHCJZNOTJLF-UHFFFAOYSA-N tert-butyl 4-[4-(hydroxymethyl)phenyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=CC=C(CO)C=C1 YPAVHCJZNOTJLF-UHFFFAOYSA-N 0.000 description 2
- BGGAUBUWJOBQTL-UHFFFAOYSA-N tert-butyl 5-amino-4-(5-fluoro-7-hydroxy-3-oxo-1H-isoindol-2-yl)-5-oxopentanoate Chemical compound NC(C(CCC(=O)OC(C)(C)C)N1C(C2=CC(=CC(=C2C1)O)F)=O)=O BGGAUBUWJOBQTL-UHFFFAOYSA-N 0.000 description 2
- YRMAQBVKAYGTHY-UHFFFAOYSA-N tert-butyl 5-amino-4-(7-hydroxy-3-oxo-1h-isoindol-2-yl)-5-oxopentanoate Chemical compound O=C1N(C(CCC(=O)OC(C)(C)C)C(N)=O)CC2=C1C=CC=C2O YRMAQBVKAYGTHY-UHFFFAOYSA-N 0.000 description 2
- HNTYJTSCVNWUML-UHFFFAOYSA-N tert-butyl 5-amino-4-[7-[(4-cyanophenyl)methoxy]-3-oxo-1H-isoindol-2-yl]-5-oxopentanoate Chemical compound NC(C(CCC(=O)OC(C)(C)C)N1C(C2=CC=CC(=C2C1)OCC1=CC=C(C=C1)C#N)=O)=O HNTYJTSCVNWUML-UHFFFAOYSA-N 0.000 description 2
- KUEPOWVQABAWRK-UHFFFAOYSA-N tert-butyl n-[[4-(hydroxymethyl)phenyl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(CO)C=C1 KUEPOWVQABAWRK-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000025366 tissue development Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- LGNCLGJYIFHNHO-QHCPKHFHSA-N (3S)-3-[6-(aminomethyl)-7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1H-isoindol-2-yl]azepane-2,7-dione Chemical compound NCC=1C(=C2CN(C(C2=CC=1)=O)[C@@H]1C(NC(CCC1)=O)=O)OCC1=CC=C(C=C1)CN1CCOCC1 LGNCLGJYIFHNHO-QHCPKHFHSA-N 0.000 description 1
- FVZTVKPOLCRUKM-DEOSSOPVSA-N (3S)-3-[6-[(dimethylamino)methyl]-7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN(C)CC=1C(=C2CN(C(C2=CC=1)=O)[C@@H]1C(NC(CC1)=O)=O)OCC1=CC=C(C=C1)CN1CCOCC1 FVZTVKPOLCRUKM-DEOSSOPVSA-N 0.000 description 1
- UBNCQXVIIXBOCY-SFHVURJKSA-N (3S)-3-[7-[[4-(aminomethyl)phenyl]methoxy]-3-oxo-1H-isoindol-2-yl]azepane-2,7-dione Chemical compound NCC1=CC=C(COC2=C3CN(C(C3=CC=C2)=O)[C@@H]2C(NC(CCC2)=O)=O)C=C1 UBNCQXVIIXBOCY-SFHVURJKSA-N 0.000 description 1
- LZWYEAULTHQSAP-KRWDZBQOSA-N (3S)-3-[7-[[4-(aminomethyl)phenyl]methoxy]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound NCC1=CC=C(COC2=C3CN(C(C3=CC=C2)=O)[C@@H]2C(NC(CC2)=O)=O)C=C1 LZWYEAULTHQSAP-KRWDZBQOSA-N 0.000 description 1
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
- MHSGOABISYIYKP-UHFFFAOYSA-N (4-nitrophenyl)methyl carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(COC(Cl)=O)C=C1 MHSGOABISYIYKP-UHFFFAOYSA-N 0.000 description 1
- WRUMOCUMNFEQKU-BYPYZUCNSA-N (6s)-6-amino-1,4-oxazepan-5-one Chemical compound N[C@H]1COCCNC1=O WRUMOCUMNFEQKU-BYPYZUCNSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- LKLLNYWECKEQIB-UHFFFAOYSA-N 1,3,5-triazinane Chemical compound C1NCNCN1 LKLLNYWECKEQIB-UHFFFAOYSA-N 0.000 description 1
- BGJSXRVXTHVRSN-UHFFFAOYSA-N 1,3,5-trioxane Chemical compound C1OCOCO1 BGJSXRVXTHVRSN-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- IVJFXSLMUSQZMC-UHFFFAOYSA-N 1,3-dithiole Chemical compound C1SC=CS1 IVJFXSLMUSQZMC-UHFFFAOYSA-N 0.000 description 1
- QVFHFKPGBODJJB-UHFFFAOYSA-N 1,3-oxathiane Chemical compound C1COCSC1 QVFHFKPGBODJJB-UHFFFAOYSA-N 0.000 description 1
- WJJSZTJGFCFNKI-UHFFFAOYSA-N 1,3-oxathiolane Chemical compound C1CSCO1 WJJSZTJGFCFNKI-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- JBYHSSAVUBIJMK-UHFFFAOYSA-N 1,4-oxathiane Chemical compound C1CSCCO1 JBYHSSAVUBIJMK-UHFFFAOYSA-N 0.000 description 1
- CUCJJMLDIUSNPU-UHFFFAOYSA-N 1-oxidopiperidin-1-ium Chemical compound [O-][NH+]1CCCCC1 CUCJJMLDIUSNPU-UHFFFAOYSA-N 0.000 description 1
- IKKSXFMQJAZGPN-ZDUSSCGKSA-N 1-oxo-2-[(3S)-2-oxoazepan-3-yl]-3H-isoindole-4-carbaldehyde Chemical compound O=C1N(CC=2C(=CC=CC1=2)C=O)[C@@H]1C(NCCCC1)=O IKKSXFMQJAZGPN-ZDUSSCGKSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical compound O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- SYZRZLUNWVNNNV-UHFFFAOYSA-N 2-bromoacetyl chloride Chemical compound ClC(=O)CBr SYZRZLUNWVNNNV-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- PCOFIIVWHXIDGT-UHFFFAOYSA-N 3-(hydroxymethyl)benzonitrile Chemical compound OCC1=CC=CC(C#N)=C1 PCOFIIVWHXIDGT-UHFFFAOYSA-N 0.000 description 1
- LZWYEAULTHQSAP-UHFFFAOYSA-N 3-[7-[[4-(aminomethyl)phenyl]methoxy]-3-oxo-1h-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1=CC(CN)=CC=C1COC1=CC=CC2=C1CN(C1C(NC(=O)CC1)=O)C2=O LZWYEAULTHQSAP-UHFFFAOYSA-N 0.000 description 1
- UCPKYTFFKYWRSU-IBGZPJMESA-N 3-[[1-oxo-2-[(3S)-2-oxoazepan-3-yl]-3H-isoindol-4-yl]oxymethyl]benzonitrile Chemical compound O=C1N(CC2=C(C=CC=C12)OCC=1C=C(C#N)C=CC=1)[C@@H]1C(NCCCC1)=O UCPKYTFFKYWRSU-IBGZPJMESA-N 0.000 description 1
- COCVQOWUPZJHME-SFHVURJKSA-N 3-[[2-[(3S)-2,7-dioxoazepan-3-yl]-1-oxo-3H-isoindol-4-yl]oxymethyl]benzaldehyde Chemical compound O=C1NC(CCC[C@@H]1N1C(C2=CC=CC(=C2C1)OCC=1C=C(C=O)C=CC=1)=O)=O COCVQOWUPZJHME-SFHVURJKSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- DULQZGQVLHMCAU-UHFFFAOYSA-N 3-methoxyphthalic acid Chemical compound COC1=CC=CC(C(O)=O)=C1C(O)=O DULQZGQVLHMCAU-UHFFFAOYSA-N 0.000 description 1
- YGHRJJRRZDOVPD-UHFFFAOYSA-N 3-methylbutanal Chemical compound CC(C)CC=O YGHRJJRRZDOVPD-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 1
- XYPVBKDHERGKJG-UHFFFAOYSA-N 4-(bromomethyl)benzaldehyde Chemical compound BrCC1=CC=C(C=O)C=C1 XYPVBKDHERGKJG-UHFFFAOYSA-N 0.000 description 1
- HTMXMFARWHNJDW-UHFFFAOYSA-N 4-(diethoxymethyl)benzaldehyde Chemical compound CCOC(OCC)C1=CC=C(C=O)C=C1 HTMXMFARWHNJDW-UHFFFAOYSA-N 0.000 description 1
- WWYFPDXEIFBNKE-UHFFFAOYSA-N 4-(hydroxymethyl)benzoic acid Chemical compound OCC1=CC=C(C(O)=O)C=C1 WWYFPDXEIFBNKE-UHFFFAOYSA-N 0.000 description 1
- LFNYASDMXSFJGC-KRWDZBQOSA-N 4-[[2-[(6S)-3,5-dioxo-1,4-oxazepan-6-yl]-1-oxo-3H-isoindol-4-yl]oxymethyl]benzaldehyde Chemical compound O=C1COC[C@@H](C(N1)=O)N1C(C2=CC=CC(=C2C1)OCC1=CC=C(C=O)C=C1)=O LFNYASDMXSFJGC-KRWDZBQOSA-N 0.000 description 1
- SALWNDMWKRWGTJ-UHFFFAOYSA-N 4-[[4-(chloromethyl)phenyl]methyl]morpholine Chemical compound C1=CC(CCl)=CC=C1CN1CCOCC1 SALWNDMWKRWGTJ-UHFFFAOYSA-N 0.000 description 1
- GDJQVPXQJVPHEB-KRWDZBQOSA-N 4-[[4-(hydroxymethyl)phenyl]methoxy]-2-[(3S)-2-oxoazepan-3-yl]isoindole-1,3-dione Chemical compound OCC1=CC=C(COC2=C3C(N(C(C3=CC=C2)=O)[C@@H]2C(NCCCC2)=O)=O)C=C1 GDJQVPXQJVPHEB-KRWDZBQOSA-N 0.000 description 1
- SJWJBCXAGZRZIF-QFIPXVFZSA-N 4-[[4-(morpholine-4-carbonyl)phenyl]methoxy]-2-[(3S)-2-oxoazepan-3-yl]-3H-isoindol-1-one Chemical compound N1(CCOCC1)C(=O)C1=CC=C(COC2=C3CN(C(C3=CC=C2)=O)[C@@H]2C(NCCCC2)=O)C=C1 SJWJBCXAGZRZIF-QFIPXVFZSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- MRUWJENAYHTDQG-UHFFFAOYSA-N 4H-pyran Chemical compound C1C=COC=C1 MRUWJENAYHTDQG-UHFFFAOYSA-N 0.000 description 1
- UCZQXJKDCHCTAI-UHFFFAOYSA-N 4h-1,3-dioxine Chemical compound C1OCC=CO1 UCZQXJKDCHCTAI-UHFFFAOYSA-N 0.000 description 1
- JVBLXLBINTYFPR-UHFFFAOYSA-N 5-fluoro-2-methylbenzoic acid Chemical compound CC1=CC=C(F)C=C1C(O)=O JVBLXLBINTYFPR-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 241000070928 Calligonum comosum Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100037799 DNA-binding protein Ikaros Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 101100391182 Dictyostelium discoideum forI gene Proteins 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 240000001414 Eucalyptus viminalis Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- 101150016712 IKZF1 gene Proteins 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010068964 Intracellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 102000001702 Intracellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 102100025169 Max-binding protein MNT Human genes 0.000 description 1
- FYYSQDHBALBGHX-YFKPBYRVSA-N N(alpha)-t-butoxycarbonyl-L-asparagine Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC(N)=O FYYSQDHBALBGHX-YFKPBYRVSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910003827 NRaRb Inorganic materials 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- OLRITJBPADTUBV-QHCPKHFHSA-N O=C(CCC[C@@H]1N(CC2=CC(F)=C3)CC2=C3OCC2=CC=C(CN3CCOCC3)C=C2)NC1=O Chemical class O=C(CCC[C@@H]1N(CC2=CC(F)=C3)CC2=C3OCC2=CC=C(CN3CCOCC3)C=C2)NC1=O OLRITJBPADTUBV-QHCPKHFHSA-N 0.000 description 1
- FNBVIXDWNBIYOT-DEOSSOPVSA-N O=C(CCC[C@@H]1N2CC3=C(COC4=CC=C(CN5CCOCC5)C=C4)C=CC=C3C2)NC1=O Chemical class O=C(CCC[C@@H]1N2CC3=C(COC4=CC=C(CN5CCOCC5)C=C4)C=CC=C3C2)NC1=O FNBVIXDWNBIYOT-DEOSSOPVSA-N 0.000 description 1
- SSBFDSBCDKOGRR-DEOSSOPVSA-N O=C(CCC[C@@H]1N2CC3=CC(OCC4=CC=C(CN5CCOCC5)C=C4)=CC=C3C2)NC1=O Chemical class O=C(CCC[C@@H]1N2CC3=CC(OCC4=CC=C(CN5CCOCC5)C=C4)=CC=C3C2)NC1=O SSBFDSBCDKOGRR-DEOSSOPVSA-N 0.000 description 1
- ZKMBMLATNMHIGP-NRFANRHFSA-N O=C(C[C@@H]1N(CC2=CC=C3)CC2=C3OCC2=CC=C(CN3CCOCC3)C=C2)NC1=O Chemical class O=C(C[C@@H]1N(CC2=CC=C3)CC2=C3OCC2=CC=C(CN3CCOCC3)C=C2)NC1=O ZKMBMLATNMHIGP-NRFANRHFSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 241000720974 Protium Species 0.000 description 1
- 208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 230000004156 Wnt signaling pathway Effects 0.000 description 1
- 108091007916 Zinc finger transcription factors Proteins 0.000 description 1
- 102000038627 Zinc finger transcription factors Human genes 0.000 description 1
- YWMLORGQOFONNT-UHFFFAOYSA-N [3-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=CC(CO)=C1 YWMLORGQOFONNT-UHFFFAOYSA-N 0.000 description 1
- XZIZDWTYODDCCA-UHFFFAOYSA-N [3-chloro-4-(dimethoxymethyl)phenyl]methanol Chemical compound ClC=1C=C(C=CC=1C(OC)OC)CO XZIZDWTYODDCCA-UHFFFAOYSA-N 0.000 description 1
- NJIFFRZXYZKPFQ-UHFFFAOYSA-N [4-(diethoxymethyl)phenyl]methanol Chemical compound CCOC(OCC)C1=CC=C(CO)C=C1 NJIFFRZXYZKPFQ-UHFFFAOYSA-N 0.000 description 1
- MWVQMAWLNHACQK-UHFFFAOYSA-N [4-(morpholin-4-ylmethyl)phenyl]methanol Chemical compound C1=CC(CO)=CC=C1CN1CCOCC1 MWVQMAWLNHACQK-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000002015 acyclic group Chemical class 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 101150043733 artA gene Proteins 0.000 description 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 102000055104 bcl-X Human genes 0.000 description 1
- 108700000711 bcl-X Proteins 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- MYONAGGJKCJOBT-UHFFFAOYSA-N benzimidazol-2-one Chemical compound C1=CC=CC2=NC(=O)N=C21 MYONAGGJKCJOBT-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical class C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000006009 dihaloalkoxy group Chemical group 0.000 description 1
- 125000004982 dihaloalkyl group Chemical group 0.000 description 1
- SNQXJPARXFUULZ-UHFFFAOYSA-N dioxolane Chemical compound C1COOC1 SNQXJPARXFUULZ-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000006232 ethoxy propyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- RLRKXGVCRIQSPQ-UHFFFAOYSA-N ethyl 4-[4-[(2-methylpropan-2-yl)oxycarbonyl]cyclohex-3-en-1-yl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C1CC=C(C(=O)OC(C)(C)C)CC1 RLRKXGVCRIQSPQ-UHFFFAOYSA-N 0.000 description 1
- YCBJOQUNPLTBGG-UHFFFAOYSA-N ethyl 4-iodobenzoate Chemical compound CCOC(=O)C1=CC=C(I)C=C1 YCBJOQUNPLTBGG-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000009033 hematopoietic malignancy Effects 0.000 description 1
- AHAREKHAZNPPMI-UHFFFAOYSA-N hexa-1,3-diene Chemical compound CCC=CC=C AHAREKHAZNPPMI-UHFFFAOYSA-N 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 1
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000002794 lymphocyte assay Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- TUDYPXFSYJRWDP-UHFFFAOYSA-N methoxy methyl carbonate Chemical compound COOC(=O)OC TUDYPXFSYJRWDP-UHFFFAOYSA-N 0.000 description 1
- NSPJNIDYTSSIIY-UHFFFAOYSA-N methoxy(methoxymethoxy)methane Chemical compound COCOCOC NSPJNIDYTSSIIY-UHFFFAOYSA-N 0.000 description 1
- AXBWWEUTDIIYRV-NRFANRHFSA-N methyl (2S)-4-amino-2-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1H-isoindol-2-yl]-4-oxobutanoate Chemical compound COC([C@H](CC(=O)N)N1C(C2=CC=CC(=C2C1)OCC1=CC=C(C=C1)CN1CCOCC1)=O)=O AXBWWEUTDIIYRV-NRFANRHFSA-N 0.000 description 1
- HYLGKOGJOVGRNN-UHFFFAOYSA-N methyl 2-(bromomethyl)-3-methoxybenzoate Chemical compound COC(=O)C1=CC=CC(OC)=C1CBr HYLGKOGJOVGRNN-UHFFFAOYSA-N 0.000 description 1
- HTBWDEJOUJMERN-UHFFFAOYSA-N methyl 3-chloro-4-formylbenzoate Chemical compound COC(=O)C1=CC=C(C=O)C(Cl)=C1 HTBWDEJOUJMERN-UHFFFAOYSA-N 0.000 description 1
- QAQYBHOZQQRJBA-UHFFFAOYSA-N methyl 4-(2-methoxy-2-oxoethyl)benzoate Chemical compound COC(=O)CC1=CC=C(C(=O)OC)C=C1 QAQYBHOZQQRJBA-UHFFFAOYSA-N 0.000 description 1
- OGYAVWKYDVBIMW-UHFFFAOYSA-N methyl 4-methoxy-2-methylbenzoate Chemical compound COC(=O)C1=CC=C(OC)C=C1C OGYAVWKYDVBIMW-UHFFFAOYSA-N 0.000 description 1
- FINKSGWSBJRISB-UHFFFAOYSA-N methyl 4-methoxy-2-methylbenzoate Natural products COC(=O)C1=CC=C(O)C=C1C FINKSGWSBJRISB-UHFFFAOYSA-N 0.000 description 1
- 150000005217 methyl ethers Chemical class 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 125000006393 methylpyrimidinyl group Chemical group 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 229940118537 p53 inhibitor Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- JTHRRMFZHSDGNJ-UHFFFAOYSA-N piperazine-2,3-dione Chemical compound O=C1NCCNC1=O JTHRRMFZHSDGNJ-UHFFFAOYSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical compound [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 description 1
- 229940076372 protein antagonist Drugs 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- QFYXSLAAXZTRLG-UHFFFAOYSA-N pyrrolidine-2,3-dione Chemical compound O=C1CCNC1=O QFYXSLAAXZTRLG-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- VVOPSEUXHSUTJS-UHFFFAOYSA-N tert-butyl 2,5-diamino-5-oxopentanoate Chemical compound CC(C)(C)OC(=O)C(N)CCC(N)=O VVOPSEUXHSUTJS-UHFFFAOYSA-N 0.000 description 1
- BRWIPGSUTYVUBF-UHFFFAOYSA-N tert-butyl 4,5-diamino-5-oxopentanoate Chemical compound CC(C)(C)OC(=O)CCC(N)C(N)=O BRWIPGSUTYVUBF-UHFFFAOYSA-N 0.000 description 1
- VVDCRJGWILREQH-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(B2OC(C)(C)C(C)(C)O2)=C1 VVDCRJGWILREQH-UHFFFAOYSA-N 0.000 description 1
- SFCXBQOLCFTHRT-UHFFFAOYSA-N tert-butyl 5-amino-4-[7-[(4-cyanophenyl)methoxy]-5-fluoro-3-oxo-1H-isoindol-2-yl]-5-oxopentanoate Chemical compound NC(C(CCC(=O)OC(C)(C)C)N1C(C2=CC(=CC(=C2C1)OCC1=CC=C(C=C1)C#N)F)=O)=O SFCXBQOLCFTHRT-UHFFFAOYSA-N 0.000 description 1
- FWOBBEOKTITUHK-UHFFFAOYSA-N tert-butyl n-benzylcarbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=CC=C1 FWOBBEOKTITUHK-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000005039 triarylmethyl group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000004952 trihaloalkoxy group Chemical group 0.000 description 1
- 125000004385 trihaloalkyl group Chemical group 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention provides compounds that modulate protein function to restore protein homeostasis and/or cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions of these compounds are also provided. Methods of treating, ameliorating, or preventing protein-mediated diseases, disorders, and conditions are also provided.
Description
Incorporation by reference of any priority application
Any and all applications for which a foreign or domestic priority claim is identified in a request, such as that filed with the present patent application, are hereby incorporated by reference, including U.S. provisional patent application No. 62/550489 filed on 25/8/2017.
Background
FIELD
Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent, or diagnose diseases, disorders, or conditions associated with protein dysfunction are provided.
Description of the Related Art
For example, there is a need to dynamically regulate key intracellular signaling proteins within the immune system to maintain the proper balance of proinflammatory mediators or cytokines and anti-inflammatory mediators or cytokines some cytokines promote inflammation (pro-inflammatory cytokines) while other cytokines inhibit the activity of proinflammatory cytokines (anti-inflammatory cytokines), for example, IL-4, IL-10, and IL-13 are potent activators of B lymphocytes and also act as anti-inflammatory agents.
Unregulated activity of these mediators can lead to the development of severe inflammatory states. For example, autoimmune diseases arise when cells of the immune system (lymphocytes, macrophages) become sensitized to "self". Lymphocytes and macrophages are usually under control in this system. However, misdirection of the system to the body's own tissue may occur in response to a trigger that is still unexplained. One hypothesis is that lymphocytes recognize antigens that mimic "self and cascade activation of different components of the immune system occurs, ultimately leading to tissue destruction. It has also been hypothesized that genetic susceptibility contributes to autoimmune disorders.
Overproduction of these cytokines is thought to underlie the progression of a number of inflammatory diseases, including Rheumatoid Arthritis (RA), Crohn's disease, inflammatory bowel disease, multiple sclerosis, endotoxic shock, osteoporosis, Alzheimer's disease, congestive heart failure and psoriasis.
Recent data from clinical trials support the use of protein antagonists of cytokines, such as soluble TNF α receptor fusion protein (etanercept) or monoclonal TNF α antibody (infliximab) to treat rheumatoid arthritis, crohn's disease, juvenile chronic arthritis, and psoriatic arthritis, thus, reduction of pro-inflammatory cytokines such as TNF α, IL-6, and IL-I has become an acceptable treatment for potential drug intervention in these conditions.
In addition, IL-2 is now FDA approved for the treatment of renal cancer and melanoma patients, where long-lasting, complete remission up to 148 months was achieved with IL-2. However, the half-life of IL-2 in serum is short, requiring injection of large amounts of IL-2 to achieve therapeutic levels. Many attempts have been made to minimize the side effects of systemic IL-2 treatment, such as the introduction of IL-2 directly into tumors, but this complicates treatment and is largely unsuccessful.
For a variety of reasons, local delivery of cytokines is attractive as compared to systemic delivery. It exploits the natural biology of cytokines that have been evolved to act locally in a paracrine or autocrine fashion. Local expression also significantly minimizes many of the side effects of systemic delivery of cytokines. Thus, compounds and methods that increase local expression of IL-2 are better tolerated compared to high dose IL-2 treatment, which would expand the therapeutic utility of strategies to increase IL-2.
Other targets include several candidate genes involved in apoptosis and cell survival, including casein kinase 1 α (CK1 α) and zinc finger transcription factors aiolos, helios and ikaros, alolos and ikaros being transcription factors whose expression is restricted to lymphoid lineage.
Likewise, the expression of aiolos in lung and breast cancer is predictive of a significant reduction in patient survival. aiolos reduces expression of a number of adhesion-related genes, disrupts cell-cell and cell-matrix interactions, promotes metastasis. In certain metastatic epithelial cancers, aiolos may also function as an epigenetic driver of lymphocyte mimics. Similarly, aberrant ikaros and helios expression may promote Bcl-XL expression and promote the development of hematopoietic malignancies. Thus, down-regulation of aiolos, ikaros and/or helios may reduce or eliminate metastasis.
Indeed, CK1 α also phosphorylates p53, which inhibits binding to MDM2 (a p53 inhibitor) and stabilizes the binding interaction of p53 with transcriptional mechanisms Huart, et al, j.biol.chem.2009,284, 32384-32394.
One mechanism for disrupting protein drivers of disease is to reduce the cellular concentration of these proteins. For example, regulated proteolytic degradation of cellular proteins is critical for normal cellular function. Hijacking (HIJACK) this process provides a new mechanism for treating diseases by targeting specific disease-associated proteins. The irreversibility of proteolysis makes it very suitable as a regulatory switch for controlling unidirectional processes. IKAROS, for example, is a transcriptional repressor of IL-2 expression. Accordingly, a decrease in IKAROS protein levels results in increased IL-2 expression in activated T cells. IL-2 therapy is currently being evaluated for various clinical indications, including for the treatment of Systemic Lupus Erythematosus (SLE), wound healing, and immunooncology.
Summary of The Invention
Some embodiments provide a compound of general formula (I), or a pharmaceutically acceptable salt thereof:
in some embodiments, Q1Can be CH2、O、NR2S or a bond.
In some embodiments, Q2Can be CH2Or a key.
In some embodiments, X may be CH2Or C ═ O.
In some embodiments, X1May be hydrogen, deuterium, methyl or fluorine.
In some embodiments, ring B may beWherein Y is1Is N or CR3A,Y2Is N or CR3B,Y3Is N or CR3C,Y4Is N or CR3DAnd Y5Is N or CR3E。
In some embodiments, each R is1May independently be deuterium, hydroxy, halogen, nitro, substituted or unsubstituted amino, substituted or unsubstituted C1-C6Alkoxy, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C2-C6Alkenyl, substituted or unsubstituted C3-C8Cycloalkyl, substituted or unsubstituted 3 to 10 membered heterocyclyl, substituted or unsubstituted C6-C10Aryl, substituted or unsubstituted 5 to 10 membered heteroaryl or L-Y.
In some embodiments, R2Can be hydrogen, deuterium, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C2-C6Alkenyl, acyl or- (SO)2)-C1-C6An alkyl group.
In some embodiments, R3A、R3B、R3C、R3DAnd R3EEach of which may be independently hydrogen, deuterium, hydroxy, halogen, nitro, substituted or unsubstituted amino, substituted or unsubstituted C1-C6Alkoxy, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C2-C6Alkenyl, substituted or unsubstituted C3-C8Cycloalkyl, substituted or unsubstituted 3 to 10 membered heterocyclyl, substituted or unsubstituted alkoxyalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted heteroaralkyl or L-Y.
In some embodiments, m may be 0, 1,2, or 3.
In some embodiments, n may be 1,2,3, or 4. In some embodiments, n may be 1 or 2.
In some embodiments, L may be-Z1-(R4)t-Z2–;–Z1-(R4-O-R4)t-Z2–;–Z1(R4-NH-R4)t-Z2–;–Z1-(R4-(NHCO)-R4)t-Z2–;–Z1-(R4-(NHC(O)NH)-R4)t-Z2-; or-Z1-(R4-(CONH)-R4)t-Z2–。
In some embodiments, Z1Can be-CH2NH(CO)–;–NH–;–O–;–CH2–;–NH(CO)–;–(CO)NH–;–CH2NH–;–(CO)NHCH2–;–CH2CH2NH–;–NHCH2-; or-NHCH2CH2–。
In some embodiments, Z2May be-NH-; -O-; -CH2–;–NH(CO)–;–(CO)NH–;–CH2NH–;–NHCH2–;–(CO)NHCH2–;–CH2CH2NH–;–CH2NH(CO)–。
In some embodiments, each R is4C which may independently be unsubstituted1-C6An alkylene group.
In some embodiments, t may be 1,2,3, 4,5, or 6.
In some embodiments, Y is1、Y2、Y3、Y4And Y5At least one of which may be carbon (respectively with R)3A、R3B、R3C、R3DAnd R3EA bond, e.g. CR3A、CR3B、CR3C、CR3DAnd/or CR3E)。
In some embodiments, when Q1Can be CH2Or when a bond is present, then R3A、R3B、R3C、R3DAnd R3EOne or more of which cannot be hydrogen. In other embodiments, when R1When L-Y can be mentioned, R3A、R3B、R3C、R3DAnd R3EMay not be L-Y. In still other embodiments, when Q1When the number is a bond, m is not 0. In some embodiments, when Q1When is a bond, R1Is L-Y. In some embodiments, when Q1Can be a bond, X1Is hydrogen or methyl, and Q2Is CH2When the current is over; then m is not 0. In other embodiments, when Q1Can be a bond, X1May be hydrogen or methyl, and Q2Can be CH2When the current is over; then R is1、R3A、R3B、R3C、R3DAnd R3EOne of them is L-Y. In some embodiments, when Q2When can be a bond, Q1Can be a bond or CH2。
Some embodiments provide compounds of general formula (I):
or a pharmaceutically acceptable salt thereof, wherein: q1Is CH2、O、NR2S or a bond; q2Is CH2Or a bond; x is CH2Or C ═ O; x1Is hydrogen, deuterium or fluorine; ring B isWherein Y is1Is N or CR3A;Y2Is N or CR3B;Y3Is N or CR3C;Y4Is N or CR3D;Y5Is N or CR3E(ii) a Each R1Independently is deuterium, hydroxy, halogen, nitro, substituted or unsubstituted amino, substituted or unsubstituted C1To C6Haloalkyl, substituted or unsubstituted C1-C6Alkoxy, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C2-C6Alkenyl, substituted or unsubstituted C3-C8Cycloalkyl, substituted or unsubstituted 3 to 10 membered heterocyclyl, substituted or unsubstituted C6-C10Aryl, substituted or unsubstituted 5 to 10 membered heteroaryl or L-Y; r2Is hydrogen, deuterium, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C2-C6Alkenyl, acyl or- (SO)2)-C1-C6An alkyl group; each R3A、R3B、R3C、R3DAnd R3EIndependently hydrogen, deuterium, hydroxyl, halogen, nitro, substituted or unsubstituted amino, substituted or unsubstituted C1To C6Haloalkyl, substituted or unsubstituted C1-C6Alkoxy, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C2-C6Alkenyl, substituted or unsubstituted C3-C8Cycloalkyl, substituted or unsubstituted 3 to 10 membered heterocyclyl, substituted or unsubstituted alkoxyalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted heteroaralkyl or L-Y; m is 0, 1,2 or 3; n is 1,2 or 3; l is-Z1-(R4-O-R4)t-Z2–;–Z1(R4-NH-R4)t-Z2–;–Z1-(R4-(NHCO)-R4)t-Z2–;–Z1-(R4-(NHC(O)NH)-R4)t-Z2-; or-Z1-(R4-(CONH)-R4)t-Z2–;Z1is-NH-; -O-; -CH2–;–NH(CO)–;–(CO)NH–;–CH2NH–;–NHCH2–;–CH2NH (CO) -or-NHCH2CH2–;Z2is-NH-; -O-; -CH2-; -nh (co) -; or- (CO) NH-; -CH2NH–;–NHCH2-; or-NHCH2CH2-; each R4Independently is unsubstituted C1-C6An alkylene group; t is 1,2,3, 4,5 or 6; and Y isWherein Y is derivatized to link to L; and wherein Y is1、Y2、Y3、Y4And Y5At least one of which is R respectively3A、R3B、R3C、R3DOr R3E(ii) a When Q is1Is CH2Or when a bond is present, then R3A、R3B、R3C、R3DOr R3EIs not hydrogen; when R is1When L-Y is present, R3A、R3B、R3C、R3DAnd R3EEach of which is not L-Y; and when Q1When the number is a bond, m is not 0.
In some embodiments, X may be CH2. In some embodiments, X may be C ═ O.
In some embodiments, X1May be hydrogen. In other embodiments, X1May be deuterium. In still other embodiments, X1May be a methyl group. In some embodiments, X1May be fluorine.
In some embodiments, Q1May be NR2. In some embodiments, R2May be hydrogen. In some embodiments, R2C which may be substituted or unsubstituted1-C6An alkyl group. In some embodiments, R2May be unsubstituted C1-C6An alkyl group. In some embodiments, R2May be an acyl group. In some embodiments, R2Can be- (SO)2)-C1-C6An alkyl group. In some embodiments, R2May be a methyl group.
In some casesIn the embodiment, Q1Can be CH2. In some embodiments, Q1May be O. In some embodiments, Q1May be S. In some embodiments, Q1May be a key. In some embodiments, when Q1When the number is a bond, m is not 0. In some embodiments, Q2Can be CH2. In some embodiments, Q2May be a key. In some embodiments, when Q2When can be a bond, Q1Can be a bond or CH2。
In some embodiments, n may be 1. In some embodiments, n may be 2. In some embodiments, n may be 3. In some embodiments, m may be 1. In some embodiments, m may be 2. In some embodiments, m may be 3. In some embodiments, m may be 0.
In some embodiments, each R is1May be independently halogen, substituted or unsubstituted amino, substituted or unsubstituted C1-C6Alkoxy or substituted or unsubstituted C1-C6An alkyl group. In some embodiments, each R is1May independently be halogen, unsubstituted amino, unsubstituted C1-C6Haloalkyl, unsubstituted C1-C6Alkoxy or unsubstituted C1-C6An alkyl group.
In some embodiments, each R is1Can independently be fluorine, chlorine, -NH2、–NH(CH3)、–N(CH3)2、–CF3、–OCH3、–OCH2CH3、–OCH(CH3)2、–CH3、–CH2CH3or-CH (CH)3)2。
In some embodiments, ring B may be selected from:
in some embodiments,R3A、R3B、R3C、R3DAnd R3EEach of which may be independently hydrogen, deuterium, hydroxy, halogen, nitro, substituted or unsubstituted amino, substituted or unsubstituted C1-C6Alkoxy, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C2-C6Alkenyl, substituted or unsubstituted C3-C8A cycloalkyl group, a substituted or unsubstituted 3 to 10 membered heterocyclyl group, a substituted or unsubstituted alkoxyalkyl group, a substituted or unsubstituted cycloalkylalkyl group, a substituted or unsubstituted heterocyclylalkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted heteroaralkyl group.
In some embodiments, R3A、R3B、R3C、R3DAnd R3EEach of which may be independently hydrogen, hydroxy, halogen, nitro, unsubstituted amino, unsubstituted C1-C6Haloalkyl, unsubstituted C1-C6Alkoxy, unsubstituted C1-C6Alkyl, substituted or unsubstituted C3-C8A cycloalkyl group, a substituted or unsubstituted 3 to 10 membered heterocyclyl group, a substituted or unsubstituted alkoxyalkyl group, a substituted or unsubstituted cycloalkylalkyl group, a substituted or unsubstituted heterocyclylalkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted heteroaralkyl group.
In some embodiments, R3A、R3B、R3C、R3DAnd R3EEach of which may be independently hydrogen, hydroxy, halogen, nitro, unsubstituted amino, unsubstituted C1-C6Haloalkyl, unsubstituted C1-C6Alkoxy, unsubstituted C1-C6Alkyl, unsubstituted C3-C8Cycloalkyl, unsubstituted 3 to 10 membered heterocyclyl, unsubstituted cycloalkylalkyl, unsubstituted 3 to 10 membered heterocyclylalkyl, unsubstituted aralkyl, or unsubstituted 5 to 10 membered heteroaralkyl.
In some embodiments, R3A、R3B、R3C、R3DAnd R3EEach of which may be independently hydrogen, halogen, unsubstituted C1-C6Haloalkyl, unsubstituted C1-C6Alkoxy, unsubstituted C1-C6An alkyl group, an unsubstituted 3 to 10 membered heterocyclyl group or an unsubstituted 3 to 10 membered heterocyclylalkyl group.
In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne of which may be halogen, unsubstituted C1-C6Haloalkyl, unsubstituted C1-C6Alkoxy, unsubstituted C1-C6An alkyl group, an unsubstituted 3-to 10-membered heterocyclyl group or an unsubstituted 3-to 10-membered heterocyclylalkyl group, and R3A、R3B、R3C、R3DAnd R3EThe others in (a) are hydrogen.
In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne of them may be fluorine, chlorine, -CF3、-OCH3Unsubstituted C1-C6An alkyl group, an unsubstituted 3-to 10-membered heterocyclyl group or an unsubstituted 3-to 10-membered heterocyclylalkyl group, and R3A、R3B、R3C、R3DAnd R3EThe others in (a) are hydrogen.
In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne of which may be
In some embodiments, one R is1May be L-Y. In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne of which may be L-Y. In some embodiments, Y is3May be C-L-Y.
In some embodiments, L may be-Z1-(R4)t-Z2-. In other embodiments, L may be-Z1-(R4-O-R4)t-Z2-. In still other embodiments, L may be-Z1(R4-NH-R4)t-Z2-. In some embodiments, L may be Z1-(R4-(NHCO)-R4)t-Z2-. In some embodiments, L may be-Z1-(R4-(CONH)-R4)t-Z2-. In other embodiments, L may be-Z1-(R4-(NHC(O)NH)-R4)t-Z2–。
In some embodiments, Z1Can be-CH2NH (CO) -. In other embodiments, Z1May be-NH-. In still other embodiments, Z1May be-O-. In some embodiments, Z1Can be-CH2-. In other embodiments, Z1May be-NH (CO) -. In still other embodiments, Z1Can be-CH2NH-. In some embodiments, Z1Can be-NHCH2-. In other embodiments, Z1May be- (CO) NH-. In still other embodiments, Z1Can be-NHCH2CH2-. In some embodiments, Z1Can be- (CO) NHCH2-. In still other embodiments, Z1Can be-CH2CH2NH–。
In some embodiments, Z2May be-NH-. In other embodiments, Z2May be-O-. In still other embodiments, Z2Can be-CH2-. In some embodiments, Z2May be-NH (CO) -. In other embodiments, Z2Can be made into-(CO) NH-. In still other embodiments, Z2Can be-CH2NH-. In some embodiments, Z2Can be-NHCH2-. In other embodiments, Z2May be- (CO) NH-. In still other embodiments, Z2Can be-NHCH2CH2-. In some embodiments, Z2Can be- (CO) NHCH2-. In other embodiments, Z2Can be-CH2CH2NH-. In still other embodiments, Z2Can be-CH2NH(CO)–。
In some embodiments, each R is4C which may independently be unsubstituted1-C4An alkylene group. In some embodiments, each R is4C which may independently be unsubstituted1-C2An alkylene group.
In some embodiments, t may be 1. In some embodiments, t may be 2. In some embodiments, t may be 3. In some embodiments, t may be 4. In some embodiments, t may be 5. In some embodiments, t may be 6.
Some embodiments provide a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
Some embodiments provide a method of inhibiting cytokine activity comprising contacting a cell with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, other embodiments provide a use of a compound of formula (I) or a pharmaceutically acceptable salt of any of the foregoing for inhibiting cytokine activity, comprising contacting a cell with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt of any of the foregoing, yet other embodiments provide a use of a compound of formula (I) or a pharmaceutically acceptable salt of any of the foregoing for the manufacture of a medicament for inhibiting cytokine activity, comprising contacting a cell with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt of any of the foregoing.
Some embodiments provide methods of inhibiting aiolos activity comprising contacting a cell with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. Other embodiments provide the use of a compound of formula (I) or a pharmaceutically acceptable salt of any of the foregoing for inhibiting aiolos activity, comprising contacting a cell with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt of any of the foregoing. Yet other embodiments provide the use of a compound of formula (I) or a pharmaceutically acceptable salt of any of the foregoing for the preparation of a medicament for inhibiting aiolos activity, comprising contacting a cell with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, the cell is a cancer cell.
Some embodiments provide a method of inhibiting ikaros activity comprising contacting a cell with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. Other embodiments provide the use of a compound of formula (I) or a pharmaceutically acceptable salt of any of the foregoing for inhibiting ikaros activity, comprising contacting a cell with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt of any of the foregoing. Yet other embodiments provide the use of a compound of formula (I) or a pharmaceutically acceptable salt of any of the foregoing for the preparation of a medicament for inhibiting ikaros activity comprising contacting a cell with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, the cell is a cancer cell.
Some embodiments provide methods of inhibiting hellios activity comprising contacting a cell with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. Other embodiments provide the use of a compound of formula (I) or a pharmaceutically acceptable salt of any of the foregoing for inhibiting hellios activity, comprising contacting a cell with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt of any of the foregoing. Yet other embodiments provide the use of a compound of formula (I) or a pharmaceutically acceptable salt of any of the foregoing for the preparation of a medicament for inhibiting activity of hellios, comprising contacting a cell with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, the cell is a cancer cell.
Some embodiments provide a method of inhibiting CK-1 α activity comprising contacting a cell with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, other embodiments provide the use of a compound of formula (I) or a pharmaceutically acceptable salt of any of the foregoing for inhibiting CK-1 α activity comprising contacting a cell with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt of any of the foregoing, yet other embodiments provide the use of a compound of formula (I) or a pharmaceutically acceptable salt of any of the foregoing for the manufacture of a medicament for inhibiting CK-1 α activity comprising contacting a cell with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt of any of the foregoing.
In some embodiments, the cell is a small cell lung cancer cell, a non-small cell lung cancer cell, a breast cancer cell, a prostate cancer cell, a head and neck cancer cell, a pancreatic cancer cell, a colon cancer cell, a rectal cancer cell, a teratoma cell, an ovarian cancer cell, an endometrial cancer cell, a brain cancer cell, a retinoblastoma cell, a leukemia cell, a skin cancer cell, a melanoma cell, a squamous cell carcinoma cell, an liposarcoma cell, a lymphoma cell, a multiple myeloma cell, a testicular cancer cell, a liver cancer cell, an esophageal cancer cell, a kidney cancer cell, an astrocytic proliferating cell, a relapsed/refractory multiple myeloma cell, or a neuroblastoma cell.
Some embodiments provide a method of treating, ameliorating, or preventing a disease, disorder, or condition associated with a protein selected from the group consisting of cytokines, aiolos, ikaros, helioss, CK1 α, and a combination of any of the foregoing, in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof.
In some embodiments, the disease, disorder, or condition is a cancer selected from a hematologic malignancy and a solid tumor. In some embodiments, the disease, disorder, or condition is a cancer selected from small cell lung cancer, non-small cell lung cancer, breast cancer, prostate cancer, head and neck cancer, pancreatic cancer, colon cancer, rectal cancer, teratoma, ovarian cancer, endometrial cancer, brain cancer, retinoblastoma, leukemia, skin cancer, melanoma, squamous cell carcinoma, liposarcoma, lymphoma, multiple myeloma, testicular cancer, liver cancer, esophageal cancer, renal cancer, astrocytosis, relapsed/refractory multiple myeloma, and neuroblastoma.
In some embodiments, the disease, disorder, or condition is selected from inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, uveitis, inflammatory lung disease, chronic obstructive pulmonary disease, and alzheimer's disease. In some embodiments, the disease, disorder, or condition is selected from fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, crohn's disease, and ulcerative colitis.
In some embodiments, the cytokine is selected from the group consisting of IL-1 β, IL-2, IL-6, and TNF α in some embodiments, the cytokine is TNF α in some embodiments, the protein is aiolos.
Any feature of an embodiment is applicable to all embodiments identified herein. Furthermore, any feature of an embodiment, independently, may be combined in any manner, either in whole or in part, with other embodiments described herein, e.g., one, two, or three or more embodiments may be combined in whole or in part. In addition, any feature of one embodiment may be made optional with respect to other embodiments. Any embodiment of a method may comprise another embodiment of the compound, and any embodiment of the compound may be configured to perform the method of another embodiment.
Brief Description of Drawings
FIG. 1 shows anti-IL-1- β activity in Peripheral Blood Mononuclear Cells (PBMC) seeded in 96-well plates and pre-treated with compound for 1 hour, followed by induction with 100ng/mL LPS for 18 to 24 hours.
FIG. 2 shows anti-IL-6 activity in Peripheral Blood Mononuclear Cells (PBMC) seeded in 96-well plates and pre-treated with compound for 1 hour, followed by induction with 100ng/mL LPS for 18 to 24 hours. Cytokines were measured according to the MesoScale protocol. Negative control wells were treated with DMSO. Compound activity was measured as a percentage of LPS-induced activity.
FIG. 3 shows anti-TNF α activity in Peripheral Blood Mononuclear Cells (PBMC) seeded in 96-well plates and pre-treated with compound for 1 hour, followed by induction with 100ng/mL LPS for 18 to 24 hours cytokine in the medium was measured according to the MesoScale protocol.
FIG. 4 shows anti-CD 3-induced IL-2 secretion in PBMCs. A PBS solution of 1. mu.g/mL anti-CD 3(OKT-3) antibody was plated onto 96-well plates and left overnight at 4 ℃. Approximately 550,000PBMC were added to each well followed by DMSO (control) or compound 1 alone. The induction was measured after 24 hours as fold difference from DMSO stimulated control.
FIG. 5A shows a Western blot of Jurkat cells treated with control (DMSO only) or compound 1 at the indicated concentrations Western blot was performed using RIPA buffer (Pierce) to lyse the cells and using anti-casein kinase 1 α (CK1- α) and anti- β actin antibodies FIG. 5B shows a Western blot of Jurkat cells treated with control (DMSO only) or compound 1,2,3 or 4 at the indicated concentrations Western blot was performed using RIPA buffer (Pierce) to lyse the cells and performing Western blot using anti-ikaros and anti- β -actin antibodies.
Detailed Description
Some embodiments provide a compound of general formula (I) or a pharmaceutically acceptable salt thereof:
in some embodiments, Q1Can be CH2、O、NR2S or a bond. In some embodiments, when Q1When the number is a bond, m is not 0. In some embodiments, Q2Can be CH2Or a key. In some embodiments, when Q2When can be a bond, Q1Can be a bond or CH2。
In some embodiments, X may be CH2Or C ═ O. In some embodiments, X may be CH2. In some embodiments, X may be C ═ O.
In some embodiments, X1May be hydrogen, deuterium, methyl or fluorine. In some embodiments, X1May be hydrogen. In other embodiments, X1May be fluorine. In still other embodiments, X1May be a methyl group. In some embodiments, X1May be deuterium.
In some embodiments, ring B may beWherein Y is1Is N or CR3A;Y2Is N or CR3B;Y3Is N or CR3C;Y4Is N or CR3D;Y5Is N or CR3E. In some embodiments, ring B may be selected from:
in some embodiments, ring B is a phenyl group. In other embodiments, ring B is a pyridyl group, such as a 2-pyridyl, 3-pyridyl, or 4-pyridyl group.
In some embodiments, m may be 0, 1,2, or 3. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3.
In some embodiments, each R is1May independently be deuterium, hydroxy, halogen, nitro, substituted or unsubstituted amino, substituted or unsubstituted C1-C6Alkoxy, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C2-C6Alkenyl, substituted or unsubstituted C3-C8Cycloalkyl, substituted or unsubstituted 3 to 10 membered heterocyclyl, substituted or unsubstituted C6-C10Aryl, substituted or unsubstituted 5 to 10 membered heteroaryl or L-Y. In some embodiments, R1May be deuterium. In some embodiments, R1May be a hydroxyl group. In some embodiments, R1May be halogen, such as fluorine, chlorine or bromine. In some embodiments, R1May be a nitro group. In some embodiments, R1Amino groups which may be substituted, e.g. (C)1-C6Alkyl) amino, (3-to 10-membered heterocyclyl) amino or (C)6-C10Aryl) amino. In some embodiments, R1May be an unsubstituted amino group. In some embodiments, R1May be substituted C1-C6Alkyl which is unsubstituted C1-C6Haloalkyl, for example halomethyl, haloethyl, halo-n-propyl, haloisopropyl, halo-n-butyl, haloisobutyl, halo-sec-butyl, halo-tert-butyl, halopentyl (linear or branched) or halohexyl (linear or branched). In some embodiments, R1May be unsubstituted C1-C6A fluoroalkyl group. In some embodiments, R1May be unsubstituted C1-C6A chloroalkyl group. In some embodiments, R1May be unsubstituted C1-C6Haloalkyl groups including fluorine and chlorine. In some embodiments, R1C which may be substituted or unsubstituted1-C6Alkoxy, for example methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy (linear or branched) or hexoxy (linear or branched). In some embodiments, R1May be unsubstituted C1-C6Alkoxy, for example methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy (linear or branched) or hexoxy (linear or branched). In some embodiments, R1C which may be substituted or unsubstituted1-C6Alkyl radicals, e.g. methyl, ethyl, n-propyl, isopropyl,N-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (linear or branched) or hexyl (linear or branched). In some embodiments, R1May be unsubstituted C1-C6Alkyl, for example methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (linear or branched) or hexyl (linear or branched). In some embodiments, R1C which may be substituted or unsubstituted2-C6Alkenyl groups, such as methylene, vinyl, n-propenyl, isopropenyl, n-butenyl, isobutenyl, sec-butenyl, tert-butenyl, pentenyl (linear or branched) or hexenyl (linear or branched). In some embodiments, R1May be unsubstituted C2-C6Alkenyl groups, such as methylene, vinyl, n-propenyl, isopropenyl, n-butenyl, isobutenyl, sec-butenyl, tert-butenyl, pentenyl (linear or branched) or hexenyl (linear or branched). In some embodiments, R1C which may be substituted or unsubstituted3-C8Cycloalkyl radicals, e.g. C3-C8Monocyclic cycloalkyl or C6-C8Bridged, fused or spiro bicyclic cycloalkyl. In some embodiments, R1May be unsubstituted C3-C8C8Cycloalkyl radicals, e.g. C3-C8Monocyclic cycloalkyl or C6-C8Bridged, fused or spiro bicyclocycloalkyl, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, octahydropentalene, decahydronaphthalene, bicyclo [4.2.0]Octane and bicyclo [3.1.1]Heptane. In some embodiments, R1May be a substituted or unsubstituted 3 to 10 membered heterocyclic group, such as a 3 to 8 membered monocyclic heterocyclic group, a 6 to 8 membered bridged, fused or spiro bicyclic heterocyclic group, or a 3 to 8 membered nitrogen containing heterocyclic group. In some embodiments, R1May be an unsubstituted 3-to 10-membered heterocyclic group, such as a 3-to 8-membered monocyclic heterocyclic group, a 6-to 8-membered bridged, fused or spiro bicyclic heterocyclic group, or a 3-to 8-membered nitrogen-containing heterocyclic group. In some embodiments, R1Can be used forIs substituted or unsubstituted C6-C10Aryl, such as phenyl or naphthyl. In some embodiments, R1May be unsubstituted C6-C10Aryl, such as phenyl or naphthyl. In some embodiments, R1May be a substituted or unsubstituted 5 to 10 membered heteroaryl group, for example a 5 membered heteroaryl group, a 6 membered heteroaryl group, a 10 membered heteroaryl group or a 5 to 10 membered heteroaryl group having one or two nitrogen atoms. In some embodiments, R1May be an unsubstituted 5 to 10 membered heteroaryl group, such as a 5 membered heteroaryl group, a 6 membered heteroaryl group, a 10 membered heteroaryl group or a 5 to 10 membered heteroaryl group having one or two nitrogen atoms. In some embodiments, R1May be L-Y, for example:
where ". x" denotes the point of attachment of the L-Y moiety to the rest of the molecule. In some embodiments, when R1When L-Y can be mentioned, R3A、R3B、R3C、R3DAnd R3EMay not be L-Y.
In some embodiments, R2Can be hydrogen, deuterium, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C2-C6Alkenyl, acyl or- (SO)2)-C1-C6An alkyl group. In some embodiments, R2May be hydrogen. In some embodiments, R2May be deuterium. In some embodiments, R2C which may be substituted or unsubstituted1-C6For example methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (linear or branched) or hexyl (linearOr branched). In some embodiments, R2May be unsubstituted C1-C6For example methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (linear or branched) or hexyl (linear or branched). In some embodiments, R2C which may be substituted or unsubstituted2-C6Alkenyl groups, such as methylene, vinyl, n-propenyl, isopropenyl, n-butenyl, isobutenyl, sec-butenyl, tert-butenyl, pentenyl (linear or branched) or hexenyl (linear or branched). In some embodiments, R2May be unsubstituted C2-C6Alkenyl groups, such as methylene, vinyl, n-propenyl, isopropenyl, n-butenyl, isobutenyl, sec-butenyl, tert-butenyl, pentenyl (linear or branched) or hexenyl (linear or branched). In some embodiments, R2May be acyl, e.g. C1-C6Alkylcarbonyl such as acetyl (ethan-1-one), propan-1-one or 3-methylbutan-1-one. In some embodiments, R2Can be- (SO)2)-C1-C6Alkyl radicals, e.g., - (SO)2) -methyl, - (SO)2) -ethyl, - (SO)2) -n-propyl, - (SO)2) -isopropyl, - (SO)2) -n-butyl, - (SO)2) -isobutyl, - (SO)2) -sec-butyl, - (SO)2) -tert-butyl, - (SO)2) -pentyl (linear or branched) or- (SO)2) -hexyl (linear or branched).
In some embodiments, n may be 1,2, or 3. In some embodiments, n may be 1 or 2. In some embodiments, n may be 1. In some embodiments, n may be 2.
In some embodiments, R3A、R3B、R3C、R3DAnd R3EEach of which may be independently hydrogen, deuterium, hydroxy, halogen, nitro, substituted or unsubstituted amino, substituted or unsubstituted C1-C6Alkoxy, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C2-C6Alkenyl, substituted or unsubstituted C3-C8Cycloalkyl, substituted or unsubstituted 3 to 10 membered heterocyclyl, substituted or unsubstituted alkoxyalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted heteroaralkyl or L-Y. In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne or more of which may be hydrogen. In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne or more of which may be deuterium. In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne or more of which may be hydroxyl. In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne or more of which may be halogen, for example fluorine, chlorine or bromine. In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne or more of which may be nitro. In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne or more of which may be substituted amino, e.g. (C)1-C6Alkyl) amino, (3-to 10-membered heterocyclyl) amino or (C)6-C10Aryl) amino. In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne or more of which may be unsubstituted amino. In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne or more of which may be substituted C1-C6Alkyl which is unsubstituted C1-C6Haloalkyl, for example halomethyl, haloethyl, halo-n-propyl, haloisopropyl, halo-n-butyl, haloisobutyl, halo-sec-butyl, halo-tert-butyl, halopentyl (linear or branched) or halohexyl (linear or branched). In some casesIn embodiments, R3A、R3B、R3C、R3DAnd R3EMay be unsubstituted C1-C6A fluoroalkyl group. In some embodiments, R3A、R3B、R3C、R3DAnd R3EMay be unsubstituted C1-C6A chloroalkyl group. In some embodiments, R3A、R3B、R3C、R3DAnd R3EMay be unsubstituted C1-C6Haloalkyl groups including fluorine and chlorine. In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne or more of which may be substituted or unsubstituted C1-C6Alkoxy, for example methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy (linear or branched) or hexoxy (linear or branched). In some embodiments, R3A、R3B、R3C、R3DAnd R3EMay be unsubstituted C1-C6Alkoxy, for example methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy (linear or branched) or hexoxy (linear or branched). In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne or more of which may be substituted or unsubstituted C1-C6Alkyl, for example methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (linear or branched) or hexyl (linear or branched). In some embodiments, R3A、R3B、R3C、R3DAnd R3EMay be unsubstituted C1-C6Alkyl, for example methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (linear or branched) or hexyl (linear or branched). In some casesIn embodiments, R3A、R3B、R3C、R3DAnd R3EOne or more of which may be substituted or unsubstituted C2-C6Alkenyl groups, such as methylene, vinyl, n-propenyl, isopropenyl, n-butenyl, isobutenyl, sec-butenyl, tert-butenyl, pentenyl (linear or branched) or hexenyl (linear or branched). In some embodiments, R3A、R3B、R3C、R3DAnd R3EMay be unsubstituted C2-C6Alkenyl groups, such as methylene, vinyl, n-propenyl, isopropenyl, n-butenyl, isobutenyl, sec-butenyl, tert-butenyl, pentenyl (linear or branched) or hexenyl (linear or branched). In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne or more of which may be substituted or unsubstituted C3-C8Cycloalkyl radicals, e.g. C3-C8Monocyclic cycloalkyl or C6-C8Bridged, fused or spiro bicyclic cycloalkyl. In some embodiments, R3A、R3B、R3C、R3DAnd R3EMay be unsubstituted C3-C8Cycloalkyl radicals, e.g. C3-C8Monocyclic cycloalkyl or C6-C8Bridged, fused or spiro bicyclocycloalkyl, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, octahydropentalene, decahydronaphthalene, bicyclo [4.2.0]Octane and bicyclo [3.1.1]Heptane. In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne or more of which may be a substituted or unsubstituted 3-to 10-membered heterocyclic group, such as a 3-to 8-membered monocyclic heterocyclic group, a 6-to 8-membered bridged, fused or spiro bicyclic heterocyclic group, or a 3-to 8-membered nitrogen-containing heterocyclic group. In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne or more of which may be unsubstituted 3 to 10 membered heterocyclyl, e.g. 3 to 8 membered monocyclic heterocyclyl,A 6-to 8-membered bridged, fused or spiro bicyclic heterocyclic group or a 3-to 8-membered nitrogen-containing heterocyclic group. In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne or more of which may be substituted or unsubstituted alkoxyalkyl, e.g. C as described herein1-C4Alkoxy and C as described herein1-C4An alkyl group. In some embodiments, R3A、R3B、R3C、R3DAnd R3EMay be unsubstituted alkoxyalkyl, e.g. C as described herein1-C4Alkoxy and C as described herein1-C4Alkyl groups such as methoxymethyl, ethoxymethyl or ethoxypropyl. In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne or more of which may be substituted or unsubstituted cycloalkylalkyl, e.g. C3-C8Monocyclic cycloalkyl or C6-C8Bridged, fused or spiro bicyclic cycloalkyl and C1-C6Alkyl, as described herein. In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne or more of which may be unsubstituted cycloalkylalkyl, e.g. C3-C8Monocyclic cycloalkyl or C6-C8Bridged, fused or spiro bicyclic cycloalkyl and C1-C6An alkyl group, as described herein, such as cyclopropylmethyl, cyclobutylmethyl, cyclopentylethyl, or cyclohexylethyl. In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne or more of which may be a substituted or unsubstituted heterocyclylalkyl group, e.g., a 3-to 8-membered monocyclic heterocyclyl group, a 6-to 8-membered bridged, fused, or spiro bicyclic heterocyclyl group, or a 3-to 8-membered nitrogen-containing heterocyclyl group and C1-C6Alkyl, as described herein. In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne or more of which may be unsubstituted heterocyclylalkyl, e.g. 3 to 8 memberedMonocyclic heterocyclic group, 6-to 8-membered bridged, fused or spiro bicyclic heterocyclic group, or 3-to 8-membered nitrogen-containing heterocyclic group and C1-C6Alkyl, as described herein, for example pyrrolidinylmethyl, piperidinyl methyl, piperazinyl methyl, or morpholinylmethyl. In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne or more of which may be substituted or unsubstituted aralkyl, e.g. C6-C10Aryl (e.g. phenyl or naphthyl) and C1-C6Alkyl, as described herein. In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne or more of which may be unsubstituted aralkyl, e.g. C6-C10Aryl (e.g. phenyl or naphthyl) and C1-C6Alkyl, as described herein, for example benzyl or phenethyl. In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne or more of which may be substituted or unsubstituted heteroaralkyl, e.g., 5-membered heteroaryl, 6-membered heteroaryl, 10-membered heteroaryl, or 5-to 10-membered heteroaryl having one or two nitrogen atoms and C1-C6Alkyl, as described herein. In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne or more of which may be unsubstituted heteroaralkyl, e.g., 5-membered heteroaryl, 6-membered heteroaryl, 10-membered heteroaryl, or 5-to 10-membered heteroaryl having one or two nitrogen atoms and C1-C6Alkyl, as described herein, for example pyridylmethyl, pyrimidinylmethyl, or imidazolylmethyl. In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne of these may be L-Y, for example:
In some embodiments, when R3A、R3B、R3C、R3DAnd R3EWhen any one of them may be L-Y, R1And cannot be L-Y. In some embodiments, R3AAnd cannot be hydrogen. In some embodiments, R3BAnd cannot be hydrogen. In some embodiments, R3CAnd cannot be hydrogen. In some embodiments, R3DAnd cannot be hydrogen. In some embodiments, R3EAnd cannot be hydrogen.
In some embodiments, L may be-Z1-(R4)t-Z2–;–Z1-(R4-O-R4)t-Z2–;–Z1(R4-NH-R4)t-Z2–;–Z1-(R4-(NHCO)-R4)t-Z2-; or-Z1-(R4-(CONH)-R4)t-Z2-. In some embodiments, L may be-Z1-(R4-O-R4)t-Z2-. In other embodiments, L may be-Z1(R4-NH-R4)t-Z2-. In still other embodiments, L may be-Z1-(R4-(NHCO)-R4)t-Z2-. In some embodiments, L may be Z1-(R4-(CONH)-R4)t-Z2-. In other embodiments, L may be-Z1-(R4)t-Z2-. In still other embodiments, L may be-Z1-(R4-(NHC(O)NH)-R4)t-Z2–。
In some embodiments, each R is4C which may independently be unsubstituted1-C6Alkylene, for example methylene, ethylene, n-propylene, isopropylene, n-butylene, isobutylene, sec-butylene, tert-butylene, pentylene (linear or branched) or hexylene (linear or branched). In some embodiments, each R is4The groups are the same. In some embodiments, each R is4The groups are different.
In some embodiments, t may be 1,2,3, 4,5, or 6. In some embodiments, t may be 1. In some embodiments, t may be 2. In some embodiments, t may be 3. In some embodiments, t may be 4. In some embodiments, t may be 5. In some embodiments, t may be 6.
Some embodiments of L are shown in table a below.
TABLE A
In some embodiments of table a, each R is4May independently be C1-C4Alkylene, for example methylene, ethylene, n-propylene, isopropylene, n-butylene, isobutylene or sec-butylene. In some embodiments of table a, each R is4Is methylene. In some embodiments of table a, each R is4Is an ethylene group. In some embodiments of table a, each R is4Is n-propylene. In some embodiments of table a, each R is4Is n-butylene. In some embodiments of table a, each R is4May be the same. In some embodiments of table a, each R is4May be different. For example, one R4May be methylene and the other R4May be an ethylene group; a R4May be methylene and the other R4May be n-propylene; a R4May be methylene and the other R4May be n-butylene; a R4May be ethylene and the other R4May be n-propylene; or a R4May be ethylene and the other R4May be n-butylene.
In some embodiments, Y may beWherein Y may be derivatized to link to L. As used herein, the phrase "Y derivatized to link to L" is used with ordinary skill in the artAs understood by the person using it. For example, when Y is derivatized to be attached to L, Y may be: wherein denotes the point of attachment to the L group.
In some embodiments, Y is1、Y2、Y3、Y4And Y5Is carbon (e.g. CR)3A、CR3B、CR3C、CR3DAnd/or CR3E). In some embodiments, Y is1、Y2、Y3、Y4And Y5Is carbon. In some embodiments, Y is1、Y2、Y3、Y4And Y5Two of which are carbon. In some embodiments, Y is1、Y2、Y3、Y4And Y5Three of which are carbon. In some embodiments, Y is1、Y2、Y3、Y4And Y5Four of which are carbon. In some embodiments, Y is1、Y2、Y3、Y4And Y5All five of which are carbon.
In some embodiments, when Q1Is CH2When then R is3A、R3B、R3C、R3DAnd R3EOne or more of which cannot be hydrogen. In some embodiments, when Q1When it is a bond, then R3A、R3B、R3C、R3DAnd R3EOne or more of which cannot be hydrogen. In some embodiments, when R1When L-Y is present, R3A、R3B、R3C、R3DAnd R3ENone of which is L-Y. In some embodiments, when Q1Is a bond, X1Is hydrogen or methyl and Q2Is CH2When the current is over; then R is1、R3A、R3B、R3C、R3DAnd R3EOne of them is L-Y. In some embodiments, when Q2When can be a bond, Q1Can be a bond or CH2。
In some embodiments, each R is1May independently be halogen (e.g. fluorine, chlorine or bromine), substituted or unsubstituted amino (e.g. -NH)2Dimethylamino, diethylamino, isopropylethylamino, phenylamino, or benzylamino), unsubstituted C1-C6Haloalkyl (e.g., -CF)3、-CHF2、-CH2F、-CH2CF3or-CH2CH2CF3) Substituted or unsubstituted C1-C6An alkoxy group (e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy (linear or branched), or hexyloxy (linear or branched)) or a substituted or unsubstituted C1-C6Alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (linear or branched), or hexyl (linear or branched)). In some embodiments, each R is1May independently be halogen (e.g. fluorine, chlorine or bromine), unsubstituted amino, unsubstituted C1-C6Haloalkyl, unsubstituted C1-C6Alkoxy (e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy (linear or branched), or hexoxy (linear or branched)) or unsubstituted C1-C6Alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (linear or branched), or hexyl (linear or branched)).
In some embodiments, each R is1Can independently be fluorine, chlorine, -NH2、-NH(CH3)、-N(CH3)2、-CF3、-OCH3、-OCH2CH3、-OCH(CH3)2、-CH3、-CH2CH3or-CH (CH)3)2。
In some embodiments, ring B may be selected from:
in some embodiments, R3A、R3B、R3C、R3DAnd R3EEach of which may be independently hydrogen, deuterium, hydroxy, halogen (e.g., fluorine, chlorine or bromine), nitro, substituted or unsubstituted amino (e.g., -NH2Dimethylamino, diethylamino, isopropylethylamino, phenylamino, or benzylamino), substituted or unsubstituted C1-C6An alkoxy group (e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy (linear or branched), or hexyloxy (linear or branched)) or a substituted or unsubstituted C1-C6Alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (linear or branched) or hexyl (linear or branched)), substituted or unsubstituted C2-C6Alkenyl (e.g., ethenyl, n-propenyl, isopropenyl, n-butenyl, isobutenyl, secondary butenyl, tertiary butenyl, pentenyl (linear or branched) or hexenyl (linear or branched)), substituted or unsubstituted C3-C8Cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl), substituted or unsubstituted 3-to 10-membered heterocyclyl (e.g., 3-to 8-membered monocyclic heterocyclyl containing one or two heteroatoms selected from oxygen and nitrogen, or 6-to 8-membered bicyclic heterocyclyl containing one or two heteroatoms selected from oxygen and nitrogen), substituted or unsubstituted alkoxyalkyl (e.g., methoxymethyl, ethoxyethyl, or methoxy-t-heterocyclyl)Butyl), substituted or unsubstituted cycloalkylalkyl (e.g., C)3-C8Cycloalkyl radicals, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, via C1-C3An alkyl group (e.g., methyl, ethyl, n-propyl, or isopropyl) attached to the remainder of the compound), a substituted or unsubstituted heterocyclylalkyl group (e.g., a 3-to 8-membered monocyclic heterocyclyl containing one or two heteroatoms selected from oxygen and nitrogen, via C)1-C3Alkyl groups (e.g. methyl, ethyl, n-propyl or isopropyl) attached to the remainder of the compound), substituted or unsubstituted aralkyl groups (e.g. phenyl or naphthyl, which are linked via C1-C3Alkyl groups (e.g. methyl, ethyl, n-propyl or isopropyl) attached to the remainder of the compound) or substituted or unsubstituted heteroaralkyl groups, e.g. five-, six-or ten-membered heteroaryl groups containing one oxygen, one nitrogen, one oxygen and one nitrogen, two nitrogens or three nitrogens, which is via C1-C3An alkyl group (e.g., methyl, ethyl, n-propyl, or isopropyl) is attached to the remainder of the compound).
In some embodiments, R3A、R3B、R3C、R3DAnd R3EEach of which may independently be hydrogen, deuterium, hydroxy, halogen (e.g., fluoro, chloro or bromo), nitro, substituted or unsubstituted amino (e.g., -NH)2Dimethylamino, diethylamino, isopropylethylamino, phenylamino, or benzylamino), unsubstituted C1-C6Haloalkyl (e.g., -CF)3、–CHF2、–CH2F、–CH2CF3or-CH2CH2CF3) Unsubstituted C1-C6Alkoxy (e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy (linear or branched) or hexoxy (linear or branched)) or unsubstituted C1-C6Alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (straight chain)Or branched) or hexyl (linear or branched)), unsubstituted C2-C6Alkenyl (e.g. ethenyl, n-propenyl, isopropenyl, n-butenyl, isobutenyl, sec-butenyl, tert-butenyl, pentenyl (linear or branched) or hexenyl (linear or branched)), unsubstituted C3-C8Cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl), unsubstituted 3 to 10 membered heterocyclyl (e.g., 3 to 8 membered monocyclic heterocyclyl containing one or two heteroatoms selected from oxygen and nitrogen, or 6 to 8 membered bicyclic heterocyclyl containing one or two heteroatoms selected from oxygen and nitrogen), unsubstituted alkoxyalkyl (e.g., methoxymethyl, ethoxyethyl, or methoxy-tert-butyl), unsubstituted cycloalkylalkyl (e.g., C)3-C8Cycloalkyl radicals, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, via C1-C3An alkyl group (e.g., methyl, ethyl, n-propyl, or isopropyl) attached to the remainder of the compound), an unsubstituted heterocyclylalkyl group (e.g., a 3-to 8-membered monocyclic heterocyclyl containing one or two heteroatoms selected from oxygen and nitrogen, via C)1-C3Alkyl groups (e.g. methyl, ethyl, n-propyl or isopropyl) attached to the remainder of the compound), unsubstituted aralkyl groups (e.g. phenyl or naphthyl, via C)1-C3An alkyl group (e.g., methyl, ethyl, n-propyl, or isopropyl) attached to the remainder of the compound) or unsubstituted heteroaralkyl (e.g., a five-, six-, or ten-membered heteroaryl group containing one oxygen, one nitrogen, one oxygen, and one nitrogen, two nitrogens, or three nitrogens, which is linked via C)1-C3An alkyl group (e.g., methyl, ethyl, n-propyl, or isopropyl) is attached to the remainder of the compound).
In some embodiments, R3A、R3B、R3C、R3DAnd R3EEach of which may independently be hydrogen, halogen (e.g. fluorine, chlorine or bromine), unsubstituted C1-C6Haloalkyl (e.g., -CF)3、–CHF2、–CH2F、–CH2CF3or-CH2CH2CF3) Unsubstituted C1-C6Alkoxy (e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy (linear or branched) or hexoxy (linear or branched)), unsubstituted C1-C6Alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (linear or branched), or hexyl (linear or branched)), an unsubstituted 3 to 10-membered heterocyclyl group (e.g., a 3 to 8-membered monocyclic heterocyclyl group containing one or two heteroatoms selected from oxygen and nitrogen, or a 6 to 8-membered bicyclic heterocyclyl group containing one or two heteroatoms selected from oxygen and nitrogen) or an unsubstituted 3 to 10-membered heterocyclylalkyl group (e.g., a 3 to 8-membered monocyclic heterocyclyl group containing one or two heteroatoms selected from oxygen and nitrogen, or a 6 to 8-membered bicyclic heterocyclyl group containing one or two heteroatoms selected from oxygen and nitrogen, which is linked to the remainder of the compound by a methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (linear or branched), or hexyl (linear or branched) group).
In some embodiments, R3A、R3B、R3C、R3DAnd R3ECan be halogen (e.g. fluorine, chlorine or bromine), unsubstituted C1-C6Haloalkyl, unsubstituted C1-C6Alkoxy (e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy (linear or branched) or hexoxy (linear or branched)), unsubstituted C1-C6An alkyl group (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (linear or branched), or hexyl (linear or branched)), an unsubstituted 3-to 10-membered heterocyclic group (e.g., a 3-to 8-membered monocyclic heterocyclic group containing one or two heteroatoms selected from oxygen and nitrogen, or a 6-to 8-membered bicyclic heterocyclic group containing one or two heteroatoms selected from oxygen and nitrogen), or an unsubstituted 3-to 10-membered heterocyclylalkylheterocyclic group(e.g., a 3-to 8-membered monocyclic heterocyclic group containing one or two heteroatoms selected from oxygen and nitrogen, or a 6-to 8-membered bicyclic heterocyclic group containing one or two heteroatoms selected from oxygen and nitrogen, which is linked to the remainder of the compound through a methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (linear or branched), or hexyl (linear or branched) group), and R3A、R3B、R3C、R3DAnd R3EThe others in (a) are hydrogen.
In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne of them may be fluorine, chlorine, -CF3、-OCH3Unsubstituted C1-C6Alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (linear or branched) or hexyl (linear or branched)), unsubstituted 3 to 10 membered heterocyclyl (e.g., 3 to 8 membered monocyclic heterocyclyl containing one or two heteroatoms selected from oxygen and nitrogen, or 6 to 8 membered bicyclic heterocyclyl containing one or two heteroatoms selected from oxygen and nitrogen), or unsubstituted 3 to 10 membered heterocyclylalkyl (e.g., 3 to 8 membered monocyclic heterocyclyl containing one or two heteroatoms selected from oxygen and nitrogen, or 6 to 8 membered bicyclic heterocyclyl containing one or two heteroatoms selected from oxygen and nitrogen) linked to the rest of the compound through a methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (linear or branched) or hexyl (linear or branched) group), and R is3A、R3B、R3C、R3DAnd R3EThe others in (a) are hydrogen.
In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne of which may be selected from:
In some embodiments, one R is1May be L-Y. In some embodiments, R3A、R3B、R3C、R3DAnd R3EOne of which may be L-Y. In some embodiments, Y is3May be C-L-Y.
In some embodiments, L may be-Z1-(R4-O-R4)t-Z2-. In some embodiments, L may be-Z1(R4-NH-R4)t-Z2-. In some embodiments, L may be Z1-(R4-(NHCO)-R4)t-Z2-. In some embodiments, L may be-Z1-(R4-(CONH)-R4)t-Z2-. In other embodiments, L may be-Z1-(R4-(NHC(O)NH)-R4)t-Z2-. In some embodiments of this paragraph, t is 1. In some embodiments of this paragraph, t is 2.
In some embodiments, Z1May be-NH-. In some embodiments, Z1May be-O-. In some embodiments, Z1Can be-CH2-. In some embodiments, Z1May be-NH (CO) -. In some embodiments, Z1Can be-CH2NH-. In some embodiments, Z1Can be-NHCH2-. In some embodiments, Z2May be-NH-. In some embodiments, Z2May be-O-. In some embodiments, Z2Can be-CH2-. In some embodiments, Z2May be-NH (CO) -. In some embodiments, Z2May be- (CO) NH-. In some embodiments, Z2Can be-CH2NH-. In some embodiments, Z2Can be used foris-NHCH2-. In some embodiments of this paragraph, Z1And Z2The same is true. In some embodiments of this paragraph, Z1And Z2Different. In some embodiments of this paragraph, when Z is1Can be-NH-or Z2May be-NH-. In some embodiments of this paragraph, when Z is1Can be-O-or-Z2May be-O-. In some embodiments of this paragraph, when Z is1Can be-CH2When is, Z2Can be-CH2-. In some embodiments of this paragraph, when Z is1May be-NH (CO) -, Z2May be-NH (CO) -. In some embodiments of this paragraph, when Z is1Can be-CH2NH-is, Z2Can be-CH2NH-. In some embodiments of this paragraph, when Z is1Can be-CH2NH (CO) -, Z2May be-NH-. In some embodiments of this paragraph, when Z is1Can be-CH2NH (CO) -, Z2May be-O-. In some embodiments of this paragraph, when Z is1Can be-CH2NH (CO) -, Z2Can be-CH2-. In some embodiments of this paragraph, when Z is1Can be-CH2NH (CO) -, Z2May be-NH (CO) -. In some embodiments of this paragraph, when Z is1Can be-CH2NH (CO) -, Z2Can be-CH2NH–。
In some embodiments, each R is4C which may independently be unsubstituted1-C4Alkylene, for example methylene, ethylene, n-propylene, isopropylene, n-butylene, sec-butylene or tert-butylene. In some embodiments, each R is4C which may independently be unsubstituted1-C2Alkylene, such as methylene or ethylene.
In some embodiments, t may be 1. In some embodiments, t may be 2. In some embodiments, t may be 3. In some embodiments, t may be 4. In some embodiments, t may be 5. In some embodiments, t may be 6.
In some embodiments, the compound of formula (I) is selected from:
Some embodiments of the compounds of general formula (I) are shown in table B below.
TABLE B
In some embodiments of table B, R2May be hydrogen. In some embodiments of table B, R2C which may be substituted or unsubstituted1-C6Alkyl radicals, e.g. methylEthyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (linear or branched) or hexyl (linear or branched). In some embodiments of table B, R2May be unsubstituted C1-C6Alkyl, for example methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (linear or branched) or hexyl (linear or branched). In some embodiments of table B, R2May be an acyl group, for example- (C ═ O) -methyl, - (C ═ O) -ethyl, - (C ═ O) -n-propyl, - (C ═ O) -isopropyl, - (C ═ O) -n-butyl, - (C ═ O) -isobutyl, - (C ═ O) -sec-butyl, - (C ═ O) -tert-butyl, - (C ═ O) -pentyl (linear or branched) or- (C ═ O) -hexyl (linear or branched). In some embodiments of table B, R2Can be- (SO)2)-C1-C6Alkyl radicals, e.g., - (SO)2) -methyl, - (SO)2) -ethyl, - (SO)2) -n-propyl, - (SO)2) -isopropyl, - (SO)2) -n-butyl, - (SO)2) -isobutyl, - (SO)2) -sec-butyl, - (SO)2) -tert-butyl, - (SO)2) -pentyl (linear or branched) or- (SO)2) -hexyl (linear or branched).
In some embodiments, the compound of formula (I) is selected from:
in some embodiments of this paragraph, R1May be fluorine. In some embodiments of this paragraph, R1May be chlorine. In some embodiments of this paragraph, R1May be a hydroxyl group. In some embodiments of this paragraph, R1May be-NH2. In some embodiments of this paragraph, R1May be-CF3、–CHF2or-CH2F. In some embodiments of this paragraph, R1May be unsubstituted C1-C6Alkoxy, for example methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy (linear or branched) or hexoxy (linear or branched). In some embodiments of this paragraph, R1May be unsubstituted C1-C6Alkyl, for example methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (linear or branched) or hexyl (linear or branched). In some embodiments of this paragraph, R1May be unsubstituted C3-C8Cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. In some embodiments of this paragraph, R1May be an unsubstituted 3 to 10 membered heterocyclic group such as a monocyclic heterocyclic group, a bridged heterocyclic group or a fused heterocyclic group, including groups such as pyrrolidine, piperidine, piperazine and morpholine. In some embodiments of this paragraph, R3BMay be a hydroxyl group. In some embodiments of this paragraph, R3BMay be fluorine. In some embodiments of this paragraph, R3BMay be chlorine. In some embodiments of this paragraph, R3BAmino which may be substituted or unsubstituted, e.g. -NH2Dimethylamino, diethylamino, isopropylethylamino, phenylamino, or benzylamino. In some embodiments of this paragraph, R3BMay be-CF3、–CHF2or-CH2F. Some practice in this paragraphIn the embodiment, R3BMay be unsubstituted C1-C6Alkoxy, for example methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy (linear or branched) or hexoxy (linear or branched). In some embodiments of this paragraph, R3BMay be unsubstituted C1-C6Alkyl, for example methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (linear or branched) or hexyl (linear or branched). In some embodiments of this paragraph, R3BMay be unsubstituted C3-C8Cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. In some embodiments of this paragraph, R3CC which may be substituted or unsubstituted3-C8Cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. In some embodiments of this paragraph, R3CMay be unsubstituted C3-C8Cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. In some embodiments of this paragraph, R3CA 3 to 10 membered heterocyclic group which may be substituted or unsubstituted, such as a monocyclic heterocyclic group, a bridged heterocyclic group or a fused heterocyclic group, including groups such as pyrrolidine, piperidine, piperazine and morpholine. In some embodiments of this paragraph, R3CMay be an unsubstituted 3 to 10 membered heterocyclic group such as a monocyclic heterocyclic group, a bridged heterocyclic group or a fused heterocyclic group, including groups such as pyrrolidine, piperidine, piperazine and morpholine. In some embodiments of this paragraph, R3CA 5 to 10 membered heteroaryl group which may be substituted or unsubstituted, for example a 5 or 6 membered heteroaryl group containing at least one nitrogen, for example pyrrole, imidazole, oxazole, thiazole, pyridine or pyrimidine. In some embodiments of this paragraph, R3CMay be an unsubstituted 5 to 10 membered heteroaryl group, for example a 5 or 6 membered heteroaryl group containing at least one nitrogen, for example pyrrole, imidazole, oxazole, thiazole, pyridine or pyrimidine.
The compounds of general formula (I) may be provided in the form of pharmaceutically acceptable salts, solvates or tautomers thereof.
Some embodiments provide a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition further comprises at least one pharmaceutically acceptable inactive ingredient. The pharmaceutical composition may be formulated for intravenous injection, subcutaneous injection, oral administration, buccal administration, inhalation, nasal administration, topical administration, transdermal administration, ocular administration, or otic administration. The pharmaceutical composition may be in the form of tablets, pills, capsules, liquids, inhalants, nasal spray solutions, suppositories, suspensions, gels, colloids, dispersions, solutions, emulsions, ointments, lotions, eye drops or ear drops.
In some embodiments, the pharmaceutical composition is formulated as a gel, salve, ointment, cream, emulsion, or paste for topical application to the skin.
Some embodiments provide a method of inhibiting the activity of a cytokine comprising contacting a cell with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
Some embodiments provide methods of inhibiting aiolos activity comprising contacting a cell with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
Some embodiments provide a method of inhibiting ikaros activity comprising contacting a cell with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, the cell is a cancer cell.
Some embodiments provide methods of inhibiting hellios activity comprising contacting a cell with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, the cell is a cancer cell.
Some embodiments provide methods of inhibiting CK-1 α activity comprising contacting a cell with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
In some embodiments, the cell is a small cell lung cancer cell, a non-small cell lung cancer cell, a breast cancer cell, a prostate cancer cell, a head and neck cancer cell, a pancreatic cancer cell, a colon cancer cell, a rectal cancer cell, a teratoma cell, an ovarian cancer cell, an endometrial cancer cell, a brain cancer cell, a retinoblastoma cell, a leukemia cell, a skin cancer cell, a melanoma cell, a squamous cell carcinoma cell, an liposarcoma cell, a lymphoma cell, a multiple myeloma cell, a testicular cancer cell, a liver cancer cell, an esophageal cancer cell, a kidney cancer cell, an astrocytic proliferating cell, a relapsed/refractory multiple myeloma cell, or a neuroblastoma cell.
In some embodiments, inhibiting protein activity may comprise reducing protein activity by 20-50%, 30-70%, 40-90%, or any value in between. For example, inhibiting protein activity can include decreasing protein activity by 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or any value in between.
Some embodiments provide a method of treating, ameliorating, or preventing a disease, disorder, or condition associated with a protein selected from the group consisting of cytokines, aiolos, ikaros, helioss, CK1 α, and a combination of any of the foregoing, in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
In some embodiments, the disease, disorder, or condition is a cancer selected from a hematologic malignancy and a solid tumor. In some embodiments, the disease, disorder, or condition is a cancer selected from small cell lung cancer, non-small cell lung cancer, breast cancer, prostate cancer, head and neck cancer, pancreatic cancer, colon cancer, rectal cancer, teratoma, ovarian cancer, endometrial cancer, brain cancer, retinoblastoma, leukemia, skin cancer, melanoma, squamous cell carcinoma, liposarcoma, lymphoma, multiple myeloma, testicular cancer, liver cancer, esophageal cancer, renal cancer, astrocytosis, relapsed/refractory multiple myeloma, and neuroblastoma.
In some embodiments, the disease, disorder, or condition is selected from inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, uveitis, inflammatory lung disease, chronic obstructive pulmonary disease, and alzheimer's disease. In some embodiments, the disease, disorder, or condition is selected from fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, crohn's disease, and ulcerative colitis.
In some embodiments, the cytokine is selected from the group consisting of IL-1 β, IL-2, IL-6, and TNF α in some embodiments, the individual is known to have wild-type IL-1 β, IL-2, IL-6, and TNF α in some embodiments, the individual is known to overexpress one or more of IL-1 β, IL-2, IL-6, and TNF α in some embodiments, the individual is known to have mutated forms of IL-1 β, IL-2, IL-6, and/or TNF α.
In some embodiments, the cytokine is TNF α in some embodiments, the individual is known to have wild-type TNF α in some embodiments, the individual is known to overexpress TNF α in some embodiments, the individual is known to have a mutant form of TNF α in some embodiments, the protein is aiolos in some embodiments, the individual is known to have a wild-type aiolos in some embodiments, the individual is known to overexpress aiolos in some embodiments, the individual is known to have a mutant form of aiolos in some embodiments, the protein is ikaros in some embodiments, the individual is known to have a wild-type ikaros in some embodiments, the individual is known to overexpress arik in some embodiments, the individual is known to have a mutant form of ikaros in some embodiments, the protein is known to have a hemis in some embodiments, the protein is known to have a mutant form of hepios in some embodiments, the wild-type hepios in some embodiments, the individual is known to have a mutant form of hepios in some embodiments, the mutant form of hepios 3, the individual is known to have no, some embodiments, the mutant form of hepios in some embodiments, the individual is known to have No. 3, the mutant form of hepios in some embodiments, the embodiment, the protein is known to have some embodiments, the mutant form of hepios.
Other objects, features, and advantages of the compounds, methods, and compositions described herein will become apparent from the following detailed description. However, it should be understood that the detailed description and specific examples, while indicating specific embodiments, are given by way of illustration only, since various changes and modifications within the spirit and scope of the disclosure will become apparent to those skilled in the art from this detailed description.
Definition of
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. All patents, applications, published applications and other publications mentioned herein are incorporated by reference in their entirety, unless otherwise indicated. Unless otherwise indicated, where there are multiple definitions for terms herein, the definition in this section controls. As used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Unless otherwise specified, conventional mass spectrometry, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA techniques and pharmacological methods are employed. Unless otherwise stated, the use of "or" and "means" and/or ". Furthermore, the use of the term "including" as well as other forms such as "includes", "includes" and "included" is not limited. As used in this specification, the terms "comprises(s)", and "comprising" should be interpreted as having an open-ended meaning, whether in transitional phrases or in the context of the claims. In other words, the term should be interpreted synonymously with the phrases "having at least" or "including at least". When used in the context of a method, the term "comprising" means that the method includes at least the recited steps, but may include additional steps. The term "comprising" when used in the context of a compound, composition or device means that the compound, composition or device includes at least the recited features or components/ingredients, but may also include additional external features or components/ingredients.
The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
The term "co-administration" and similar terms as used herein are broad terms and are to be given their ordinary and customary meaning to those of ordinary skill in the art (and are not to be limited to a specific or customized meaning) and refer to, but are not limited to, administration of a selected therapeutic agent to a single patient and are intended to encompass treatment regimens in which the agents are administered by the same or different routes of administration or at the same or different times.
The terms "effective amount" and "therapeutically effective amount" are broad terms and are to be given their ordinary and customary meaning to those of ordinary skill in the art (and are not to be limited to a specific or customized meaning) and refer to, but are not limited to, the administration of a sufficient amount of an agent or compound that will alleviate one or more symptoms of the disease or condition being treated to some extent. The result can be a reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an "effective amount" for therapeutic use is the amount of a composition comprising a compound disclosed herein that is required to provide a clinically significant reduction in disease symptoms. An appropriate "effective" amount in any individual case can be determined using techniques such as dose escalation studies. When a drug has been approved by the U.S. Food and Drug Administration (FDA) or corresponding foreign drug agency, a "therapeutically effective amount" optionally refers to a dose approved by the FDA or its corresponding foreign agency for the treatment of the identified disease or condition.
As herein describedAs used, any "R" group, such as but not limited to R2、R3、R4、R5、R6、R9And R10And represents a substituent which may be attached to the indicated atom. The R group may be substituted or unsubstituted. If two "R" groups are described as "together," the R groups, together with the atoms to which they are attached, can form a cycloalkyl, aryl, heteroaryl, or heterocyclic ring. For example, without limitation, if R2And R3Or R is2、R3Or R4And the atoms to which they are attached are designated as "linked together" or "joined together," meaning that they are covalently bonded to each other to form a ring:
whenever a group is described as "substituted" or "optionally substituted," the group may be unsubstituted or substituted with one or more of the indicated substituents. Likewise, when a group is described as "unsubstituted or substituted," if substituted, the substituent may be selected from one or more of the specified substituents. If no substituent is specified, it is intended that the specified or "substituted" group may be individually and independently substituted with one or more groups individually and independently selected from: alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, aralkyl, heteroaralkyl, (heterocyclyl) alkyl, hydroxy, protected hydroxy, alkoxy, aryloxy, acyl, cyano, halogen, ester, nitro, silyl, haloalkyl, haloalkoxy, unsubstituted amino, substituted amino, and protected derivatives thereof.
As used herein, "C" isaTo Cb"(wherein" a "and" b "are integers) means the number of carbon atoms in an alkyl, alkenyl, or alkynyl group, or the number of carbon atoms in the ring of a cycloalkyl, aryl, heteroaryl, or heterocyclyl group. That is, the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl ring may contain "a" through "b" (both inclusive)Carbon atoms. Thus, for example, "C1To C4Alkyl "or" C1-C4Alkyl "refers to all alkyl groups having 1 to 4 carbons, i.e., CH3-、CH3CH2-、CH3CH2CH2-、(CH3)2CH-、CH3CH2CH2CH2-、CH3CH2CH(CH3) -and (CH)3)3C-. Likewise, for example, a heterocyclyl group can contain "a" through "b" (both inclusive) total atoms, e.g., a 3-to 10-membered heterocyclyl group, which includes 3 to ten total atoms (carbon and heteroatoms). If "a" and "b" are not specified with respect to alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, the broadest ranges described in these definitions are assumed.
As used herein, "alkyl" refers to a straight or branched hydrocarbon chain comprising a fully saturated (no double or triple bonds) hydrocarbon group. The alkyl group can have 1 to 20 carbon atoms (whenever appearing herein, a numerical range such as "1 to 20" refers to each integer in the given range; e.g., "1 to 20 carbon atoms" means that the alkyl group can consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, although the present definition also encompasses occurrences of the term "alkyl" where no numerical range is specified). The alkyl group can also be a medium size alkyl group having 1 to 10 carbon atoms. The alkyl group may also be a lower alkyl group having 1 to 6 carbon atoms. The alkyl group in the compound may be designated as "C1-C4Alkyl "or similar names. By way of example only, "C1-C4Alkyl "indicates the presence of one to four carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl. Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, and hexyl. Alkyl groups may be substituted or unsubstituted.
As used herein, "alkenyl" refers to an alkyl group, as defined herein, that contains one or more double bonds in a straight or branched hydrocarbon chain. Alkenyl groups may be unsubstituted or substituted.
As used herein, "alkynyl" refers to an alkyl group, as defined herein, that contains one or more triple bonds in a straight or branched hydrocarbon chain. Alkynyl groups may be unsubstituted or substituted.
As used herein, "alkylene" is a straight or branched chain alkyl group that refers to a bond formed to connect molecular fragments through their terminal carbon atoms. Examples include, but are not limited to, methylene (-CH)2-) ethylene (-CH2CH2-) propylene (-CH)2CH2CH2-) and butylene (-CH)2CH2CH2CH2-). Alkylene groups may be substituted by replacing one or more hydrogens of the alkylene group with substituents listed under the definition of "substituted".
As used herein, "cycloalkyl" refers to a fully saturated (no double or triple bonds) monocyclic or polycyclic hydrocarbon ring system. When composed of two or more rings, the rings may be joined together in a fused manner. Cycloalkyl groups may contain 3 to 10 atoms in the ring or 3 to 8 atoms in the ring. Typical cycloalkyl groups include, but are in no way limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Cycloalkyl groups may be unsubstituted or substituted.
As used herein, "cycloalkyl" refers to an all-carbocyclic system. Such systems may be unsaturated, may include some unsaturation, or may contain some aromatic moieties, or be fully aromatic. Cycloalkyl groups may contain 3 to 30 carbon atoms. Cycloalkyl groups may be unsubstituted or substituted.
As used herein, "cycloalkylalkyl" refers to a- (alkylene) -R group, wherein R is cycloalkyl as defined above. Examples include, but are not limited to, cyclopropylmethyl and cyclohexylmethyl. Cycloalkylalkyl radicals may also be referred to as, for example, (C)1-C6Alkyl) -cycloalkyl. Cycloalkylalkyl groups may be unsubstituted or substituted.
As used herein, "aryl" refers to a carbocyclic (all-carbon) monocyclic or polycyclic aromatic ring system (including, e.g., fused, bridged, or spiro ring systems) having a fully delocalized pi-electron system throughout at least one of the ringsWherein two carbocycles share a chemical bond, e.g., one or more aryl rings and one or more aryl or non-aryl rings). The number of carbon atoms in the aryl group can vary. For example, aryl may be C6-C14Aryl radical, C6-C10Aryl or C6And (4) an aryl group. Examples of aryl groups include, but are not limited to, benzene, naphthalene, and azulene. The aryl group may be substituted or unsubstituted.
As used herein, "aralkyl" refers to a- (alkylene) -R group, wherein R is aryl as defined above. Examples include, but are not limited to, benzyl and phenethyl. Aralkyl may also be referred to as, for example, (C)1-C6Alkyl) -aryl. Aralkyl groups may be substituted or unsubstituted.
As used herein, "heteroaryl" refers to a monocyclic or polycyclic aromatic ring system (having at least one ring containing a fully delocalized pi-electron system) containing one or more heteroatoms (i.e., elements other than carbon, including but not limited to nitrogen, oxygen, and sulfur) and at least one aromatic ring. The number of atoms in the ring of the heteroaryl group can vary. For example, heteroaryl groups can contain 4 to 14 atoms in the ring, 5 to 10 atoms in the ring, or 5 to 6 atoms in the ring. Furthermore, the term "heteroaryl" includes fused ring systems in which two rings (such as at least one aryl ring and at least one heteroaryl ring or at least two heteroaryl rings) share at least one chemical bond. Examples of heteroaryl rings include, but are not limited to, furan, furazan, thiophene, benzothiophene, phthalazine, pyrrole, oxazole, benzoxazole, 1,2, 3-oxadiazole, 1,2, 4-oxadiazole, thiazole, 1,2, 3-thiadiazole, 1,2, 4-thiadiazole, benzothiazole, imidazole, benzimidazole, indole, indazole, pyrazole, benzopyrazole, isoxazole, benzisoxazole, isothiazole, triazole, benzotriazole, thiadiazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine, purine, pteridine, quinoline, isoquinoline, quinazoline, quinoxaline, cinnoline, and triazine. Heteroaryl groups may be substituted or unsubstituted.
As used herein, "heteroaralkyl" refers to a- (alkylene) -R group, wherein R is heteroaryl as defined above. Examples include, but are not limited to, picolinesAnd methyl pyrimidinyl. Heteroaralkyl radicals may also be referred to as, for example, (C)1-C6Alkyl) -heteroaryl. Heteroaralkyl groups may be substituted or unsubstituted.
As used herein, "heterocycle" or "heterocyclyl" refers to ternary, quaternary, five-membered, six-membered, seven-membered, eight-membered, nine-membered, ten-membered, up to 18-membered monocyclic, bicyclic, and tricyclic ring systems, wherein carbon atoms, together with 1 to 5 heteroatoms, form the ring system. The heterocyclic ring may optionally contain one or more unsaturated bonds, however, the unsaturated bonds are located in such a way that there are no completely delocalized pi-electron systems throughout all rings. The heteroatoms are independently selected from oxygen, sulfur and nitrogen. The heterocyclic ring may also contain one or more carbonyl or thiocarbonyl functional groups so that this definition includes oxo and thioxo systems such as lactams, lactones, cyclic imides, cyclic thioimides and cyclic carbamates. When composed of two or more rings, the rings may be joined together in a fused manner. In addition, any nitrogen in the heterocycle may be quaternized. Examples of such "heterocyclic" groups include, but are not limited to, 1, 3-dioxine, 1, 3-dioxane, 1, 4-dioxane, 1, 2-dioxolane, 1, 3-dioxolane, 1, 4-dioxolane, 1, 3-oxathiacyclohexane, 1, 4-oxathiadiene, 1, 3-oxathiacyclopentane, 1, 3-dithiolene, 1, 3-dithiolane, 1, 4-oxathiane, tetrahydro-1, 4-thiazine, 2H-1, 2-oxazine, maleimide, succinimide, barbituric acid, thiobarbituric acid, dioxopiperazine, hydantoin, dihydrouracil, trioxane, hexahydro-1, 3, 5-triazine, Imidazoline, imidazolidine, isoxazoline, isoxazolidine, oxazoline, oxazolidine, oxazolidinone, thiazoline, thiazolidine, morpholine, ethylene oxide, piperidine N-oxide, piperidine, piperazine, pyrrolidine, pyrrolidone, pyrrolidinedione, 4-piperidone, pyrazoline, pyrazolidine, 2-oxopyrrolidine, tetrahydropyran, 4H-pyran, tetrahydrothiopyran, thiomorpholine sulfoxide, thiomorpholine sulfone, and benzo-fused analogs thereof (e.g., benzimidazolone, tetrahydroquinoline, and 3, 4-methylenedioxyphenyl). Heterocyclyl groups may be unsubstituted or substituted.
As used herein, "heterocyclylalkyl" refers to a- (alkylene) -R group, wherein R is a heterocyclyl as defined above. Examples include, but are not limited to, methylpyrrolidinyl and methylpiperidinyl. Heterocyclylalkyl radicals may also be referred to as, for example, (C)1-C6Alkyl) -heterocyclyl. Heterocyclylalkyl groups may be substituted or unsubstituted.
As used herein, "alkoxy" refers to the formula-OR, wherein R is alkyl as defined above. A non-limiting list of alkoxy groups is methoxy, ethoxy, n-propoxy, n-butoxy, isobutoxy, sec-butoxy and tert-butoxy. Alkoxy groups may be substituted or unsubstituted.
As used herein, "alkoxyalkyl" refers to an alkyl group, as defined above, substituted with one or two alkoxy groups, as defined above. Examples include, but are not limited to, methoxyethyl, ethoxyethyl, and methoxypropyl. Alkoxyalkyl groups may be substituted or unsubstituted.
As used herein, "acyl" refers to hydrogen, alkyl, alkenyl, alkynyl or aryl as defined above as a substituent attached via a carbonyl as defined herein. Examples include formyl, acetyl, benzoyl and acryloyl, the preferred acyl group being C1-C6An alkylcarbonyl group. The acyl group may be substituted or unsubstituted.
As used herein, "hydroxyalkyl" refers to an alkyl group in which one or more hydrogen atoms are replaced by a hydroxyl group. Exemplary hydroxyalkyl groups include, but are not limited to, 2-hydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl, and 2, 2-dihydroxyethyl. Hydroxyalkyl groups may be substituted or unsubstituted.
As used herein, "haloalkyl" refers to an alkyl group in which one or more hydrogen atoms are replaced with a halogen (e.g., monohaloalkyl, dihaloalkyl, and trihaloalkyl). Such groups include, but are not limited to, chloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, and 1-chloro-2-fluoromethyl, 2-fluoroisobutyl. Haloalkyl groups may be substituted or unsubstituted.
As used herein, "haloalkoxy" refers to an alkoxy group in which one or more hydrogen atoms are replaced with a halogen (e.g., monohaloalkoxy, dihaloalkoxy, and trihaloalkoxy). Such groups include, but are not limited to, chloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, and 1-chloro-2-fluoromethoxy, 2-fluoroisobutoxy. Haloalkoxy groups may be substituted or unsubstituted.
As used herein, "aryloxy" refers to — OR, wherein R is aryl as defined above, such as (but not limited to) phenyl. The aryloxy group may be substituted or unsubstituted.
The term "ester" refers to a "-C (═ O) OR" group, where R can be, for example, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, OR cycloalkyl. The esters may be substituted or unsubstituted.
As used herein, the term "unsubstituted amino" refers to-NH2A group.
As used herein, the term "substituted amino" refers to-NRaRbGroup, wherein RaAnd RbIndependently selected from hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, aralkyl, heteroaralkyl, cycloalkylalkyl and heterocyclylalkyl groups as defined herein; and wherein RaAnd RbNo more than one of which may be hydrogen.
As used herein, the term "hydroxy" refers to an-OH group.
"cyano" refers to the "-CN" group.
"carbonyl" refers to a C ═ O group.
The term "halogen atom" or "halogen" as used herein means any one of the radio-stable atoms in column 7 of the periodic table of elements, such as fluorine, chlorine, bromine and iodine.
In all definitions set forth herein, the terms used to define the new terms are as previously defined herein.
In the case where the number of substituents is not specified (e.g., haloalkyl), one or more substituents may be present. For example, "haloalkyl" may include one or more of the same or different halogens. As another exampleExample, "C1-C3Alkoxyphenyl "may include one or more of the same or different alkoxy groups containing one, two or three atoms.
As used herein, abbreviations for any protecting group, amino acid and other compounds are in accordance with their common usage, accepted abbreviations or the IUPAC-IUB Commission on Biochem.11:942-944(1972)) unless otherwise indicated.
The terms "protecting group" and "protecting group" as used herein refer to any atom or group of atoms added to a molecule to prevent an existing group in the molecule from undergoing unwanted chemical reactions. Examples of protecting group moieties are described in t.w.greene and p.g.m.wuts, Protective Groups in Organic Synthesis, 3 rd edition john wiley & Sons, 1999; and j.f.w.mcomie, Protective Groups in Organic Chemistry plenum, 1973, both of which are incorporated herein by reference for the limited purpose of disclosing suitable protecting Groups. The protecting group moiety may be selected in such a way that it is stable to certain reaction conditions and is readily removed at a convenient stage using methodology known in the art. A non-limiting list of protecting groups includes benzyl; a substituted benzyl group; alkylcarbonyl (e.g., tert-Butoxycarbonyl (BOC), acetyl, or isobutyryl); an arylalkyl carbonyl group (e.g., benzyloxycarbonyl or benzoyl); substituted methyl ethers (e.g., methoxymethyl ether); substituted ethyl ethers; substituted benzyl ethers; tetrahydropyranyl ether; silyl ethers (e.g., trimethylsilyl, triethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl or tert-butyldiphenylsilyl); esters (e.g., benzoates); carbonates (e.g., methoxymethyl carbonate); sulfonates (e.g., tosylate or mesylate); acyclic ketals (e.g., dimethyl acetal); cyclic ketals (e.g., 1, 3-dioxane or 1, 3-dioxolane); an acyclic acetal; a cyclic acetal; an acyclic hemiacetal; a cyclic hemiacetal; cyclic dithioketals (e.g., 1, 3-dithiane or 1, 3-dithiolane); and triarylmethyl groups (e.g., trityl; monomethoxytrityl (MMTr); 4,4 '-dimethoxytrityl (DMTr); or 4,4' -trimethoxytrityl (TMTr)).
As used herein, "leaving group" refers to any atom or moiety that is capable of being substituted by another atom or moiety in a chemical reaction. More specifically, in some embodiments, a "leaving group" refers to an atom or moiety that is substituted in a nucleophilic substitution reaction. In some embodiments, a "leaving group" is any atom or moiety that is the conjugate base of a strong acid. Examples of suitable leaving groups include, but are not limited to, tosylate and halogen. Non-limiting characteristics and examples of leaving groups can be found in, for example, Organic Chemistry, second edition, Francis Carey (1992), pp 328-331; introductions to Organic Chemistry, second edition, Andrew Streittwieser and Clayton HeathCock (1981), pp.169-171; and Organic Chemistry, fifth edition, John McMurry (2000), pages 398 and 408; for the limited purpose of disclosing features and examples of leaving groups, they are all incorporated herein by reference.
The term "pharmaceutically acceptable salt" as used herein is a broad term and is to be given its ordinary and customary meaning to those of ordinary skill in the art (and is not to be limited to a specific or customized meaning) and refers to, but is not limited to, salts of compounds that do not cause significant irritation to the organism to which they are administered and do not abrogate the biological activity and properties of the compound. In some embodiments, the salt is an acid addition salt of the compound. Pharmaceutically acceptable salts can be obtained by reacting the compounds with inorganic acids, such as hydrohalic acids (e.g., HCl or HBr), H2SO4、HNO3And H3PO4. Pharmaceutically acceptable salts can also be obtained by reacting a compound with an organic acid, such as an aliphatic or aromatic carboxylic or sulfonic acid, for example formic acid, AcOH, propionic acid, glycolic acid, pyruvic acid, malonic acid, maleic acid, fumaric acid, trifluoroacetic acid, benzoic acid, cinnamic acid, mandelic acid, succinic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, nicotinic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, hexadiene diacid, butyric acid, phenylacetic acid, phenylbutyric acid, valproic acid, 1, 2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid or naphthalenesulfonic acid. Pharmaceutically acceptable salts can also be obtained by reacting a compound with a base to form a salt, such as an ammonium salt; alkali metal salts such as Li salts, Na salts or K salts; alkaline earth metal salts, such as Ca salts, Mg salts; or an Al salt; salts of organic bases, e.g. dicyclohexylamine, N-methyl-D-reduced glucamine, tris (hydroxymethyl) methylamine, C1-C7Alkylamines, cyclohexylamine, dicyclohexylamine, triethanolamine, ethylenediamine, ethanolamine, diethanolamine, triethanolamine, tromethamine and salts with amino acids (e.g. arginine and lysine); or salts with inorganic bases, e.g. Al (OH)3、Ca(OH)2、KOH、Na2CO3NaOH, etc.
Some embodiments provide pharmaceutically acceptable salts of formula (II). In some embodiments, the salt is selected from the group consisting of hydrochloride, sulfate, hemisulfate, acetate, fumarate, malate, and citrate.
The term "solvate" as used herein is a broad term and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not limited to a special or customized meaning) and refers to, but is not limited to, a solvent complexed with a compound in a reproducible molar ratio, including, but not limited to, 0.5:1, 1:1, or 2: 1. Thus, the term "pharmaceutically acceptable solvate" refers to a solvate, wherein the solvent is one that does not cause significant irritation to the organism to which it is administered and does not abrogate the biological activity of the compound.
Some embodiments provide solvates of formula (I). In some embodiments, the solvent in the solvate is selected from water, ethanol, and acetone or combinations thereof.
It is to be understood that in any compound described herein having one or more chiral centers, each center can independently have the R configuration or the S configuration or mixtures thereof if absolute stereochemistry is not explicitly specified. Thus, the compounds provided herein can be enantiomerically pure, enantiomerically enriched, or can be stereoisomeric mixtures and include all diastereomeric and enantiomeric forms. Additionally, it is to be understood that in any of the compounds described herein having one or more double bonds that result in geometric isomers that can be defined as E or Z, each double bond can independently be E or Z or a mixture thereof. If desired, the stereoisomers are obtained by methods such as stereoselective synthesis and/or separation of stereoisomers by chiral chromatography columns. Likewise, it is to be understood that in any compound described, all tautomeric forms are also intended to be included.
Unless otherwise specified, whenever a substituent is depicted as a diradical (i.e., having two points of attachment to the rest of the molecule), it is understood that the substituent may be attached in any directed configuration. Thus, for example, depicted as-AE-orIncludes the case where the substituents are oriented such that a is attached at the leftmost attachment point of the molecule and a is attached at the rightmost attachment point of the molecule.
It is understood that when a compound disclosed herein has an unfilled valence, then the valence is intended to be filled with hydrogen and/or deuterium.
It is to be understood that the compounds described herein may be isotopically labeled or labeled by another other method including, but not limited to, the use of a chromophore or fluorescent moiety, a bioluminescent label, or a chemiluminescent label. Substitution with isotopes such as deuterium can afford certain therapeutic advantages resulting from greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements. Each chemical element present in the structure of the compound may include any isotope of that element. For example, in a compound structure, a hydrogen atom may be explicitly disclosed or understood as being present in the compound. At any position of the compound where a hydrogen atom may be present, the hydrogen atom may be any isotope of hydrogen including, but not limited to, hydrogen-1 (protium), hydrogen-2 (deuterium), and hydrogen-3 (tritium). Thus, unless the context clearly indicates otherwise, a reference herein to a compound encompasses all possible isotopic forms.
It is understood that the methods and formulations described herein include the use of the salts, solvates, hydrates, and conformers of the compounds of the preferred embodiments, as well as metabolites and active metabolites of these compounds having the same type of activity. Conformers are structures that are conformationally isomeric. Conformational isomerism is the phenomenon in which molecules have the same structural formula but the conformation of the atoms around the rotating bond (conformers) is different. In certain embodiments, the compounds described herein exist in solvated forms with pharmaceutically acceptable solvents (such as water, ethanol, and the like). In other embodiments, the compounds described herein exist in unsolvated forms. Solvates contain either stoichiometric or non-stoichiometric amounts of solvent and may be formed during crystallization with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. In addition, the compounds provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to unsolvated forms for the purposes of the compounds and methods provided herein. The compounds of formula (I) may also be provided in, for example, amorphous form, milled form and nanoparticle form.
Likewise, it is to be understood that a compound described herein, e.g., a compound of the preferred embodiments, includes any form of the compound described herein (e.g., pharmaceutically acceptable salts, crystalline forms, amorphous forms, solvated forms, enantiomeric forms, tautomeric forms, and the like).
Dosing regimens
In some embodiments, about 1mg to about 5g of a compound of formula (I) is administered per day. In some embodiments, about 2mg to about 2g of a compound of formula (I) is administered per day. In some embodiments, the amount of the compound of formula (I) administered per day is or about 5mg to 1 g; 10mg to 800 mg; 20mg to 600 mg; 30mg to 400 mg; 40mg to 200 mg; 50mg to 100 mg; or any amount in between.
In some embodiments, about 1mg to about 5g of a compound of formula (I) is administered weekly. In some embodiments, about 2mg to about 2g of a compound of formula (I) is administered weekly. In some embodiments, the amount of the compound of formula (I) administered weekly is or about 5mg to 1 g; 10mg to 800 mg; 20mg to 600 mg; 30mg to 400 mg; 40mg to 200 mg; 50mg to 100 mg; or any amount in between.
In some embodiments, about 1mg to about 5g of a compound of formula (I) is administered per treatment cycle. In some embodiments, about 2mg to about 2g of a compound of formula (I) is administered per treatment cycle. In some embodiments, the amount of the compound of formula (I) administered per treatment cycle is or is from about 5mg to about 1 g; 10mg to 800 mg; 20mg to 600 mg; 30mg to 400 mg; 40mg to 200 mg; 50mg to 100 mg; or any amount therebetween.
In some embodiments, at least once per day; twice a day; three times a day; or four times daily administration of a compound of formula (I). In some embodiments, at least once per week; twice a week; three times per week; or four times a week. In some embodiments, each treatment cycle lasts for 1 day; 2 days; 3 days; 4 days; 5 days; 6 days; 7 days; 8 days; 9 days; 10 days; 11 days; 12 days; 13 days; 14 days, or any time in between. In some embodiments, each treatment cycle has at least 1 day between administrations of the compound of formula (I); 2 days; 3 days; 4 days; 5 days; 6 days; 7 days; 8 days; 9 days; 10 days; 11 days; 12 days; 13 days; or 14 days.
In some embodiments, the compound of formula (I) is provided intravenously in about 10min, about 20min, about 30min, about 1h, about 1.5h, about 2h, about 2.5h, about 3h, about 3.5h, about 4h, or any time therebetween.
Examples
Further embodiments are disclosed in further detail in the following examples, which are not intended to limit the scope of the claims in any way.
The compounds disclosed herein were characterized using Bruker AV-500 and DRX-500NMR spectrometers and a Perkin Elmer PE-SCIEX API-150 mass spectrometer.
In the synthetic procedures described herein, "work-up and purification" means that after extraction of the aqueous phase the organic layers are combined, washed with brine, washed with Na2SO4Drying, filtering, concentrating, and using the specified solvent systemThe product was purified by silica gel chromatography. Work-up and purification may also include 10% Na before washing with brine2S2O3Aqueous solution/saturated NaHCO3The aqueous solution (1:1) is subjected to an optional washing step.
Example 1
Compound 1: (S) -3- (4- ((4- (morpholinylmethyl) benzyl) oxy) -1-oxoisoindolin-2-yl) azepine
Cycloheptane-2, 7-diones
To a solution of 4- (diethoxymethyl) benzaldehyde (2.43g,11.67mmol) in MeOH (40mL) at 0 deg.C was added NaBH4(886.7mg,23.34 mmol). The suspension was stirred at RT for 3 h. The solvent was then removed, the residue diluted with water and extracted with DCM. The combined organic layers were washed with Na2SO4Drying, filtration, concentration and purification of the residue by silica gel chromatography with EtOAc/petroleum ether (10% to 23%) gave (4- (diethoxymethyl) phenyl) methanol 1.1 as a colourless oil (2.21g, 90% yield). MS (ESI) M/z 165.1[ M-42 ]]+.
To a solution of compound 1.2(323mg,1.24mmol) in THF (20mL) at 0 deg.C was added 1.1(326.5mg,1.55mmol) followed by PPh3(650.4mg,2.48 mmol). A solution of DEAD (431.9mg,2.48mmol) in THF (1mL) was added dropwise and the suspension was stirred at RT for 16 h. The solvent was removed and the residue was purified by silica gel chromatography using EtOAc/petroleum ether (40% to 100%) to give compound 1.3 as a white solid (373mg, 66.7% yield). MS (ESI) M/z407.1[ M-45 ]]+.
To a solution of compound 1.3(473mg,1.05mmol) in THF (10mL) at RT was added 4M HCl (1.31mL) and the reaction was stirred at RT for 30 min. The solvent was removed and the residue was dried under vacuum to give compound 1.4 as a white solid (397mg, 100% yield). MS (ESI) M/z 379.1[ M +1 ]]+.
To a solution of compound 1.4(396.9mg,1.05mmol) in fluorobenzene/DMSO (30mL/5mL with 1 drop in DMSO) was added Dess-Martin reagent (1.12g,2.63 mmol). Heating the suspension at 80 deg.C to 18h. Additional Dess-Martin reagent (550mg) was added and the mixture was heated at 80 ℃ for 5 h. The mixture was cooled to RT and filtered. The filtrate was added to saturated Na2S2O3In aqueous solution. The suspension was stirred at 0 ℃ for 5min and then extracted with DCM. Work-up and purification by silica gel chromatography using EtOAc/petroleum ether (40-100%) afforded compound 1.5(184mg, 45% yield) as a white solid. MS (ESI) M/z 393.1[ M +1 ]]+.
To a solution of Compound 1.5(76mg,0.194mmol) in DCM (10mL) was added morpholine (25.3mg,0.291mmol), followed by NaBH (OAc)3(82.3mg,0.384 mmol). The mixture was stirred at RT for 48H, concentrated, purified by prep-TLC using EtOAc, then further purified by prep-HPLC (5 μ M C18 column, 0.1% TFA in H)2O solution, 0.1% TFA in ACN, 5% -95% 0.1% TFA in ACN) to give compound 1 as a white solid (30.7mg, 21.7% yield).1H NMR(DMSO-d6,400MHz)δ:10.70(s,1H),7.49-7.45(m,3H),7.35-7.31(m,4H),5.24-5.21(m,3H),4.47(s,2H),3.57(s,4H),3.47(s,2H),3.08(t,J=11.2Hz,1H),2.59-2.54(m,1H),2.35(s,5H),2.12-1.97(m,2H),1.86-1.74(m,1H).MS(ESI)m/z464.1[M+H]+.
Example 2
Compound 2: (S) -3- (4- ((4- ((2, 3-dihydro-4H-benzo [ b)][1,4]Oxazin-4-yl) methyl) benzyl) oxy
1-oxoisoindolin-2-yl) azepane-2, 7-dione
To a solution of compound 1.5(90mg,0.229mmol) in AcOH (4mL) at RT was added 3, 4-dihydro-2H-benzo [ b ] b][1,4]Oxazine (46.5mg,0.344mmol), followed by addition of NaBH (OAc)3(145.6mg,0.687 mmol). The mixture was stirred at RT for 3h, the solvent was removed, and the residue was purified by prep-TLC with EtOAc/petroleum ether (1:2) and then further purified by prep-HPLC as described previously to give compound 2 as a white solid (45.0mg, 39% yield).1H NMR(DMSO-d6,400MHz)δ:10.69(s,1H),7.49-7.45(m,3H),7.35-7.31(m,4H),6.70-6.63(m,3H),6.51(t,J=7.2Hz,1H),5.23-5.19(m,3H),4.47(d,J=8.8Hz,4H),4.21(t,J=3.6Hz,2H),3.39-3.35(m,2H),3.06(t,J=13.2Hz,1H),2.57(d,J=18.0Hz,1H),2.36-2.29(m,1H),2.09-1.99(m,2H),1.85-1.74(m,1H).MS(ESI)m/z 512.2[M+H]+.
Example 3
Compound 3: ((S) -3- (4- ((3-chloro-4- (morpholinylmethyl) benzyl) oxy) -1-oxoisoindoline-2-)
Yl) azepane-2, 7-dione
To a solution of methyl 3-chloro-4-formylbenzoate (500mg,2.52mmol) in methanol (10mL) at RT was added 2, 2-dimethoxypropane (393.6mg,3.78mmol) followed by p-TsOH (48mg,0.252 mmol). The mixture was refluxed for 16h, the solvent was removed, and the residue was diluted with EtOAc (10mL) and saturated NaHCO3Washing with aqueous solution over Na2SO4Dried, filtered and concentrated to give methyl 3-chloro-4- (dimethoxymethyl) benzoate as a yellow oil (540mg, 87.8% yield).1HNMR(DMSO-d6,300MHz)δ7.94(s,2H),7.71(d,J=8.4Hz,1H),5.60(s,1H),3.87(s,3H),3.31(d,J=0.9Hz,6H).
To a solution of methyl 3-chloro-4- (dimethoxymethyl) benzoate (480mg,2.05mmol) in THF (20mL) at 0 deg.C was added LiAlH4(3.074mL,1M in THF). The suspension was stirred at RT for 2 h. Water (1mL) was added slowly to the reaction, followed by 10% NaOH (2mL), and then water (1 mL). The suspension was filtered and the filtrate was extracted with EtOAc. The combined organic layers were washed with Na2SO4Dried, filtered and concentrated to give crude (3-chloro-4- (dimethoxymethyl) phenyl) methanol 3.1(380mg) as a yellow oil, which was used directly in the next step without further purification.1H NMR(CDCl3,300MHz)δ7.60(d,J=8.1Hz,1H),7.39(s,1H),7.26(d,J=7.2Hz,1H),5.63(s,1H),4.67(s,2H),3.38(d,J=0.9Hz,6H).
To compound 3.1(264mg,1.22mmol) in THF (15mL) at 0 deg.C) To the solution was added compound 3.2(260mg,1.0mmol) followed by PPh3(524.6mg,2.0 mmol). A solution of DEAD (348.3mg,2.0mmol) in THF (1mL) was added dropwise and the suspension was stirred at RT for 16 h. The solvent was removed and the residue was purified by silica gel chromatography with EtOAc/petroleum ether (40% to 100%) to give compound 3.3 as a white solid (262mg, 39% yield). MS (ESI) M/z427.1[ M-31 ]]+.
To a solution of compound 3.3(262mg,0.572mmol) in THF (10mL) at RT was added 4M HCl (0.72 mL). The reaction was stirred at RT for 1 hour. The solvent was removed and the residue was dried under vacuum to give compound 3.4 as a white solid (235.7mg, 100% yield). MS (ESI) M/z 413.0[ M +1 ]]+.
To a solution of compound 3.4(235.7mg,0.572mmol) in fluorobenzene/DMSO (30mL/5mL, DMSO with 1 drop of water) was added Dess-Martin reagent (607mg,1.43 mmol). The suspension was heated at 80 ℃ for 18h and then cooled to RT. Additional Dess-Martin reagent (303mg) was added and the mixture was heated at 80 ℃ for 5h and then cooled to RT. The suspension was filtered and the filtrate was added to saturated Na2S2O3Aqueous solution (30 mL). The suspension was stirred at 0 ℃ for 5min and then extracted with DCM. Work-up and purification by silica gel chromatography using EtOAc/petroleum ether (20% to 80%) afforded compound 3.5(72mg, 30% yield) as a white solid. MS (ESI) M/z 427.0[ M +1 ]]+.
To a solution of compound 3.5(54mg,0.127mmol) in DCM (5mL) at RT was added morpholine (22.1mg,0.254mmol) followed by NaBH (OAc)3(80.8mg,0.38 mmol). The mixture was stirred at RT for 24 h. The solvent was removed and the residue was purified by preparative TLC using EtOAc/petroleum ether (2:1) and then by preparative HPLC as described previously to give compound 3 as a white solid (19.9mg, 32% yield).1H NMR(DMSO-d6,400MHz)δ:10.70(s,1H),7.57(s,1H),7.53-7.45(m,3H),7.33(t,J=6.8Hz,2H),5.27(s,2H),5.20(d,J=5.2Hz,1H),4.49(s,2H),3.59-3.56(m,6H),3.11-3.03(m,1H),2.58(d,J=17.2Hz,1H),2.42(s,4H),2.38-2.33(m,1H),2.14-1.99(m,2H),1.86-1.76(m,1H).MS(ESI)m/z 498.1[M+H]+.
Example 4
Compound 4: (S) -3- (4- { [ p- (4-piperidinyl) phenyl]Methoxy } -2-isoindolinyl) -2, 7-aza
Cycloheptanediones
To a solution of ethyl 4-iodobenzoate (750mg,2.72mmol), 4- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -5, 6-dihydropyridine-1 (2H) -carboxylic acid tert-butyl ester (923mg,2.99mmol) in DMF (50mL) at RT was added [1,1' -bis (diphenylphosphino) ferrocene]Palladium (II) dichloride (400mg) and K2CO3(1.12g,8.16 mmol). The suspension was stirred at 85 ℃ for 16 hours. The mixture was filtered through a pad of celite. The filtrate was diluted with water and extracted with EtOAc. Work-up and purification with Petroleum ether/EtOAc (8: 1) afforded 4-tert-butyl-4 '-ethyl-1, 2,3, 6-tetrahydro- [1,1' -biphenyl]4,4' -dicarboxylic acid ester (720mg, 80% yield) as a white solid.
To a solution of 4-tert-butyl 4' - ethyl 1,2,3, 6-tetrahydro- [1,1' -biphenyl ] -4,4' -dicarboxylate (720mg,2.18mmol) in EtOH (20mL) at RT was added palladium on charcoal (80 mg). The mixture was stirred at RT for 3 hours. The mixture was filtered through a pad of celite and the filtrate was concentrated to give the crude product which was purified by silica gel chromatography eluting with petroleum ether/EtOAc (7: 1) to give ethyl 4- (4- (tert-butoxycarbonyl) cyclohexyl) benzoate (680mg, 93% yield) as a colorless oil.
LAH (1.0M in THF, 1.63mL,4.08mmol) was added dropwise to a solution of ethyl 4- (4- (tert-butoxycarbonyl) cyclohexyl) benzoate (680mg,2.04mmol) in THF (15mL) at 0 deg.C. The mixture was stirred at RT for 2 hours. With Na2SO4The reaction was quenched with decahydrate (5.0 g). After stirring at RT for 1 hour, the mixture was filtered, concentrated and purified by silica gel chromatography eluting with MeOH/DCM (3%) to give tert-butyl 4- (4- (hydroxymethyl) phenyl) piperidine-1-carboxylate (410mg, 69% yield) as a white solid.
To tert-butyl 4- (4- (hydroxymethyl) phenyl) piperidine-1-carboxylate (186mg,0.64mmol), (S) -4-hydroxy-2- (2-oxoazepane at 0 deg.CTo a solution of alk-3-yl) isoindolin-1-one (200mg,0.51mmol) and triphenylphosphine (524mg,1.024mmol) in THF (10mL) was added DEAD (178mg,1.024mmol) dropwise. The mixture was stirred at RT for 16H, then concentrated to give the crude product, which was purified by preparative-HPLC (5 μ M C18 column, H with 0.1% TFA)2O solution, 0.1% TFA in ACN, 5% -95% 0.1% TFA in ACN) to afford tert-butyl (S) -4- (4- (((1-oxo-2- (2-oxoazepan-3-yl) isoindolin-4-yl) oxy) methyl) phenyl) piperidine-1-carboxylate (200mg, 56% yield) as a white solid. MS (ESI) M/z 478.1[ M + H-tBu]+.
To a solution of tert-butyl (S) -4- (4- (((1-oxo-2- (2-oxoazepan-3-yl) isoindolin-4-yl) oxy) methyl) phenyl) piperidine-1-carboxylate (200mg,0.375mmol) in fluorobenzene/DMSO (10mL/1mL, DMSO containing 1 drop of water) at RT was added Dess-Martin reagent (397mg,0.94 mmol). The mixture was heated to 80 ℃ for 18 hours. The mixture was then cooled to 0 ℃ and quenched with saturated aqueous sodium thiosulfate (25 mL). After stirring at 0 ℃ for 15min, the mixture was extracted with DCM. Work-up and purification with EtOAc/petroleum ether (20% to 80%) afforded (S) -tert-butyl 4- (4- (((2- (2, 7-dioxoazepan-3-yl) -1-oxoisoindolin-4-yl) oxy) methyl) phenyl) piperidine-1-carboxylate (32mg, 15% yield) as a white solid.
To a solution of tert-butyl (S) -4- (4- (((2- (2, 7-dioxoazepan-3-yl) -1-oxoisoindolin-4-yl) oxy) methyl) phenyl) piperidine-1-carboxylate (110mg,0.2mmol) in DCM (4mL) was added TFA (1 mL). The mixture was stirred at RT for 2h, then saturated NaHCO was added3The solution was brought to pH 7 and the mixture was extracted with DCM. The combined organic phases were passed over anhydrous Na2SO4Drying, filtration and concentration gave the crude product, which was purified by prep-HPLC as previously described to give compound 4 as a white solid (2.5mg, 6.2% yield).1H NMR(DMSO-d6,400MHz)δ:10.71(s,1H),8.64(s,1H),8.40(s,1H),7.49(m,3H),7.31(m,4H),5.23(m,3H),3.12(s,2H),2.85(m,2H),2.55(m,3H),2.32(m,1H),2.12(m,4H),2.07(m,3H).MS(ESI)m/z 448.0[M+H]+.
Example 5
Compound 5: (S) -3- (4- { [ p- (aminomethyl) phenyl]Methoxy } -2-isoindolinyl) -2, 7-aza
Cycloheptanedione trifluoroacetic acid
To a solution of tert-butyl (3- (4- ((4- ((3- (N- (tert-butyl) sulfamoyl) phenyl) amino) -5-methylpyrimidin-2-yl) amino) phenoxy) propyl) carbamate (120mg,0.205mmol) in DCM (8mL) at RT was added TFA (2 mL). The mixture was stirred for 2 hours. The solvent was evaporated to give 3- ((2- ((4- (3-aminopropoxy) phenyl) amino) -5-methylpyrimidin-4-yl) amino) -N- (tert-butyl) benzenesulfonamide (102mg, crude) which was used directly in the next step without further purification. MS (ESI) M/z 485.1[ M + H ]]+.
To a solution of (S) -4-hydroxy-2- (2-oxoazepan-3-yl) isoindolin-1-one (700mg,2.69mmol), tert-butyl 4- (hydroxymethyl) benzylcarbamate (804mg,3.37mmol) and triphenylphosphine (1.41g,5.38mmol) in THF (10mL) at RT was added a solution of DEAD (938.7mg,5.38mmol) in THF (1 mL). The mixture was stirred at RT for 16 h. The solvent was evaporated and the residue was purified by silica gel chromatography, eluting with MeOH/DCM (0% to 7%) to give tert-butyl (S) -4- (((1-oxo-2- (2-oxoazepan-3-yl) isoindolin-4-yl) oxy) methyl) benzylcarbamate (674mg, 52% yield) as a white solid. MS (ESI) M/z 480.2[ M + H ]]+.
To tert-butyl (S) -4- (((1-oxo-2- (2-oxoazepan-3-yl) isoindolin-4-yl) oxy) methyl) benzylcarbamate (674mg,1.41mmol) at RT was added fluorobenzene/DMSO (30mL/5mL, containing 1 drop of H2O in DMSO) was added Dess-Martin reagent (1.49g,3.52 mmol). The mixture was stirred at 80 ℃ for 16 hours. The mixture was cooled to RT and filtered. The filtrate was added to a cooled saturated aqueous solution of sodium thiosulfate (30mL), stirred at 0 ℃ for 5min, and then extracted with DCM. Workup and purification using 40% to 100% EtOAc/petroleum ether afforded (S) -4- (((2- (2, 7-dioxoazepan-3-yl) -1-oxoisoindolin-4-yl) oxy) methyl) benzylamino-methylTert-butyl ester (320mg, 46% yield) as a white solid. MS (ESI) M/z 494.2[ M + H ]]+.
To a solution of tert-butyl (S) -4- (((2- (2, 7-dioxoazepan-3-yl) -1-oxoisoindolin-4-yl) oxy) methyl) benzylcarbamate (22mg,0.0446mmol) in DCM (2mL) at RT was added TFA (0.5mL). The mixture was stirred at RT for 2 hours. Evaporation of the solvent afforded the desired product, which was lyophilized to afford compound 5 as a white solid (17.6mg, 78% yield). MS (ESI) M/z 394.1[ M +1 ]]+.1H NMR(400MHz,DMSO-d6)δ10.71(s,1H),8.18(s,1H),7.55(d,J=7.6Hz,2H),7.48-7.45(m,3H),7.33-7.30(m,2H),5.30(s,2H),5.23(dd,J=4.8,12.4Hz,1H),4.48(s,2H),4.05(d,J=5.2Hz,2H),3.11-3.05(m,1H),2.60-2.53(m,1H),2.34-2.31(m,1H),2.11-1.99(m,2H),1.85-1.80(m,1H).
Example 6
Compound 6: (S) -3- (4- { [ p- ({2- [3- (p- { 5-methyl-4- [ m- (tert-butylaminosulfonyl) phenyl)
Amino group]-2-pyrimidinylamino } phenoxy) propylamino]Acetylamino } methyl) phenyl]Methoxy } -2-isoindolinoyl
2, 7-azacycloheptanediones
To a solution of (S) -3- (4- ((4- (aminomethyl) benzyl) oxy) -1-oxoisoindolin-2-yl) azepan-2, 7-dione (112mg,0.284mmol) in DCM (5mL) at RT was added TEA (24.2mg,0.175mmol) followed by 2-bromoacetyl chloride (45mg,0.284 mmol). The mixture was stirred for 1 hour. The solvent was evaporated and the residue was purified by silica gel chromatography, eluting with EtOAc/petroleum ether (20% to 100%) to give (S) -2-bromo-N- (4- (((2- (2, 7-dioxoazepan-3-yl) -1-oxoisoindolin-4-yl) oxy) methyl) benzyl) acetamide as a white solid. MS (ESI) M/z 514.1[ M + H ]]+.
To a solution of (S) -2-bromo-N- (4- (((2- (2, 7-dioxoazepan-3-yl) -1-oxoisoindolin-4-yl) oxy) methyl) benzyl) acetamide (45mg,0.0877mmol) in DMF (5mL) at RT was added K2CO3(24.2mg,0.175mmol) followed by 3- (2- ((4- (3-aminopropoxy) phenyl) amino) -5-methylpyrimidin-4-yl) amino) -N- (tert-butyl) benzenesulfonamide (45mg,0.0877 mmol). The mixture was heated at 50 ℃ for 2 hours. The solvent was evaporated and the residue was purified by prep-HPLC as described before to give compound 6 as a white solid (12.6mg, 16% yield). MS (ESI) M/z 917.7[ M + H ]]+.1H NMR(400MHz,DMSO-d6)δ10.71(s,1H),8.77(s,1H),8.53(s,1H),8.12(d,J=8.0Hz,2H),7.89(s,1H),7.55-7.41(m,9H),7.31-7.27(m,4H),6.77(d,J=8.8Hz,2H),5.23-5.18(m,3H),4.44(s,2H),4.31(d,J=5.6Hz,2H),3.96(t,J=6.4Hz,2H),3.09-3.01(m,2H),2.74-2.67(m,2H),2.58-2.53(m,2H),2.32-2.26(m,1H),2.11(s,3H),2.04-1.97(m,3H),1.87-1.84(m,3H),1.12(s,9H).
Example 7
Compound 7: (S) -3- (6-fluoro-4- { [ p- (morpholinylmethyl) phenyl]Methoxy } -2-isoindolinyl) -
2, 7-azacycloheptanediones
To a cooled (-15 ℃) solution of 5-fluoro-2-methylbenzoic acid (1.0g,6.5mmol) in sulfuric acid (8mL) was added nitric acid (0.44mL) dropwise at RT. The mixture was stirred for 1 hour, then warmed to 0 ℃ and stirred for 1 hour. The mixture was poured slowly into ice water and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na2SO4Dried, filtered and concentrated to give 5-fluoro-2-methyl-3-nitrobenzoic acid (830mg, crude) which was used in the next step without further purification.
Thionyl chloride (1mL) was added dropwise to a solution of 5-fluoro-2-methyl-3-nitrobenzoic acid (830mg crude) in MeOH (8mL) at 0 deg.C. The mixture was then heated to reflux for 3 hours. The solvent was evaporated to give the crude product which was purified by silica gel chromatography using petroleum ether/EtOAc (100: 1 to 50: 1) to give methyl 5-fluoro-2-methyl-3-nitrobenzoate as a yellow solid (530mg, 59% yield).
To methyl 5-fluoro-2-methyl-3-nitrobenzoate (530mg,2.66mmol) in MeOH (6mL) at RTPd/C (400mg) was added to the solution. At RT in H2The suspension was stirred for 3 hours. The suspension was filtered through a pad of celite and the filtrate was concentrated to give methyl 3-amino-5-fluoro-2-methylbenzoate (420mg, crude) which was used in the next step without further purification.
Sulfuric acid (5mL) was added dropwise to water containing methyl 3-amino-5-fluoro-2-methylbenzoate (420mg,2.28mmol) at 0 deg.C, followed by sodium nitrate (165mg,2.39mmol in 2.5mL of water). After stirring at 0 ℃ for 2.5hr, the mixture was added dropwise to sulfuric acid (50% aqueous) at 100 ℃ and held for 20min, then the mixture was cooled to RT and extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4Dried, filtered and concentrated to give methyl 5-fluoro-3-hydroxy-2-methylbenzoate which was used in the next step without further purification.
To a solution of methyl 5-fluoro-3-hydroxy-2-methylbenzoate (320mg,1.74mmol) in DMF (6mL) at 0 deg.C was added sodium hydride (60%, 84mg,2.1 mmol). The mixture was stirred at this temperature for 15min, then methyl iodide was added. After stirring at 0 ℃ for 15min, the mixture was warmed to RT and stirred for 1 h. The reaction was quenched with water and extracted with tert-butyl methyl ether. The combined organic layers were washed with brine and dried over anhydrous Na2SO4Dried, filtered and concentrated to give methyl 5-fluoro-3-methoxy-2-methylbenzoate (327mg crude) which was used in the next step without further purification.
To a solution of methyl 5-fluoro-3-methoxy-2-methylbenzoate (5.4g,30.8mmol) in carbon tetrachloride (40mL) was added NBS (8.2g,46.3mmol) and 2,2' -azobis (2-methylpropanenitrile) (2.0mg,12.3mmol) at RT. The mixture was refluxed overnight, the solvent was evaporated, and the crude product was purified by silica gel chromatography (petroleum ether/EtOAc, 100: 1 to 20: 1) to give methyl 2- (bromomethyl) -5-fluoro-3-methoxybenzoate as a white solid (4.6g, 59% yield).
To a solution of (S) -3-aminoazepan-2-one (56mg,0.43mmol) and TEA (72mg,0.72mmol in DMF (2mL) was added a solution of methyl 2- (bromomethyl) -5-fluoro-3-methoxybenzoate (100mg,0.36mmol) in DMF (2mL) the mixture was stirred at 50 ℃ for 3hr, concentrated and washed with EtOAc to give (S) -6-fluoro-4-methoxy-2-(2-Oxoazepan-3-yl) isoindolin-1-one (100mg, 95% yield) as a white solid. MS (ESI) M/z 293.0[ M + H ]]+.
To a solution of (S) -6-fluoro-4-methoxy-2- (2-oxoazepan-3-yl) isoindolin-1-one (100mg,0.34mmol) in DCM (6mL) at 0 deg.C was added boron tribromide (515mg,2.05mmol in 2mL DCM). After stirring at this temperature for 15min, the mixture was warmed to RT and stirred for 3 h. The reaction was quenched with water at 0 ℃, concentrated, and purified by silica gel chromatography (DCM/MeOH, 100: 1 to 20: 1) to give (S) -6-fluoro-4-hydroxy-2- (2-oxoazepan-3-yl) isoindolin-1-one (20mg, 21% yield) as a white solid. MS (ESI) M/z 279.0[ M + H ]]+.
To a solution of (S) -6-fluoro-4-hydroxy-2- (2-oxoazepan-3-yl) isoindolin-1-one (250mg,0.90mmol) and (4- (diethoxymethyl) phenyl) MeOH (284mg,1.35mmol), triphenylphosphine (472mg,1.8mmol) in THF (2.5mL) at 0 deg.C was added DEAD (373mg,1.80 mmol). The mixture was stirred for 15min, warmed to RT and stirred for 1hr, the solvent was evaporated and the crude product was purified by silica gel chromatography (DCM/MeOH, 100: 1 to 50: 1) to give (S) -4- ((4- (diethoxymethyl) benzyl) oxy) -6-fluoro-2- (2-oxoazepan-3-yl) isoindolin-1-one (310mg, 73% yield) as a white solid.
To a solution of (S) -4- ((4- (diethoxymethyl) benzyl) oxy) -6-fluoro-2- (2-oxoazepan-3-yl) isoindolin-1-one (120mg,0.303mmol) in fluorobenzene/DMSO (24mL/6mL) was added Dess-Martin periodinane reagent (321.3mg,0.758 mmol). The mixture was stirred at 80 ℃ for 16 hours. After cooling to room temperature, Dess-Martin reagent (160mg) was added. The suspension was heated to 80 ℃ and continued for a further 16 hours. After cooling to RT, the reaction was quenched with saturated aqueous sodium thiosulfate (15mL) and stirred for 5 min. The resulting mixture was extracted with DCM. Work-up and purification with 10% to 69% EtOAc/petroleum ether gave (S) -4- ((2- (2, 7-dioxoazepan-3-yl) -6-fluoro-1-oxoisoindolin-4-yl) oxy) methyl) benzaldehyde (45mg, 36% yield) as a white solid. MS (ESI) M/z 411.1[ M + H ]]+.
To (S) -4- ((2- (2, 7-dioxoazepan-3-yl) at RT) -6-fluoro-1-oxoisoindolin-4-yl) oxy) methyl) benzaldehyde (30mg,0.076mmol) in DCM (4mL) was added morpholine (13mg,0.152mmol) followed by sodium triacetoxyborohydride (32mg,0.152 mmol). The mixture was stirred at RT for 16h, then the solvent was evaporated. The residue was purified by prep-tlc (etoac) to give the crude product, which was purified by prep-HPLC as described previously to give compound 7 as a white solid (5.5mg, 15% yield). MS (ESI) M/z 481.8[ M + H ]]+.1H NMR(400MHz,DMSO-d6)δ10.72(s,1H),7.45(d,J=7.2Hz,2H),7.34(d,J=7.6Hz,2H),7.30(d,J=8.1Hz,1H),7.11(d,J=7.2Hz,1H),5.32-5.19(m,1H),5.24(s,2H),4.44(s,2H),3.57(s,4H),3.47(s,2H),3.21-3.06(m,1H),2.59-2.57(m,1H),2.34(s,5H),2.02-1.96(m,2H),1.82-1.75(m,1H).
Example 8
Compound 8: (S) -3- {4- [ (p-morpholinylcarbonylphenyl) methoxy]-2-isoindolinyl } -2, 7-aza
Cycloheptanediones
To a solution of 4- (hydroxymethyl) benzoic acid (500mg,3.28mmol) in DMF (5mL) was added morpholine (326mg,3.94mmol) followed by HOBt (678.9mg,4.92mmol), EDAC & HCl (944mg,4.92mmol) and DIEA (846.2mg,6.56 mmol). The mixture was stirred at RT for 16 h. The reaction was diluted with water (5mL) and extracted with DCM. Work-up and purification with 30% to 90% EtOAc/petroleum ether afforded (4- (hydroxymethyl) phenyl) (morpholinyl) methanone (520mg, 72% yield) as a colorless oil. MS (ESI) M/z 221.1[ M + H ]]+.
To a solution of (S) -4-hydroxy-2- (2-oxoazepan-3-yl) isoindolin-1-one (100mg,0.385mmol), (4- (hydroxymethyl) phenyl) (morpholinyl) methanone (85mg,1.55mmol), and triphenylphosphine (201mg,0.77mmol) in THF (3mL) at 0 deg.C was added dropwise a solution of DEAD (134mg,0.77mmol) in THF (1 mL). The mixture was stirred at RT for 16 h. The solvent was evaporated and the residue was purified by preparative-TLC (EtOAc) to give (S) -4- ((4- (morpholine-4-carbonyl) benzyl) oxy) -2- (2-oxoazepan-3-yl) isoindoline-1-keto (135mg, 76% yield) as a white solid. MS (ESI) M/z 333.1[ M +1 ]]+.
To (S) -4- ((4- (morpholine-4-carbonyl) benzyl) oxy) -2- (2-oxoazepan-3-yl) isoindolin-1-one (135mg,0.292mmol) in fluorobenzene/DMSO (12mL/2mL, containing 1 drop of H2O in DMSO) was added Dess-Martin periodinane (309.6mg,0.73 mmol). The suspension was stirred at 80 ℃ overnight, cooled to RT, filtered and the filtrate was added to saturated aqueous sodium thiosulfate (10 mL). After stirring at 0 ℃ for 5min, the mixture was extracted with DCM. With 10% sodium thiosulfate/saturated NaHCO3(1:1) washing the combined organic layers with brine, and passing over anhydrous Na2SO4Drying, filtration and concentration gave the crude product, which was purified by prep-tlc (etoac) to give compound 8 as a white solid (52.5mg, 38% yield). MS (ESI) M/z 333.1[ M + H ]]+.1H NMR(400MHz,DMSO-d6)δ10.68(s,1H),7.57(d,J=8.0Hz,2H),7.51-7.44(m,3H),7.33(d,J=8.0Hz,2H),5.31(s,2H),5.23(dd,J=5.2,12.4Hz,1H),4.49(s,2H),3.60(s,6H),3.11-3.03(m,1H),2.60-2.54(m,1H),2.38-2.29(m,1H),2.12-1.98(m,2H),1.86-1.76(m,1H).
Example 9
Compound 9: (S) -3- (4- { [ m- (aminomethyl) phenyl]Methoxy } -2-isoindolinyl) -2, 7-aza
Cycloheptanedione trifluoroacetic acid
To a solution of (S) -4-hydroxy-2- (2-oxoazepan-3-yl) isoindolin-1-one (150mg,0.577mmol), 3- (hydroxymethyl) benzonitrile (154mg,1.15mmol) and triphenylphosphine (378mg,1.44mmol) in THF (3.5mL) at RT was added DEAD (251mg,1.44 mmol). The mixture was stirred for 30 min. The solvent was evaporated and the residue was purified by preparative-TLC (DCM/MeOH, 100: 1 to 30: 1) to give (S) -3- (((1-oxo-2- (2-oxoazepan-3-yl) isoindolin-4-yl) oxy) methyl) benzonitrile (235mg, 81% yield) as a white solid. MS (ESI) M/z376.2[ M + H ]]+.
To (S) -3- (((1-oxo) at RT-2- (2-Oxoazepan-3-yl) isoindolin-4-yl) oxy) methyl) benzonitrile (200mg,0.48mmol) in fluorobenzene/DMSO (15mL/2mL) was added Dess-Martin periodinane (508mg,1.2 mmol). The mixture was heated to 80 ℃ overnight and cooled to RT and 20mL of saturated sodium thiosulfate solution was added and the mixture was extracted with DCM. Work-up afforded the crude product, which was washed with tert-butyl methyl ether to give (S) -3- ((2- (2, 7-dioxoazepan-3-yl) -1-oxoisoindolin-4-yl) oxy) methyl) benzonitrile (120mg, 58% yield) as a white solid. MS (ESI) M/z 390.1[ M + H ]]+.
To a solution of (S) -3- ((2- (2, 7-dioxoazepan-3-yl) -1-oxoisoindolin-4-yl) oxy) methyl) benzonitrile (130mg,0.334mmol) in THF (8mL) at RT was added di-tert-butyl dicarbonate (146mg,0.668mmol) and Raney Ni (60 mg). Degassing and using H2After purging, the mixture was stirred at RT overnight. The suspension was filtered through a pad of celite. The filtrate was concentrated and purified by preparative-TLC (EtOAc) to give tert-butyl (S) -3- (((2- (2, 7-dioxoazepan-3-yl) -1-oxoisoindolin-4-yl) oxy) methyl) benzylcarbamate as a white solid (150mg, 59%)
To a solution of tert-butyl (S) -3- (((2- (2, 7-dioxoazepan-3-yl) -1-oxoisoindolin-4-yl) oxy) methyl) benzylcarbamate (75mg,0.152mmol) in DCM (2mL) at RT was added TFA (1 mL). The mixture was stirred at RT for 30 min. The solvent was evaporated and the residue was lyophilized to give compound 9 as a white solid (40mg, 66% yield). MS (ESI) M/z 394.2[ M + H ]]+.1H NMR(400MHz,DMSO-d6)δ10.73(s,1H),8.18(s,3H),7.58-7.43(m,5H),7.34(d,J=7.2Hz,2H),5.28-5.23(m,3H),4.80(m,2H),4.10-4.07(m,2H),3.08-3.06(m,1H),2.60-2.55(m,1H),2.32-2.29(m,1H),2.12-1.99(m,2H),1.80-1.77(m,1H).
Example 10
Compound 10: (S) -3- (4- { [ m- (morpholinomethyl) phenyl]Methoxy } -2-isoindolinyl) -2,7-
Azepane diones
To a solution of (S) -4-hydroxy-2- (2-oxoazepan-3-yl) isoindolin-1-one (160mg,0.615mmol), 1, 3-phenylenedimethanol (170mg,1.23mmol), and triphenylphosphine (402mg,1.538mmol) in THF (8mL) at RT was added DEAD (268mg,1.53 mmol). The mixture was stirred at RT for 30 min. The solvent was evaporated and the residue was purified by preparative-TLC (DCM/MeOH, 100: 1 to 30: 1) to give (S) -4- ((3- (hydroxymethyl) benzyl) oxy) -2- (2-oxoazepan-3-yl) isoindolin-1-one (156mg, 59% yield) as a white solid. MS (ESI) M/z 381.2[ M + H ]]+.
To a solution of (S) -4- ((3- (hydroxymethyl) benzyl) oxy) -2- (2-oxoazepan-3-yl) isoindolin-1-one (138mg,0.363mmol) in fluorobenzene/DMSO (4mL/1mL) at RT was added Dess-Martin periodinane (462mg,1.09 mmol). After stirring at 80 ℃ overnight, the mixture was cooled to RT and then 20mL of saturated sodium thiosulfate solution was added and the mixture was extracted with DCM. Work-up provided the crude product which was washed with tert-butyl methyl ether to give (S) -3- (((2- (2, 7-dioxoazepan-3-yl) -1-oxoisoindolin-4-yl) oxy) methyl) benzaldehyde (85mg, 60% yield) as a white solid. MS (ESI) M/z391.2[ M + H ]]+.
To a solution of (S) -3- ((2- (2, 7-dioxoazepan-3-yl) -1-oxoisoindolin-4-yl) oxy) methyl) benzaldehyde (80mg,0.204mmol) and morpholine (36mg,0.408mmol) in DCM (4mL) at RT was added NaBH (OAc)3(87mg,0.408 mmol). The mixture was stirred overnight. The solvent was evaporated and the residue was purified by preparative-TLC using DCM/MeOH (10: 1) to give compound 10 as a white solid (30.5mg, 32% yield). MS (ESI) M/z464.2[ M + H ]]+.1H NMR(400MHz,DMSO-d6)δ10.73(s,1H),7.49-7.27(m,7H),5.27-5.22(m,3H),4.47(s,2H),3.56(s,4H),3.48(s,2H),3.12-3.05(m,1H),2.58(d,J=16.8Hz,1H),2.34(s,5H),2.12-2.06(m,1H),2.04-1.99(m,1H),1.82-1.7 8(m,1H).
Example 11
Compound 11: (S) -3- (4- { [ p- (morpholinomethyl) phenyl]Methoxy } -3-oxo-2H-isoindole-2-yl
2, 7-azacycloheptanediones
To a solution of 3-methoxyphthalic acid (3.0g,15.306mmol) in THF (24mL) was added acetic anhydride (10mL) at RT. The mixture was stirred at 80 ℃ for 3 hours. Evaporation of the solvent gave 4-methoxyisobenzofuran-1, 3-dione (2.72g, quantitative yield) as a white solid. MS (ESI) M/z 178.9[ M + H ]]+.
To a solution of (S) -3-aminoazepan-2-one (1.96g,15.28mmol) in AcOH/ACN (28mL/20mL) at RT was added 4-methoxyisobenzofuran-1, 3-dione (2.71g,15.28 mmol). The mixture was stirred at 85 ℃ overnight and then cooled to RT. Sodium acetate (3.13g,38.20mmol) was added followed by AcOH (12 mL). The mixture was stirred at 85 ℃ overnight. The solvent was evaporated, then the residue was diluted with water (30mL) and stirred at RT for 30 min. The resulting suspension was filtered and the filter cake was washed with EtOAc to give (S) -4-methoxy-2- (2-oxoazepan-3-yl) isoindoline-1, 3-dione (2.154g, 49% yield) as a white solid. MS (ESI) M/z 289.1[ M + H ]]+.
To a solution of (S) -4-methoxy-2- (2-oxoazepan-3-yl) isoindoline-1, 3-dione (2.1g,7.292mmol) in DCM (40mL) at 0 deg.C is added tribromoborane (3.4mL) in DCM (10mL) dropwise. After stirring at RT for 3h, the mixture was diluted with ice water and extracted with DCM. The combined organic layers were washed with brine, over anhydrous Na2SO4Drying, filtration and concentration gave the crude product, which was washed with EtOAc to give (S) -4-hydroxy-2- (2-oxoazepan-3-yl) isoindoline-1, 3-dione (1g, 50% yield) as a pale yellow solid. MS (ESI) M/z 275.0[ M + H ]]+.
To a solution of (S) -4-hydroxy-2- (2-oxoazepan-3-yl) isoindoline-1, 3-dione (300mg,1.095mmol), 1, 4-phenylenedimethanol (272mg,1.971mmol), and triphenylphosphine (574mg,2.190mmol) in THF (5mL) at 0 deg.C was added DEAD (381mg,2.19 mmol). The mixture was stirred at RT overnight. The solvent was evaporated and the crude product was purified by silica gel chromatography using EtOAc/petroleum ether (20% to 96%) to afford(S) -4- ((4- (hydroxymethyl) benzyl) oxy) -2- (2-oxoazepan-3-yl) isoindoline-1, 3-dione (168mg, 39% yield) as a white solid. MS (ESI) M/z 395.1[ M + H ]]+.
To a solution of (S) -4- ((4- (hydroxymethyl) benzyl) oxy) -2- (2-oxoazepan-3-yl) isoindoline-1, 3-dione (140mg,0.355mmol) in 1, 2-dichloroethane/DMSO (12mL/2mL) at RT was added Dess-Martin reagent (753mg,1.775 mmol). The mixture was stirred at 80 ℃ overnight. The mixture was cooled to RT and filtered, and the filtrate was quenched with saturated sodium thiosulfate solution (15 mL). After stirring for 10min, the mixture was extracted with DCM. Work-up and purification using 20% to 96% EtOAc/petroleum ether gave (S) -4- ((2- (2, 7-dioxoazepan-3-yl) -1, 3-dioxoisoindolin-4-yl) oxy) methyl) benzaldehyde (95mg, 54% yield) as a yellow solid.
To a solution of (S) -4- ((2- (2, 7-dioxoazepan-3-yl) -1, 3-dioxoisoindolin-4-yl) oxy) methyl) benzaldehyde (75mg,0.1847mmol) in DCM (3mL) was added morpholine (32mg,0.3694mmol) and sodium triacetoxyborohydride (78mg,0.3694mmol) at RT and the mixture was stirred overnight. The solvent was evaporated and the crude product was purified by prep-TLC using DCM/MeOH (10: 1) to give compound 11 as a white solid (42mg, 48% yield). MS (ESI) M/z 477.8[ M + H ]]+.1H NMR(DMSO-d6,400MHz)δ:10.84(s,1H),7.82-7.35(m,7H),5.35(s,2H),5.19-5.15(m,1H),3.60-3.50(m,4H),3.50-3.40(m,2H),3.14-3.07(m,1H),2.70-2.60(m,1H),2.35(s,4H),2.19-1.87(m,4H).
Example 12
Compound 12: (S) -3- (4- { [ p- (morpholinomethyl) phenyl]Methoxy } -2-isoindolinyl) -2,5-
Pyrrolidinediones
To a stirred solution of (S) -4-amino-2- ((tert-butoxycarbonyl) amino) -4-oxobutanoic acid (2.0g,8.6mmol) in THF (10mL) and MeOH (10mL) at 0 deg.C was added dropwise a solution of (trimethylsilyl) diazomethane (2M in hexane, 6.5 mL). The mixture was stirred at 0 ℃ for 1 hour, then concentrated to give methyl (S) -4-amino-2- ((tert-butoxycarbonyl) amino) -4-oxobutanoate (crude) as a colorless oil.
To a stirred solution of methyl (S) -4-amino-2- ((tert-butoxycarbonyl) amino) -4-oxobutanoate (8.6mmol) in DCM (6mL) at RT was added TFA (3 mL). After stirring overnight, the mixture was concentrated to give methyl (S) -2, 4-diamino-4-oxobutanoate which was used directly in the next step.
To a solution of methyl (S) -2, 4-diamino-4-oxobutanoate (8.6mmol) and methyl 2- (bromomethyl) -3-methoxybenzoate (2.2g,8.6mmol) in DMF (20mL) was added TEA (3.6 mL). After stirring at 50 ℃ for 5h, the mixture was diluted with water and extracted with EtOAc. Work-up and purification using EtOAc/petroleum ether (20% to 80%) afforded (S) -methyl 4-amino-2- (4-methoxy-1-oxoisoindolin-2-yl) -4-oxobutanoate as a yellow solid (1.2g, 48% yield). MS (ESI) M/z 293.0[ M + H ]]+.
Boron tribromide (2.3mL) was added dropwise to a solution of methyl (S) -4-amino-2- (4-methoxy-1-oxoisoindolin-2-yl) -4-oxobutanoate (1.2g,4.1mmol) in DCM (12mL) at 0 deg.C. The mixture was stirred at RT for 2 hours and quenched with water and MeOH. The solvent was evaporated and the residue was purified by silica gel chromatography (DCM/MeOH, 20: 1) to give (S) -4-amino-2- (4-hydroxy-1-oxoisoindolin-2-yl) -4-oxobutanoic acid (3g, crude) as a yellow solid. MS (ESI) M/z 265.0[ M + H ]]+.
To a solution of (S) -4-amino-2- (4-hydroxy-1-oxoisoindolin-2-yl) -4-oxobutanoic acid (3g of crude) in THF (15mL) and MeOH (15mL) at 0 deg.C was added dropwise a solution of (trimethylsilyl) diazomethane (2M in hexane, 6.8 mL). The mixture was stirred at 0 ℃ for 1.5h and concentrated. The residue was purified by silica gel chromatography (DCM/MeOH, 10: 1) to give methyl (S) -4-amino-2- (4-hydroxy-1-oxoisoindolin-2-yl) -4-oxobutanoate (470mg, 43% yield) as a white solid. MS (ESI) M/z 279.0[ M + H ]]+.
To methyl (S) -4-amino-2- (4-hydroxy-1-oxoisoindolin-2-yl) -4-oxobutanoate (300mg,1.08mmol), (4- (morpholinylmethyl) phenyl) methanol (335mg, 1) at 0 ℃.62mmol) and triphenylphosphine (567mg,2.16mmol) in THF (8mL) DEAD (376mg,2.16mmol) was added and the mixture was stirred at RT overnight. The solvent was evaporated and the residue was purified by preparative-TLC (DCM/MeOH, 10: 1) to give methyl (S) -4-amino-2- (4- (4- (morpholinylmethyl) benzyl) oxy) -1-oxoisoindolin-2-yl) -4-oxobutanoate (150mg, 30% yield) as a white solid. MS (ESI) M/z 468.1[ M + H ]]+.
To a solution of methyl (S) -4-amino-2- (4- ((4- (morpholinylmethyl) benzyl) oxy) -1-oxoisoindolin-2-yl) -4-oxobutanoate (100mg,0.21mmol) in THF (6mL) at RT was added lithium hydroxide (11mg,0.42 mmol). The mixture was stirred for 3 hours, then diluted with water and adjusted to pH 3 with 1N HCl. Work-up and purification using preparative-TLC (DCM/MeOH, 10: 1) gave compound 12 as a yellow solid (13mg, 14% yield). MS (ESI) M/z 453.9[ M + H ]]+.1H NMR(400MHz,DMSO-d6)δ11.49(brs,1H),7.51-7.44(m,3H),7.34-7.30(m,4H),5.27(t,J=8.0Hz,1H),5.23(s,2H),4.61(d,J=17.2Hz,1H),4.27(d,J=17.2Hz,1H),3.57(t,J=4.0Hz,4H),3.46(s,2H),2.94(d,J=7.6Hz,2H),2.34(s,4H).
Example 13
Compound 13: (S) -3- (4- { [ p- ({3- [3- (p- { 5-methyl-4- [ m- (tert-butylaminosulfonyl) benzene)
Radical amino]-2-pyrimidinylamino } phenoxy) propyl]Ureido } methyl) phenyl]Methoxy } -2-isoindolinyl) -2,7-
Azepane diones
To a solution of tert-butyl 3- (4- ((4- ((3- (N- (tert-butyl) sulfamoyl) phenyl) amino) -5-methylpyrimidin-2-yl) amino) phenoxy) propyl) carbamate (100mg,0.171mmol) in anhydrous DCM (8mL) at 0 ℃ was added TFA (2 mL). The reaction was stirred at RT for 16 h. The solvent was evaporated and the residue dried to give amine TFA salt (100mg, crude). The amine TFA salt was dissolved in THF (5mL) and TEA (34.5mg,0.342mmol) was added at RT followed by 4-nitrobenzyl chloroformate (34.2mg,0.171 mmol). The mixture was stirred for 1 hour. Evaporation ofSolvent to give 4-nitrophenyl 3- (4- ((4- ((3- (N- (tert-butyl) sulfamoyl) phenyl) amino) -5-methylpyrimidin-2-yl) amino) phenoxy) propyl) carbamate (30mg, crude) which was used directly in the next step. MS (ESI) M/z 650.2[ M + H ]]+.
To a solution of tert-butyl (S) -4- ((2- (2, 7-dioxoazepan-3-yl) -1-oxoisoindolin-4-yl) oxy) methyl) benzylcarbamate (23mg,0.046mmol) in DCM (4mL) at RT was added TFA (1 mL). The solvent was evaporated and the residue dried to give amine TFA salt (30mg, crude) as a yellow gum. The amine TFA salt was dissolved in THF (5mL) and TEA (10mg,0.092mmol) was added at RT followed by a suspension of 4-nitrophenyl (3- (4- ((4- ((3- (N- (tert-butyl) sulfamoyl) phenyl) amino) -5-methylpyrimidin-2-yl) amino) phenoxy) propyl) carbamate (30mg,0.046mmol) in THF (1 mL). The reaction was stirred at 60 ℃ for 3 hours. The solvent was evaporated and the residue was purified by silica gel chromatography, eluting with MeOH/DCM (0% to 9%) to give compound 13 as a white solid (22.3mg, 53% yield). MS (ESI) M/z903.7[ M + H ]]+.1H NMR(400MHz,DMSO-d6)δ10.72(s,1H),8.82(s,1H),8.57(s,1H),8.15-8.12(m,2H),7.89(s,1H),7.59(s,1H),7.54-7.41(m,7H),7.31-7.25(m,4H),6.79(d,J=8.8Hz,2H),6.37(t,J=6.0Hz,1H),6.06(t,J=5.2Hz,1H),5.23-5.19(m,3H),4.45(s,2H),4.21(d,J=6.4Hz,2H),3.91(t,J=5.6Hz,2H),3.19-3.15(m,2H),3.09-3.02(m,1H),2.58-2.54(m,1H),2.35-2.31(m,1H),2.11(s,3H),2.04-1.97(m,1H),1.82-1.78(m,3H),1.12(s,9H).
Example 14
Compound 14: (S) -3- (4- { [ p- (morpholinomethyl) phenoxy]Methyl } -2-isoindolinyl) -2,7-
Azepane diones
To a solution of (S) -1-oxo-2- (2-oxoazepan-3-yl) isoindoline-4-carbaldehyde (910mg,3.35mmol) in THF (25mL) at RT was added sodium borohydride (254mg,6.70 mmol). The mixture was stirred for 2 hours. The reaction was concentrated to give the crude product which was passed through silica gelPurification by chromatography eluting with MeOH/DCM (1: 10) gave (S) -4- (hydroxymethyl) -2- (2-oxoazepan-3-yl) isoindolin-1-one (539mg, 59% yield) as a white solid. MS (ESI) M/z 275.1[ M + H ]]+.
To a solution of (S) -4- (hydroxymethyl) -2- (2-oxoazepan-3-yl) isoindolin-1-one (539mg,1.97mmol), 4-hydroxybenzaldehyde (288mg,2.36mmol) and triphenylphosphine (1.03g,3.93mmol) in THF (30mL) at 0 deg.C was added DEAD (685mg,3.93 mmol). The mixture was stirred for 15min, then warmed to RT and stirred overnight. The solvent was evaporated to give the crude product, which was purified by silica gel chromatography eluting with MeOH/DCM (0% to 5%) to give (S) -4- ((1-oxo-2- (2-oxoazepan-3-yl) isoindolin-4-yl) methoxy) benzaldehyde (520mg, 70% yield) as a white solid. MS (ESI) M/z 379.1[ M + H ]]+.
To a solution of (S) -4- ((1-oxo-2- (2-oxoazepan-3-yl) isoindolin-4-yl) methoxy) benzaldehyde (520mg,1.38mmol) in fluorobenzene/DMSO (24mL/4mL, DMSO with 1 drop of water) was added Dess-Martin reagent (1.46g,3.44 mmol). The suspension was heated at 80 ℃ for 18 hours. The suspension was cooled to RT and then added to saturated aqueous sodium thiosulfate (20mL) at 0 ℃ and stirred for 5min before being extracted with DCM. Work-up and purification using 20% to 96% EtOAc/petroleum ether gave (S) -4- ((2- (2, 7-dioxoazepan-3-yl) -1-oxoisoindolin-4-yl) methoxy) benzaldehyde (174.2mg, 32% yield) as a white solid. MS (ESI) M/z 393.1[ M + H ]]+.
To a solution of (S) -4- ((2- (2, 7-dioxoazepan-3-yl) -1-oxoisoindolin-4-yl) methoxy) benzaldehyde (100mg,0.255mmol) in THF (5mL) at RT was added morpholine (88mg,1.02mmol) followed by sodium cyanoborohydride (64mg,1.02 mmol). The mixture was stirred for 2 hours. The solvent was evaporated and the residue was purified by prep-HPLC as described before to give compound 14 as a white solid (22.1mg, 19% yield). MS (ESI) M/z 498.1[ M + H ]]+.1H NMR(DMSO-d6,400MHz)δ:10.76(s,1H),7.73-7.71(m,2H),7.55(t,J=7.6Hz,1H),7.23(d,J=8.4Hz,2H),7.01(d,J=8.4Hz,2H),5.25(s,2H),4.63(s,2H),3.55(s,4H),3.36(s,2H),3.13-3.06(m,1H),2.59-2.55(m,1H),2.32(s,4H),2.17-1.97(m,3H),1.86-1.76(m,1H).
Example 15
Compound 15: (S) -3- (5- { [ p- (morpholinomethyl) phenyl]Methoxy } -2-isoindolinyl) -2,7-
Azepane diones
NBS (10g,55.57mmol) and 2,2' -azobis (2-methylpropanenitrile) (4.0mg,9.43mmol) were added to a solution of methyl 4-methoxy-2-methylbenzoate (10g,55.56mmol) in carbon tetrachloride (150mL) at RT. The mixture was stirred at reflux for 6 hours. The solvent was evaporated to give the crude product which was purified by silica gel chromatography (EtOAc/petroleum ether, 1:20 to 1:5) to give methyl 2- (bromomethyl) -4-methoxybenzoate (13.6g, 94% yield) as a white solid.
To a solution of (S) -3-aminoazepan-2-one (1.6g,12.4mmol) in DMF (16mL) at RT was added TEA (2.9mL,20.6mmol) and methyl 2- (bromomethyl) -4-methoxybenzoate (2.7g,10.3mmol) in 4mL DMF. The mixture was stirred at 85 ℃ overnight. The solvent was evaporated and the crude product was purified by silica gel chromatography (DCM/MeOH, 50: 1) to give (S) -5-methoxy-2- (2-oxoazepan-3-yl) isoindolin-1-one (1.39g, 49% yield) as a white solid. MS (ESI) M/z 275.0[ M + H ]]+.
To a solution of (S) -5-methoxy-2- (2-oxoazepan-3-yl) isoindolin-1-one (1.0g,3.65mmol) in DCM (12mL) at 0 deg.C was added boron tribromide (2.0mL,21.89mmol in 4mL DCM) dropwise. The mixture was stirred at this temperature for 30 minutes, then warmed to RT for 2 hours and quenched with water and MeOH. The solvent was evaporated and the residue was purified by silica gel chromatography (DCM/MeOH, 20: 1) to give (S) -5-hydroxy-2- (2-oxoazepan-3-yl) isoindolin-1-one (1.7g crude) as a white solid. MS (ESI) M/z 261.0[ M + H ]]+.
To (S) -5-hydroxy-2- (2-oxoazepan-3-yl) isoindolin-1-one (500mg,1.92mmol), 1, 4-phenylenedimethanol (1.0g,7.68 m) at RTmol) and triphenylphosphine (2.0g,7.68mmol) in THF (2mL) DEAD (1.3mg,7.68mmol) was added. The mixture was stirred for 2 hours. The solvent was evaporated and the residue was purified by silica gel chromatography (DCM/MeOH, 50: 1 to 20: 1) to give (S) -5- ((4- (hydroxymethyl) benzyl) oxy) -2- (2-oxoazepan-3-yl) isoindolin-1-one as a white solid (90mg, 12% yield). MS (ESI) M/z 381.1[ M + H ]]+.
To a solution of (S) -5- ((4- (hydroxymethyl) benzyl) oxy) -2- (2-oxoazepan-3-yl) isoindolin-1-one (60mg,0.157mmol) in fluorobenzene/DMSO (6.0mL/1.5mL) at RT was added Dess-Martin periodinane (268mg,0.631 mmol). After stirring at 80 ℃ overnight, the mixture was cooled to RT, then 20mL of saturated sodium thiosulfate solution was added and the mixture was stirred at RT for 5 min. Work-up and purification by preparative-TLC using hexane/EtOAc (1:1) afforded (S) -4- ((2- (2, 7-dioxoazepan-3-yl) -1-oxoisoindolin-5-yl) oxy) methyl) benzaldehyde (15mg, 16% yield) as a white solid. MS (ESI) M/z 393.0[ M + H ]]+.
To a solution of (S) -4- ((2- (2, 7-dioxoazepan-3-yl) -1-oxoisoindolin-5-yl) oxy) methyl) benzaldehyde (15mg,0.038mmol) and morpholine (7mg,0.076mmol) in DCM at RT was added sodium triacetoxyborohydride (16mg,0.076 mmol). The mixture was stirred for 28 hours. The solvent was evaporated and the crude product was purified by preparative-TLC using DCM/MeOH (10: 1) to give compound 15 as a white solid (6.5mg, 38% yield). MS (ESI) M/z464.2[ M + H ]]+.1H NMR(400MHz,DMSO-d6)δ10.71(s,1H),7.64(d,J=8.4Hz,1H),7.43(d,J=8.0Hz,2H),7.34(d,J=8.0Hz,2H),7.27(s,1H),7.13(d,J=8.8Hz,1H),5.23-5.19(m,3H),4.48-4.47(m,2H),3.58-3.56(m,4H),3.47(s,2H),3.08-3.06(m,1H),2.60-2.51(m,1H),2.35(s,4H),2.27-2.24(m,1H),2.10-2.00(m,2H),1.80-1.77(m,1H).
Example 16
Compound 16: (S) -6- (4- { [ p- (morpholinomethyl) phenyl]Methoxy } -2-isoindolinyl) -1,4-
Oxaazacycloheptane-3, 5-diones
Thionyl chloride was added dropwise to a solution of 3-hydroxy-2-methylbenzoic acid (20g,0.13mmol) in MeOH (240mL) at 0 deg.C, and the mixture was stirred at reflux for 3 hr. The solvent was evaporated and the residue was purified by silica gel chromatography (petroleum ether/EtOAc, 20: 1 to 5: 1) to give methyl 3-hydroxy-2-methylbenzoate (18.7g, 86% yield) as a yellow solid.
To a solution of methyl 3-hydroxy-2-methylbenzoate (18.7g,0.11mol) and imidazole (19.0g,0.25mol) in DMF (28mL) at RT was added tert-butyldimethylchlorosilane (20.4g,0.12 mol). After stirring at 60 ℃ for 3 hours, the mixture was cooled to RT and extracted with tert-butyl methyl ether. The combined organic layers were passed over anhydrous Na2SO4Dried, filtered and concentrated to give methyl 3- ((tert-butyldimethylsilyl) oxy) -2-methylbenzoate (32g crude) as a yellow solid which was used in the next step without further purification.
To a solution of methyl 3- ((tert-butyldimethylsilyl) oxy) -2-methylbenzoate (5.0g,17.8mmol) in carbon tetrachloride (30mL) was added NBS (4.7g,26.8mmol) and 2,2' -azobis (2-methylpropanenitrile) (1.1g,7.1mmol) at RT. The suspension was stirred at reflux for 5 hours. The solvent was evaporated and the residue was purified by silica gel chromatography (petroleum ether/EtOAc, 100: 1 to 50: 1) to give methyl 2- (bromomethyl) -3- ((tert-butyldimethylsilyl) oxy) benzoate (5.8g, 90% yield) as a yellow oil.
To a solution of methyl 2- (bromomethyl) -3- ((tert-butyldimethylsilyl) oxy) benzoate (490mg,1.4mmol) in DMF (6mL) at RT was added TEA (0.4mL,2.8mmol) and (S) -6-amino-1, 4-oxazepan-5-one (200mg,1.5mmol in 2mL DMF). The mixture was stirred at RT for 4 hours, then heated to 80 ℃ and overnight. The mixture was concentrated and the residue diluted with THF (10 mL). TBAF (200mg,0.76mmol) was added and the mixture was stirred at reflux for 2 h. The solvent was evaporated and the residue was purified by silica gel chromatography (DCM/MeOH, 50: 1 to 20: 1) to give (S) -6- (4-hydroxy-1-oxoisoindolin-2-yl) -1, 4-oxazepan-5-one (183mg, 50% yield) as a white solid. MS (ESI) M/z 263.0[ M ]+H]+.
To a solution of (S) -6- (4-hydroxy-1-oxoisoindolin-2-yl) -1, 4-oxazepan-5-one (230mg,0.87mmol), 1, 4-phenylenedimethanol (182mg,1.31mmol), and triphenylphosphine (568mg,2.17mmol) in THF (2.5mL) at RT was added DEAD (377mg,2.17 mmol). The mixture was stirred at RT for 3 hours. The solvent was evaporated and the crude product was purified by silica gel chromatography (DCM/MeOH, 100: 1 to 20: 1) to give (S) -6- (4- ((4- (hydroxymethyl) benzyl) oxy) -1-oxoisoindolin-2-yl) -1, 4-oxazepan-5-one as a white solid (110mg, 33% yield). MS (ESI) M/z 383.1[ M + H ]]+.
To a solution of (S) -6- (4- ((4- (hydroxymethyl) benzyl) oxy) -1-oxoisoindolin-2-yl) -1, 4-oxazepan-5-one (110mg,0.288mmol) in ACN/DMSO (8mL/2mL) at RT was added Dess-Martin periodinane (732mg,1.72 mmol). The mixture was stirred at 80 ℃ for 4 hours, then cooled to RT and 20mL of saturated sodium thiosulfate solution was added, then stirred for 5 min. The mixture was extracted with DCM. With DCM then DCM/EtOAc, 5:1 to 1:1 to yield (S) -4- (((2- (3, 5-dioxo-1, 4-oxazepan-6-yl) -1-oxoisoindolin-4-yl) oxy) methyl) benzaldehyde (58mg, 51% yield) as a white solid. MS (ESI) M/z 395.0[ M + H ]]+.
To a solution of (S) -4- ((2- (3, 5-dioxo-1, 4-oxazepan-6-yl) -1-oxoisoindolin-4-yl) oxy) methyl) benzaldehyde (58mg,0.147mmol) and morpholine (26mg,0.294mmol) in DCM (1.5mL) at RT was added sodium triacetoxyborohydride (64mg,0.294 mmol). The mixture was stirred at RT for 4 hours and then concentrated. The crude product was purified by prep-TLC using DCM/MeOH (10: 1) to give compound 16 as a white solid (19mg, 20% yield). MS (ESI) M/z 465.9[ M + H ]]+.1H NMR(400MHz,DMSO-d6)δ11.11(s,1H),7.48-7.44(m,3H),7.35-7.32(m,4H),5.67-5.66(m,1H),5.24(s,2H),4.71(d,J=17.2Hz,1H),4.55(d,J=10.4Hz,2H),4.40-4.35(m,2H),4.06-4.05(m,1H),3.57-3.55(m,4H),3.47(s,2H),2.35(s,4H).
Example 17
Compound 17: 3- (4- { [ p- ({2- [3- (p- { 5-methyl))-4- [ m- (tert-butylaminosulfonyl) phenylamino
Base of]-2-pyrimidinylamino } phenoxy) propylamino]Acetylamino } methyl) phenyl]Methoxy } -2-isoindolinoyl
2, 6-piperidinedione
Thionyl chloride (30mL,0.41mol) was added dropwise to a solution of 3-hydroxy-2-methylbenzoic acid (20g,0.13mol) in MeOH (240mL) at 0 deg.C. The mixture was stirred at reflux for 3 hours. The solvent was evaporated and the residue was purified by silica gel chromatography using petroleum ether/EtOAc (20: 1 to 5: 1) to give methyl 3-hydroxy-2-methylbenzoate (18.7g, 86% yield) as a yellow solid.
To a solution of methyl 3-hydroxy-2-methylbenzoate (18.7g,0.11mol) and imidazole (19.0g,0.25mol) in DMF (28mL) at RT was added tert-butyldimethylchlorosilane (20.4g,0.12 mol). After stirring at 60 ℃ for 3 hours, the mixture was cooled to RT and extracted with tert-butyl methyl ether. The combined organic layers were passed over anhydrous Na2SO4Dried, filtered and concentrated to give methyl 3- ((tert-butyldimethylsilyl) oxy) -2-methylbenzoate (32g crude) as a yellow solid which was used in the next step without further purification.
To a solution of methyl 3- ((tert-butyldimethylsilyl) oxy) -2-methylbenzoate (3.0g,10.7mmol) in carbon tetrachloride (22mL) was added NBS (2.9g,16.0mmol) and 2,2' -azobis (2-methylpropanenitrile) (701mg,4.3mmol) at RT. The mixture was stirred at 80 ℃ for 5 hours. Evaporation of the solvent gave the crude product which was purified by silica gel chromatography (petroleum ether/EtOAc, 30: 1) to give methyl 2- (bromomethyl) -3- ((tert-butyldimethylsilyl) oxy) benzoate as a yellow oil (3.7g 97%).
To a solution of methyl 2- (bromomethyl) -3- ((tert-butyldimethylsilyl) oxy) benzoate (1.0g,2.77mmol) and TEA (0.8mL,5.54mmol) in DMF (6mL) at RT was added a solution of tert-butyl 2, 5-diamino-5-oxopentanoate (670mg,3.32mmol) in DMF (4 mL). The mixture was stirred for 2 hours, then heated to 80 ℃ and stirred overnight. Evaporating the solvent to obtain a crude product, said crude productThe product was purified by silica gel chromatography (DCM/MeOH, 100: 1 to 50: 1) to give tert-butyl 5-amino-4- (4-hydroxy-1-oxoisoindolin-2-yl) -5-oxopentanoate as a white solid (820mg, 88% yield). MS (ESI) M/z 279.0[ M + H-56 ]]+.
To a solution of tert-butyl 5-amino-4- (4-hydroxy-1-oxoisoindolin-2-yl) -5-oxopentanoate (450mg,1.34mmol), 4- (hydroxymethyl) benzonitrile (360mg,2.69mmol) and triphenylphosphine (1.4g,5.36mmol) in THF (2mL) at RT was added DEAD (932mg,5.36mmol) dropwise. The mixture was stirred at RT for 4 hours. The solvent was evaporated and the crude product was purified by silica gel chromatography (DCM/MeOH, 100: 1 to 20: 1) to give tert-butyl 5-amino-4- (4- ((4-cyanobenzyl) oxy) -1-oxoisoindolin-2-yl) -5-oxopentanoate as a white solid (290mg, 39% yield). MS (ESI) M/z394.0[ M + H-56 ]]+.
To a solution of tert-butyl 5-amino-4- (4- ((4-cyanobenzyl) oxy) -1-oxoisoindolin-2-yl) -5-oxopentanoate (200mg,0.45mmol) in DCM (6mL) at RT was added TFA (1.5 mL). The mixture was stirred at RT for 5h, then concentrated to give 5-amino-4- (4- ((4-cyanobenzyl) oxy) -1-oxoisoindolin-2-yl) -5-oxopentanoic acid TFA salt (250mg crude) as a white solid, which was used in the next step without further purification. MS (ESI) M/z394.0[ M + H ]]+.
To a solution of 5-amino-4- (4- ((4-cyanobenzyl) oxy) -1-oxoisoindolin-2-yl) -5-oxopentanoic acid TFA salt (250mg,0.45mmol) in ACN (8mL) at RT was added CDI (291mg,1.80 mmol). The mixture was stirred at 95 ℃ for 6 hours. Evaporation of the solvent gave a crude product which was purified by silica gel chromatography (DCM/MeOH, 100: 1 to 50: 1) to give 4- (((2- (2, 6-dioxopiperidin-3-yl) -1-oxoisoindolin-4-yl) oxy) methyl) benzonitrile (130mg 77%) as a white solid. MS (ESI) M/z 376.0[ M + H ]]+.
To a solution of 4- (((2- (2, 6-dioxopiperidin-3-yl) -1-oxoisoindolin-4-yl) oxy) methyl) benzonitrile (130mg,0.346mmol) and di-tert-butyl dicarbonate (0.16mL,0.693mmol) in DCM (4mL) and THF (4mL) at RT was added Raney-Ni (80 mg). The mixture was reacted at RT in H2Stir for 16h then add MeOH (4mL) and heat the mixtureTo 80 ℃ for 5 hours. After cooling to RT, the suspension was filtered through a pad of celite and the filtrate was concentrated to give the crude product which was purified by silica gel chromatography using DCM/MeOH (50: 1 to 20: 1) to give tert-butyl 4- (((2- (2, 6-dioxopiperidin-3-yl) -1-oxoisoindolin-4-yl) oxy) methyl) benzylcarbamate (100mg, 60% yield) as a white solid. MS (ESI) M/z380.0[ M + H-100 ]]+.
To a solution of tert-butyl 4- (((2- (2, 6-dioxopiperidin-3-yl) -1-oxoisoindolin-4-yl) oxy) methyl) benzylcarbamate (100mg,0.208mmol) in DCM (4mL) at RT was added TFA (2 mL). The mixture was stirred at RT overnight. The solvent was evaporated to give 3- (4- ((4- (aminomethyl) benzyl) oxy) -1-oxoisoindolin-2-yl) piperidine-2, 6-dione TFA salt (80mg crude) as a white solid, which was used in the next step without further purification. MS (ESI) M/z380.0[ M + H ]]+.
To a solution of tert-butyl 2- ((3- (4- ((4- ((3- (N- (tert-butyl) sulfamoyl) phenyl) amino) -5-methylpyrimidin-2-yl) amino) phenoxy) propyl) amino) acetate (70mg,0.117mmol) in DCM (4mL) at RT was added TFA (1.5mL) and the mixture was stirred at RT overnight. The solvent was evaporated and the residue dissolved in DMF (4mL) followed by addition of 3- (4- ((4- (aminomethyl) benzyl) oxy) -1-oxoisoindolin-2-yl) piperidine-2, 6-dione (80mg,0.162mmol), DIEA (63mg,0.486mmol), HOBt (33mg,0.243mmol) and EDAC & HCl (47mg,0.243 mmol). The mixture was stirred at RT for 18 h. The solvent was evaporated and the crude product was purified by prep-HPLC as described before to give compound 17 as a white solid (11.3mg, 10% yield). MS (ESI) M/z 904.3[ M + H ]]+.1H NMR(400MHz,DMSO-d6)δ10.98(s,1H),8.79(s,1H),8.54(s,1H),8.32(t,J=6.0Hz,1H),8.15(s,2H),7.89(s,1H),7.58-7.40(m,9H),7.32-7.26(m,4H),6.78(d,J=8.8Hz,2H),5.19(s,2H),5.12-5.07(m,1H),4.41-4.21(m,4H),3.96(t,J=6.4Hz,2H),3.16(s,2H),2.93-2.86(m,1H),2.65-2.62(m,2H),2.59-2.51(m,1H),2.46-2.41(m,1H),2.11(s,3H),2.09-1.95(m,1H),1.90-1.80(m,2H),1.12(s,9H).
Example 18
Compound 18: (S) -3- (6-fluoro-4- { [ p- ({3- [3- (p-fluoro-))- { 5-methyl-4- [ m- (tert-butylaminosulfonyl) amino
Radical) phenylamino]-2-pyrimidinylamino } phenoxy) propyl]Ureido } methyl) phenyl]Methoxy } -2-isoindolinyl) -
2, 6-piperidinedione
To a solution of methyl 5-fluoro-3-hydroxy-2-methylbenzoate (3.2g,17.4mmol) and imidazole (2.9g,43.5mmol) in DMF (6mL) at RT was added tert-butyldimethylchlorosilane (3.1g,20.8 mmol). Stirring the mixture at 60 deg.C for 1hr, cooling to RT and extracting with tert-butyl methyl ether, and extracting with anhydrous Na2SO4Drying and concentration gave methyl 3- ((tert-butyldimethylsilyl) oxy) -5-fluoro-2-methylbenzoate (5.2g crude) as a yellow oil which was used in the next step without further purification.
To a solution of methyl 3- ((tert-butyldimethylsilyl) oxy) -5-fluoro-2-methylbenzoate (3.2g,10.7mmol) in carbon tetrachloride (30mL) was added NBS (2.9g,16.1mmol) and 2,2' -azobis (2-methylpropanenitrile) (700mg,4.3mmol) at RT. The mixture was stirred at 80 ℃ for 6 h. The solvent was evaporated to give the crude product, which was purified by silica gel chromatography (petroleum ether/EtOAc, 10: 1) to give methyl 2- (bromomethyl) -3- ((tert-butyldimethylsilyl) oxy) -5-fluorobenzoate (4.0g, quantitative yield).
To a solution of methyl 2- (bromomethyl) -3- ((tert-butyldimethylsilyl) oxy) -5-fluorobenzoate (1.0g,2.66mmol) and TEA (0.7mL,5.32mmol) in DMF (6mL) at RT was added 4mL of DMF containing tert-butyl (S) -4, 5-diamino-5-oxopentanoate (696mg,2.92 mmol). The mixture was stirred for 2 hours and then heated to 80 ℃ overnight. Evaporation of the solvent gave a crude product which was purified by silica gel chromatography (DCM/MeOH, 50: 1 to 20: 1) to give (S) -5-amino-4- (6-fluoro-4-hydroxy-1-oxoisoindolin-2-yl) -5-oxopentanoic acid tert-butyl ester (1.0g of crude product) as a white solid. MS (ESI) M/z 297.0[ M + H-56 ]]+.
To (S) -tert-butyl 5-amino-4- (6-fluoro-4-hydroxy-1-oxoisoindolin-2-yl) -5-oxopentanoate (500mg,1.42mmol), 4- (hydroxymethyl) benzonitrile (283mg,2.13mmol) at RT) And triphenylphosphine (930mg,3.55mmol) in THF (4mL) was added DEAD (617mg,3.55 mmol). The mixture was stirred at RT for 2 hours. The solvent was evaporated and the residue was purified by silica gel chromatography (DCM/MeOH, 100: 1 to 50: 1) to give tert-butyl (S) -5-amino-4- (4- ((4-cyanobenzyl) oxy) -6-fluoro-1-oxoisoindolin-2-yl) -5-oxopentanoate (350mg, 52% yield) as a yellow solid. MS (ESI) M/z 412.0[ M + H-56 ]]+.
To a solution of (S) -5-amino-4- (4- ((4-cyanobenzyl) oxy) -6-fluoro-1-oxoisoindolin-2-yl) -5-oxopentanoic acid tert-butyl ester (350mg,0.75mmol) in DCM (4mL) at RT was added TFA (4 mL). The mixture was stirred at RT overnight. The solvent was evaporated to give (S) -5-amino-4- (4- ((4-cyanobenzyl) oxy) -6-fluoro-1-oxoisoindolin-2-yl) -5-oxopentanoic acid (400mg crude) as a yellow solid, which was used in the next step without further purification. MS (ESI) M/z 412.0[ M + H ]]+.
To a solution of (S) -5-amino-4- (4- ((4-cyanobenzyl) oxy) -6-fluoro-1-oxoisoindolin-2-yl) -5-oxopentanoic acid (400mg,0.75mmol) in ACN (10mL) at RT was added CDI (485mg,2.99 mmol). The mixture was stirred at 95 ℃ for 3.5 hours. The solvent was evaporated to give the crude product, which was purified by silica gel chromatography (DCM/MeOH, 100: 1 to 50: 1) to give (S) -4- (((2- (2, 6-dioxopiperidin-3-yl) -6-fluoro-1-oxoisoindolin-4-yl) oxy) methyl) benzonitrile (200mg 68%) as a white solid. MS (ESI) M/z394.0[ M + H ]]+.
To a solution of (S) -4- (((2- (2, 6-dioxopiperidin-3-yl) -6-fluoro-1-oxoisoindolin-4-yl) oxy) methyl) benzonitrile (200mg,0.51mmol) and di-tert-butyl dicarbonate (166mg,0.76mmol) in THF (6mL) at RT was added Raney-Ni (80 mg). Mixing the mixture in H2Stirring was continued overnight. The suspension was filtered, the filtrate concentrated and purified by silica gel chromatography (DCM/MeOH, 100: 1 to 20: 1) to give tert-butyl (S) -4- (((2- (2, 6-dioxopiperidin-3-yl) -6-fluoro-1-oxoisoindolin-4-yl) oxy) methyl) benzylcarbamate (90mg, 35% yield) as a white solid. MS (ESI) M/z 398.0[ M + H-100 ]]+.
To (S) -4- (((2- (2, 6-dioxopiperidin-3-yl) -6-fluoro-1-oxoisoindolin-4-yl) oxy) methyl) at RTTo a solution of tert-butyl benzylcarbamate (70mg,0.146mmol) in DCM (2mL) was added TFA (0.5mL). The mixture was stirred at RT for 2 hours. The solvent was evaporated to give (S) -3- (4- ((4- (aminomethyl) benzyl) oxy) -6-fluoro-1-oxoisoindolin-2-yl) piperidine-2, 6-dione (80mg crude) as a white solid, which was used in the next step without further purification. MS (ESI) M/z 398.0[ M + H ]]+.
To a solution of (S) -3- (4- ((4- (aminomethyl) benzyl) oxy) -6-fluoro-1-oxoisoindolin-2-yl) piperidine-2, 6-dione (80mg,0.146mmol) and TEA (45mg,0.438mmol) in THF at RT was added 4-nitrophenyl (3- (4- ((4- ((3- (N- (tert-butyl) sulfamoyl) phenyl) amino) -5-methylpyrimidin-2-yl) amino) phenoxy) propyl) carbamate (90mg,0.138 mmol). After stirring for 15min, TEA (103mg,1.022mmol) was added and the reaction stirred for 2 hr. Evaporation of the solvent afforded the crude product, which was purified by prep-HPLC as previously described to afford compound 18 as a white solid (60.9mg, 46% yield). MS (ESI) M/z908.3[ M + H ]]+.1H NMR(400MHz,DMSO-d6)δ10.96(s,1H),8.76(s,1H),8.52(s,1H),8.14-8.12(m,2H),7.88(s,1H),7.55-7.40(m,7H),7.26-7.24(m,3H),7.11-7.08(m,1H),6.79(d,J=8.8Hz,2H),6.36(t,J=5.6Hz,1H),6.04(t,J=5.6Hz,1H),5.20(s,2H),5.11-5.06(m,1H),4.36(d,J=17.2Hz,1H),4.23-4.19(m,3H),3.91(t,J=6.0Hz,2H),3.19-3.14(m,2H),2.89-2.82(m,1H),2.58-2.50(m,1H),2.45-2.40(m,1H),2.11(s,3H),1.99-1.89(m,1H),1.82-1.79(m,2H),1.12(s,9H).
Example 19
Compound 19: 2- [ (S) -2, 7-dioxo-3-azepanyl]-4- { [ p- (morpholinomethyl) phenyl]First of all
Oxy } -1-oxo-5-isoindoline carbonitrile
To a solution of 3-hydroxy-2-methylbenzoic acid (100.0g,660mmol) in anhydrous MeOH (700mL) at 0 deg.C was added thionyl chloride (156.0g,1316 mmol). The reaction was heated to 70 ℃ and continued for 3 hours. The reaction was cooled to RT and the solvent was evaporated. The residue was diluted with water and extracted with EtOAc. Work-up and purification with 0% to 8% EtOAc/petroleum ether gave methyl 3-hydroxy-2-methylbenzoate (102g, 93% yield) as a white solid.
NBS (53.6g,301.2mmol) was added to a solution of methyl 3-hydroxy-2-methylbenzoate (50.0g,301.2mmol) in DCM (800mL) at-78 ℃. The mixture was stirred at-78 ℃ for 1 hour and then concentrated. The crude product was purified by silica gel chromatography, eluting with EtOAc/petroleum ether (0% to 8%) to give methyl 4-bromo-3-hydroxy-2-methylbenzoate (15.0g, 21% yield) as a colorless solid.
To a solution of methyl 4-bromo-3-hydroxy-2-methylbenzoate (10.0g,40.82mmol) in DMF (50mL) was added zinc cyanide (480mg,40.82mmol) and tetrakis (triphenylphosphine) palladium (240mg,2.04 mmol). The mixture was heated to 100 ℃ for 5 hours. The reaction was cooled to RT and the solvent was evaporated. The residue was diluted with water and extracted with EtOAc. Work-up and purification using EtOAc/petroleum ether (0% to 15%) gave methyl 4-cyano-3-hydroxy-2-methylbenzoate as a white solid (2.1g, 27% yield).
To a solution of methyl 4-cyano-3-hydroxy-2-methylbenzoate (2.1g,11.0mmol) and imidazole (1.5g,22.0mmol) in DMF (6mL) at RT was added tert-butyldimethylchlorosilane (1.98g,13.2 mmol). After stirring for 1 hour at 60 ℃, the solution was cooled to RT and extracted with tert-butyl methyl ether over anhydrous Na2SO4Dried, filtered and concentrated to give methyl 3- ((tert-butyldimethylsilyl) oxy) -4-cyano-2-methylbenzoate (3.2g crude) as a yellow oil which was used in the next step without further purification.
To a solution of methyl 3- ((tert-butyldimethylsilyl) oxy) -4-cyano-2-methylbenzoate (3.2g,10.5mmol) in carbon tetrachloride (50mL) was added NBS (2.43g,13.64mmol) and 2,2' -azobis (2-methylpropanenitrile) (690mg,4.2mmol) at RT. The suspension was stirred at 80 ℃ for 5 hours. Evaporation of the solvent gave the crude product which was purified by silica gel chromatography (petroleum ether/EtOAc, 10: 1) to give methyl 2- (bromomethyl) -3- (((tert-butyldimethylsilyl) oxy) -4-cyanobenzoate (3.5g 87%) as a colorless oil.
To a solution of methyl 2- (bromomethyl) -3- ((tert-butyldimethylsilyl) oxy) -4-cyanobenzoate (2.65g,6.92mmol) and TEA (1.39g,113.8mmol) in DMF (20mL) at RT was added (S) -3-amino azepan-2-one (1.06g,8.3 mmol). The mixture was stirred for 2 hours, then heated to 50 ℃ and left overnight. After cooling to RT tetrabutylammonium fluoride (2.61g,8.3mmol)) was added. The mixture was heated to 50 ℃ for 1 hour. The solvent was evaporated to give the crude product which was purified by silica gel chromatography (DCM/MeOH, 50: 1 to 20: 1) to give (S) -4-hydroxy-1-oxo-2- (2-oxoazepan-3-yl) isoindoline-5-carbonitrile (1.3g, crude) as a yellow solid.
To a solution of (S) -4-hydroxy-1-oxo-2- (2-oxoazepan-3-yl) isoindoline-5-carbonitrile (1.0g,3.5mmol), 4- (bromomethyl) benzaldehyde (900mg,4.6mmol) in DMF (515mL) was added K2CO3(970mg,7.1 mmol). The mixture was heated to 50 ℃ for 2 h. Evaporation of the solvent gave the crude product which was purified by silica gel chromatography (DCM/MeOH, 50: 1 to 20: 1) to give (S) -4- ((4-formylbenzyl) oxy) -1-oxo-2- (2-oxoazepan-3-yl) isoindoline-5-carbonitrile as a yellow solid (600mg, 42% yield). MS (ESI) M/z404.2[ M + H ]]+.
To a solution of (S) -4- ((4-formylbenzyl) oxy) -1-oxo-2- (2-oxoazepan-3-yl) isoindoline-5-carbonitrile (980mg,2.44mmol) in ACN/DMSO (12mL/2mL) at RT was added Dess-Martin periodinane (2.6g,6.1 mmol). The mixture was stirred at 80 ℃ overnight. The mixture was cooled to RT and 100mL of saturated sodium thiosulfate solution was added, followed by stirring for 5 min. The mixture was extracted with DCM. Using DCM/ACN, 5:1 to 3: 1 to afford (S) -2- (2, 7-dioxoazepan-3-yl) -4- ((4-formylbenzyl) oxy) -1-oxoisoindoline-5-carbonitrile (600mg, 59% yield) as a white solid. MS (ESI) M/z 418.0[ M + H ]]+.
To a solution of (S) -2- (2, 7-dioxoazepan-3-yl) -4- ((4-formylbenzyl) oxy) -1-oxoisoindoline-5-carbonitrile (700mg,1.68mmol) and morpholine (292mg,3.36mmol) in DCM (15mL) at RT was added sodium triacetoxyborohydride (850mg,4.2 mmol). The mixture was stirred for 3 hours and then concentrated. The residue was purified by silica gel chromatography (DCM/ACN, 3: 1 to 1:1)To give compound 19(800mg, 57% yield) as a white solid MS (ESI) M/z 489.2[ M + H ]]+.1H NMR(400MHz,DMSO-d6)δ10.79(s,1H),7.91(d,J=7.6Hz,1H),7.54-7.46(m,3H),7.36(d,J=8.4Hz,2H),5.47(s,2H),5.29-5.25(m,1H),4.86(t,J=2.4Hz,2H),3.58-3.56(m,4H),3.47(s,2H),3.14-3.06(m,1H),2.58(d,J=16.4Hz,,1H),2.40-2.34(m,5H),2.13-2.00(m,2H),1.83-1.81(m,1H).
Example 20
Compound 20: (S) -3- (4- { [ p- ({3- [3- (p- { 5-methyl-4- [ m- (tert-butylaminosulfonyl) benzene)
Radical amino]-2-pyrimidinylamino } phenoxy) propyl]Ureido } methyl) phenyl]Methoxy } -2-isoindolinyl) -2,6-
Piperidinones
To a solution of tert-butyl (S) -4- (((2- (2, 6-dioxopiperidin-3-yl) -1-oxoisoindolin-4-yl) oxy) methyl) benzylcarbamate (100mg,0.2mmol) in DCM (4mL) at RT was added TFA (1 mL). The mixture was stirred for 1 hour, then the solvent was evaporated to give (S) -3- (4- ((4- (aminomethyl) benzyl) oxy) -1-oxoisoindolin-2-yl) piperidine-2, 6-dione TFA salt, which was used in the next step without further purification. MS (ESI) M/z380.0[ M + H ]]+.
To a solution of (S) -3- (4- ((4- (aminomethyl) benzyl) oxy) -1-oxoisoindolin-2-yl) piperidine-2, 6-dione TFA salt (0.2mmol) in DCM (4mL) at RT was added TEA (41mg,0.4mmol) and 4-nitrophenyl chloroformate (50mg,0.24 mmol). After stirring for 2 hours, the mixture was concentrated to give (S) -4-nitrophenyl 4- (((2- (2, 6-dioxopiperidin-3-yl) -1-oxoisoindolin-4-yl) oxy) methyl) benzyl carbamate, which was used in the next step.
To a solution of tert-butyl (3- (4- ((4- ((3- (N- (tert-butyl) sulfamoyl) phenyl) amino) -5-methylpyrimidin-2-yl) amino) phenoxy) propyl) carbamate (120mg,0.2mmol) in DCM (2mL) was added TFA (1 mL). The mixture was stirred at RT for 1 hour, then the solvent was evaporated to give 3- ((2- ((4- (3-aminopropoxy) phenyl) amino) -5-methylpyrimidinePyridin-4-yl) amino) -N- (tert-butyl) benzenesulfonamide, which was used in the next step. MS (ESI) M/z 485.1[ M + H ]]+.
To a solution of phenyl (S) -4-nitrophenyl 4- (((2- (2, 6-dioxopiperidin-3-yl) -1-oxoisoindolin-4-yl) oxy) methyl) benzylcarbamate (0.2mmol) in THF (4mL) was added TEA (0.2mL), followed by DCM (4mL) containing 3- ((2- ((4- (3-aminopropoxy) phenyl) amino) -5-methylpyrimidin-4-yl) amino) -N- (tert-butyl) benzenesulfonamide (0.2mmol), and the mixture was stirred at RT overnight. The solvent was evaporated and the residue was purified by silica gel chromatography (DCM/MeOH, 10: 1) and prep-HPLC as described before to give compound 20 as a white solid (11.5mg, 6.5% yield)]+.1H NMR(400MHz,DMSO-d6)δ10.94(s,1H),8.76(s,1H),8.52(s,1H),8.11-8.14(m,2H),7.89(s,1H),7.39-7.78(m,8H),7.24-7.31(m,4H),6.79(d,J=8.8Hz,2H),6.35(t,J=6.0Hz,1H),6.03(t,J=5.6Hz,1H),5.19(s,2H),5.09(dd,J=4.8,13.2Hz,1H),4.19-4.41(m,4H),3.91(t,J=6.0Hz,2H),3.16(q,J=6.4Hz,2H),2.85-2.94(m,1H),2.53-2.58(m,1H),2.42-2.49(m,1H),2.11(s,3H),1.95-1.99(m,1H),1.77-1.84(m,2H),1.12(s,9H).
Example 21
Compound 21: (S) -3- (6-fluoro-4- { [ p- ({2- [3- (p- { 5-methyl-4- [ m- (tert-butylsulfonylamino) amino)
Radical) phenylamino]-2-pyrimidinylamino } phenoxy) propylamino]Acetylamino } methyl) phenyl]Methoxy } -2-isoindole
Indole-acyl) -2, 7-azacycloheptanediones
To a solution of (S) -3-aminoazepan-2-one (2.0g,15.9mmol) and TEA (2.8mL,19.9mmol) in DMF (30mL) at RT was added methyl 2- (bromomethyl) -3- ((tert-butyldimethylsilyl) oxy) -5-fluorobenzoate (5.0g,13.3mmol) in 10mL of DMF. The mixture was stirred for 2 hours, heated to 50 ℃ and overnight, and cooled to RT. TBAF (2.4g,9.31mmol) was added and the mixture was heated to 70 ℃ for 1 hr. The solvent was evaporated and chromatographed on silica gel (DCM/MeOH, 100: 1 to 30: 1)) The residue was purified to give (S) -6-fluoro-4-hydroxy-2- (2-oxoazepan-3-yl) isoindolin-1-one (3.1g, 83% yield) as a yellow solid. MS (ESI) M/z 279.0[ M + H ]]+.
To a solution of (S) -6-fluoro-4-hydroxy-2- (2-oxoazepan-3-yl) isoindolin-1-one (320mg,1.15mmol), tert-butyl 4- (hydroxymethyl) benzylcarbamate (409mg,1.72mmol) and triphenylphosphine (602mg,2.30mmol) in THF (2mL) at RT was added DEAD (400mg,2.30mmol) and the mixture was stirred for 30 min. The solvent was evaporated and the residue was purified by silica gel chromatography (DCM/MeOH, 100: 1 to 30: 1) to give tert-butyl (S) -4- (((6-fluoro-1-oxo-2- (2-oxoazepan-3-yl) isoindolin-4-yl) oxy) methyl) benzylcarbamate (430mg, 75% yield) as a yellow solid. MS (ESI) M/z 398.1[ M + H-100 ]]+.
To a solution of tert-butyl (S) -4- (((6-fluoro-1-oxo-2- (2-oxoazepan-3-yl) isoindolin-4-yl) oxy) methyl) benzylcarbamate (200mg,0.40mmol) in ACN/DMSO (4mL/1mL) at RT was added Dess-Martin periodinane (426mg,1.00 mmol). The mixture was stirred at 80 ℃ overnight. After cooling to RT, 20mL of saturated sodium thiosulfate solution were added and the mixture was extracted with DCM. Work-up afforded the crude product, which was washed with tert-butyl methyl ether to give tert-butyl (S) -4- (((2- (2, 7-dioxoazepan-3-yl) -6-fluoro-1-oxoisoindolin-4-yl) oxy) methyl) benzylcarbamate as a white solid (100mg, 50% yield). MS (ESI) M/z 412.0[ M + H-100 ]]+.
To a solution of tert-butyl (S) -4- (((2- (2, 7-dioxoazepan-3-yl) -6-fluoro-1-oxoisoindolin-4-yl) oxy) methyl) benzylcarbamate (61mg,0.117mmol) in DCM (4mL) at RT was added TFA (1 mL). The reaction was stirred at RT for 1 hour. Evaporation of the solvent gave the amine TFA salt as a yellow gum.
The amine TFA salt was dissolved in DMA (1mL) and 2- ((3- (4- ((4- ((3- (N- (tert-butyl) sulfamoyl) phenyl) amino) -5-methylpyrimidin-2-yl) amino) phenoxy) propyl) amino) acetic acid (76mg,0.141mmol) was added followed by HOBt (23.7mg,0.176mmol), EDAC & HCl (34.1mg,0.176mmol) and DIEA (30.0mg,0.234 mmol). The reaction was stirred at RT for 10 hours. The solvent is evaporated and the mixture is evaporated,and the residue was purified by prep-HPLC as described previously to give compound 21 as a white solid (10.8mg, 10.2% yield). ms (esi) M/z 936.4[ M + H]+.1H NMR(400MHz,DMSO-d6)δ10.69(s,1H),8.75(s,1H),8.51(s,1H),8.29(t,J=6.0Hz,1H),8.14-8.11(m,2H),7.88(s,1H),7.54-7.23(m,10H),7.09-7.07(m,1H),6.77(d,J=4.8Hz,2H),5.20-5.17(m,3H),4.40(s,2H),4.30(d,J=6.0Hz,2H),3.96(t,J=2.4Hz,2H),3.15(s,2H),3.09-3.00(m,1H),2.67-2.54(m,3H),2.32-2.25(m,3H),2.11(s,3H),2.05-1.96(m,2H),1.84-1.71(m,3H),1.12(s,9H).
Example 23
Compound 22: (S) -3- [5- (aminomethyl) -4- { [ p- (morpholinylmethyl) phenyl]Methoxy } -2-isoindole
Quinoline acyl radical]-2, 7-azepane dione bistrifluoroacetic acid
To a solution of (S) -2- (2, 7-dioxoazepan-3-yl) -4- ((4- ((morpholinylmethyl) benzyl) oxy) -1-oxoisoindoline-5-carbonitrile (700mg,1.43mmol) and di-tert-butyl dicarbonate (625mg,2.87mmol) in DMF (10mL)/THF (15mL) at RT was added Raney-Ni (500 mg). The mixture was taken at RT in H2Stirred for 48 hours. The suspension was filtered through a pad of celite and concentrated to give the crude product which was purified by silica gel chromatography (DCM/CAN, 3: 1 to 1:1) to give tert-butyl (S) - ((2- (2, 7-dioxoazepan-3-yl) -4- ((4- (morpholinylmethyl) benzyl) oxy) -1-oxoisoindolin-5-yl) methyl) carbamate (800mg, 85% yield) as a white solid. MS (ESI) M/z593.1[ M + H ]]+.
To a solution of tert-butyl (S) - ((2- (2, 7-dioxoazepan-3-yl) -4- ((4- (morpholinylmethyl) benzyl) oxy) -1-oxoisoindolin-5-yl) methyl) carbamate (70mg,0.118mmol) in DCM (3mL) at RT was added TFA (1.0 mL). The mixture was stirred for 1 hour. Evaporation of the solvent afforded compound 22 as a white solid (70mg, 83% yield). MS (ESI) M/z 493.2[ M + H ]]+.1H NMR(400MHz,DMSO-d6)δ10.75(s,1H),10.56(s,1H),8.29(s,3H),7.64-7.52(m,6H),5.36(s,2H),5.28-5.24(m,1H),4.85-4.73(m,2H),4.39(s,2H),4.14(s,2H),3.97(s,2H),3.65(s,2H),3.24-3.01(m,4H),2.61-2.57(m,2H),2.37-2.32(m,1H),2.15-2.03(m,2H),1.87-1.78(m,1H).
Example 24
Compound 23: (S) -3- [5- ({3- [3- (p- { 5-methyl-4- [ m- (tert-butylaminosulfonyl) phenylamino ] amino
Base of]-2-pyrimidinylamino } phenoxy) propyl]Ureido methyl) -4- { [ p- (morpholinylmethyl) phenyl]Methoxy } -2-iso
Indolinyl radical]-2, 6-piperidinedione
To a solution of methyl 2- (bromomethyl) -3- ((tert-butyldimethylsilyl) oxy) -4-cyanobenzoate (3.5g,9.096mmol) and TEA (1.84g,18.2mmol) in DMF (15mL) at RT was added tert-butyl (S) -4, 5-diamino-5-oxopentanoate (2.6g,10.91 mmol). The mixture was stirred for 2 hours, then heated to 50 ℃ and left overnight. After cooling to RT tetrabutylammonium fluoride (4.3g,13.6mmol) was added. The mixture was heated to 50 ℃ and held for 1 hour. The solvent was evaporated to give the crude product which was purified by silica gel chromatography (DCM/MeOH, 50: 1 to 20: 1) to give tert-butyl (S) -5-amino-4- (5-cyano-4-hydroxy-1-oxoisoindolin-2-yl) -5-oxopentanoate (1.1g, yield; 34% yield) as a yellow solid.
To a solution of (S) -5-amino-4- (5-cyano-4-hydroxy-1-oxoisoindolin-2-yl) -5-oxopentanoic acid tert-butyl ester (200mg,0.56mmol), 4- (4- (chloromethyl) benzyl) morpholine (188mg,0.835mmol) in DMF (5mL) was added K2CO3(156mg,1.13mmol) and the mixture was heated to 50 ℃ and held for 2 hr. The solvent was evaporated and the residue was purified by silica gel chromatography (DCM/MeOH, 50: 1 to 20: 1) to give tert-butyl (S) -5-amino-4- (5-cyano-4- ((4- (morpholinylmethyl) benzyl) oxy) -1-oxoisoindolin-2-yl) -5-oxopentanoate (240mg, 80% yield) as a yellow solid.
To a solution of tert-butyl (S) -5-amino-4- (5-cyano-4- ((4- (morpholinylmethyl) benzyl) oxy) -1-oxoisoindolin-2-yl) -5-oxopentanoate (240mg,0.44mmol) in DCM (5mL) at RT was added TFA (2 mL). The mixture was stirred overnight and concentrated to give (S) -5-amino-4- (5-cyano-4- ((4- (morpholinylmethyl) benzyl) oxy) -1-oxoisoindolin-2-yl) -5-oxopentanoic acid (200mg, crude) as a yellow oil which was used in the next step without further purification.
To a solution of (S) -5-amino-4- (5-cyano-4- ((4- (morpholinylmethyl) benzyl) oxy) -1-oxoisoindolin-2-yl) -5-oxopentanoic acid (200mg,0.41mmol) in ACN (10mL) at RT was added CDI (200mg,1.22 mmol). The mixture was heated to 50 ℃ for 2 hours. The solvent was evaporated and the residue was purified by silica gel chromatography (DCM/MeOH, 50: 1 to 10: 1) to give (S) -2- (2, 6-dioxopiperidin-3-yl) -4- ((4- (morpholinylmethyl) benzyl) oxy) -1-oxoisoindoline-5-carbonitrile (100mg, 52% yield) as a white solid. MS (ESI) M/z 475.2[ M + H ]]+.1HNMR(400MHz,DMSO-d6)δ11.05(s,1H),7.92(d,J=7.6Hz,1H),7.54(d,J=8Hz,1H),7.47(d,J=8Hz,2H),7.36(d,J=8Hz,2H),5.45(s,2H),5.18-5.14(m,1H),4.85-4.66(m,2H),3.58-3.56(m,4H),3.47(s,2H),2.96-2.89(m,1H),2.65-2.60(m,1H),2.47-2.44(m,1H),2.36-2.33(m,4H),2.05-1.99(m,1H).
To a solution of (S) -2- (2, 6-dioxopiperidin-3-yl) -4- ((4- (morpholinylmethyl) benzyl) oxy) -1-oxoisoindoline-5-carbonitrile (600mg,1.265mmol) and di-tert-butyl dicarbonate (550mg,2.53mmol) in DMF (5mL) and MeOH (10mL) at RT was added Raney-Ni (300 mg). The mixture is brought to RT in H2Stirred for 16 hours. The suspension was filtered through a pad of celite and concentrated to give the crude product which was purified by silica gel chromatography (DCM/MeOH, 50: 1 to 20: 1) to give tert-butyl (S) - ((2- (2, 6-dioxopiperidin-3-yl) -4- ((4- (morpholinylmethyl) benzyl) oxy) -1-oxoisoindolin-5-yl) methyl) carbamate as a white solid (400mg, 55% yield). MS (ESI) M/z 579.1[ M + H ]]+.
To a solution of tert-butyl (S) - ((2- (2, 6-dioxopiperidin-3-yl) -4- ((4- (morpholinylmethyl) benzyl) oxy) -1-oxoisoindolin-5-yl) methyl) carbamate (250mg,0.435mmol) in DCM (4mL) at RT was added TFA (1.0 mL). The mixture was stirred at RT for 1 hour. Evaporating the solvent to obtain (S) -3- (5- (amino)Methyl) -4- ((4- (morpholinylmethyl) benzyl) oxy) -1-oxoisoindolin-2-yl) piperidine-2, 6-dione (250mg, 81% yield) as a white solid. MS (ESI) M/z 479.2[ M + H ]]+.1H NMR(400MHz,DMSO-d6)δ11.02(s,1H),10.37(s,1H),8.25(s,3H),7.61-7.59(m,3H),7.55-7.53(m,3H),5.32(s,2H),5.17-5.12(m,1H),4.78-4.55(m,2H),4.36(s,2H),4.14(d,J=4.4Hz,2H),3.91(s,2H),3.71-3.60(m,2H),3.26-3.09(m,4H),2.96-2.91(m,1H),2.66-2.61(m,1H),2.46-2.42(m,1H),2.04-1.99(m,1H).
To a solution of (S) -3- (5- (aminomethyl) -4- ((4- (morpholinylmethyl) benzyl) oxy) -1-oxoisoindolin-2-yl) piperidine-2, 6-dione (150mg,0.21mmol) in formic acid (5mL) at RT was added formaldehyde (1mL, 40%). The mixture was heated to 100 ℃ for 1 hour. The solvent was evaporated and the residue was purified by prep-HPLC as described before to give (S) -3- (5- ((dimethylamino) methyl) -4- ((4- (morpholinylmethyl) benzyl) oxy) -1-oxoisoindolin-2-yl) piperidine-2, 6-dione (80mg, 79% yield) as a white solid. MS (ESI) M/z 507.2[ M + H ]]+.1H NMR(400MHz,DMSO-d6)δ11.05(s,1H),10.91(s,1H),10.01(s,1H),7.68-7.54(m,6H),5.37(s,2H),5.17-5.06(m,2H),4.85-4.78(m,1H),4.65-4.61(m,1H),4.38(s,4H),3.96(s,2H),3.67(s,2H),3.24-2.92(m,4H),2.83-2.61(m,7H),2.50-2.42(m,1H),2.07-2.01(m,1H).
To a solution of (S) -3- (5- (aminomethyl) -4- ((4- (morpholinylmethyl) benzyl) oxy) -1-oxoisoindolin-2-yl) piperidine-2, 6-dione (80mg,0.112mmol) in THF (5mL) was added TEA (113mg,1.12 mmol). The mixture was stirred at RT for 10min, then 4-nitrophenyl (3- (4- ((4- ((3- (N- (tert-butyl) sulfamoyl) phenyl) amino) -5-methylpyrimidin-2-yl) amino) phenoxy) propyl) carbamate (80mg,0.124mmol) was added, followed by TEA (90mg,0.9 mmol). After stirring at RT for 1h, the mixture was concentrated and the residue was purified by prep-HPLC as described before to give compound 23 as a white solid (40mg, 36% yield). MS (ESI) M/z 989.4[ M + H ]]+.1H NMR(400MHz,DMSO-d6)δ11.01(s,1H),8.79(s,1H),8.54(s,1H),8.13(s,2H),7.90(s,1H),7.57-7.33(m,11H),6.79(d,J=8Hz,2H),6.36-6.33(m,1H),6.16-6.13(m,1H),5.16-5.09(m,3H),4.65-4.54(m,2H),4.33(d,J=4Hz,2H),3.93-3.90(m,2H),3.56(s,4H),3.46(s,2H),3.18-3.15(m,2H),2.97-2.88(m,1H),2.62-2.58(m,1H),2.34(s,4H),2.12(s,3H),2.01-1.92(m,1H),1.89(s,1H),1.82-1.79(m,2H),1.12(s,9H).
Example 25
Compound 24: (S) -3- (4- { [ p- ({2- [3- (p- { 5-methyl-4- [ m- (tert-butylaminosulfonyl) benzene)
Radical amino]-2-pyrimidinylamino } phenoxy) propylamino]Acetylamino } methyl) phenyl]Methoxy } -2-isoindoline
Acyl) -2, 6-piperidinediones
To a solution of 2- ((3- (4- ((4- ((3- (N- (tert-butyl) sulfamoyl) phenyl) amino) -5-methylpyrimidin-2-yl) amino) phenoxy) propyl) amino) acetic acid (54mg,0.1mmol) and (S) -3- (4- ((4- (aminomethyl) benzyl) oxy) -1-oxoisoindolin-2-yl) piperidine-2, 6-dione (0.1mmol) in DMF (2mL) was added DIEA (26mg,0.2mmol), HOBt (20mg,0.15mmol) and EDAC · HCl (29mg,0.15mmol) at RT and the mixture was stirred overnight. The solvent was evaporated and the residue was purified by preparative-TLC (DCM/MeOH, 10: 1) to give compound 24 as a white solid (6.0mg, 6.7% yield). MS (ESI) M/z 904.3[ M + H ]]+.1H NMR(400MHz,DMSO-d6)δ10.95(s,1H),8.76(s,1H),8.52(s,1H),8.48(s,1H),8.11-8.14(m,2H),7.89(s,1H),7.40-7.54(m,8H),7.27-7.31(m,4H),6.78(d,J=9.2Hz,2H),5.20(s,2H),5.09(dd,J=5.2,13.2Hz,1H),4.21-4.41(m,4H),3.96(t,J=6.0Hz,2H),2.85-2.94(m,1H),2.76(t,J=6.0Hz,2H),2.53-2.58(m,1H),2.40-2.45(m,2H),2.11(s,3H),1.95-1.98(m,2H),1.87-1.90(m,2H),1.12(s,9H).
Example 26
Compound 25: (S) -3- (6-fluoro-4- { [ p- ({2- [3- (p- { 5-methyl-4- [ m- (tert-butylaminosulfonyl) amino)
Radical) phenylamino]-2-pyrimidinylamino } phenoxy) propylamino]Acetylamino } methyl) phenyl]Methoxy } -2-isoindole
Indole-acyl) -2, 6-piperidinedione
To a solution of methyl 5-fluoro-3-hydroxy-2-methylbenzoate (3.2g,17.4mmol) and imidazole (2.9g,43.5mmol) in DMF (6mL) at RT was added tert-butyldimethylchlorosilane (3.1g,20.8 mmol). The mixture was stirred at 60 ℃ for 1 hour, then cooled to RT and extracted with tert-butyl methyl ether. The combined organic layers were passed over anhydrous Na2SO4Dried, filtered and concentrated to give methyl 3- ((tert-butyldimethylsilyl) oxy) -5-fluoro-2-methylbenzoate (5.2g crude) as a yellow oil which was used in the next step without further purification.
To a solution of methyl 3- ((tert-butyldimethylsilyl) oxy) -5-fluoro-2-methylbenzoate (3.2g,10.7mmol) in carbon tetrachloride (30mL) was added NBS (2.9g,16.1mmol) and 2,2' -azobis (2-methylpropanenitrile) (700mg,4.3mmol) at RT. The mixture was stirred at 80 ℃ for 6 hours. The solvent was evaporated to give the crude product, which was purified by silica gel chromatography (petroleum ether/EtOAc, 10: 1) to give methyl 2- (bromomethyl) -3- ((tert-butyldimethylsilyl) oxy) -5-fluorobenzoate (4.0g, quantitative yield).
To a solution of methyl 2- (bromomethyl) -3- ((tert-butyldimethylsilyl) oxy) -5-fluorobenzoate (1.0g,2.66mmol) and TEA (0.7mL,5.32mmol) in DMF (6mL) at RT was added 4mL of DMF containing tert-butyl 4, 5-diamino-5-oxopentanoate (696mg,2.92 mmol). The mixture was stirred for 2 hours, then heated to 80 ℃ and left overnight. Evaporation of the solvent gave a crude product which was purified by silica gel chromatography (DCM/MeOH, 50: 1 to 20: 1) to give tert-butyl 5-amino-4- (6-fluoro-4-hydroxy-1-oxoisoindolin-2-yl) -5-oxopentanoate (1.0g crude) as a white solid. MS (ESI) M/z 297.0[ M + H-56 ]]+.
To a solution of tert-butyl 5-amino-4- (6-fluoro-4-hydroxy-1-oxoisoindolin-2-yl) -5-oxopentanoate (500mg,1.42mmol), 4- (hydroxymethyl) benzonitrile (283mg,2.13mmol) and triphenylphosphine (930mg,3.55mmol) in THF (4mL) at RT was added DEAD (617mg,3.55 mmol). The mixture was stirred at RT for 2 hours. The solvent was evaporated and the residue was purified by silica gel chromatography (DCM/MeOH, 100: 1 to 50: 1) to give 5-ammonia as a yellow solidTert-butyl yl-4- (4- ((4-cyanobenzyl) oxy) -6-fluoro-1-oxoisoindolin-2-yl) -5-oxopentanoate (350mg, 52% yield). MS (ESI) M/z 412.0[ M + H-56 ]]+.
To a solution of tert-butyl 5-amino-4- (4- ((4-cyanobenzyl) oxy) -6-fluoro-1-oxoisoindolin-2-yl) -5-oxopentanoate (350mg,0.75mmol) in DCM (4mL) at RT was added TFA (4 mL). The mixture was stirred at RT overnight. The solvent was evaporated to give 5-amino-4- (4- ((4-cyanobenzyl) oxy) -6-fluoro-1-oxoisoindolin-2-yl) -5-oxopentanoic acid (400mg, crude) as a yellow solid which was used in the next step without further purification. MS (ESI) M/z 412.0[ M + H ]]+.
To a solution of 5-amino-4- (4- ((4-cyanobenzyl) oxy) -6-fluoro-1-oxoisoindolin-2-yl) -5-oxopentanoic acid (400mg,0.75mmol) in ACN (10mL) at RT was added CDI (485mg,2.99 mmol). The mixture was stirred at 95 ℃ for 3.5 hours. The solvent was evaporated to give the crude product, which was purified by silica gel chromatography (DCM/MeOH, 100: 1 to 50: 1) to give 4- (((2- (2, 6-dioxopiperidin-3-yl) -6-fluoro-1-oxoisoindolin-4-yl) oxy) methyl) benzonitrile (200mg, 68%) as a white solid. MS (ESI) M/z394.0[ M + H ]]+.
To a solution of 4- (((2- (2, 6-dioxopiperidin-3-yl) -6-fluoro-1-oxoisoindolin-4-yl) oxy) methyl) benzonitrile (200mg,0.51mmol) and di-tert-butyl dicarbonate (166mg,0.76mmol) in THF (6mL) at RT was added Raney-Ni (80 mg). At RT in H2The mixture was stirred overnight. The suspension was filtered through a pad of celite and the filtrate was concentrated to give the crude product which was purified by silica gel chromatography (DCM/MeOH, 100: 1 to 20: 1) to give tert-butyl 4- (((2- (2, 6-dioxopiperidin-3-yl) -6-fluoro-1-oxoisoindolin-4-yl) oxy) methyl) benzylcarbamate (90mg, 35% yield) as a white solid. MS (ESI) M/z 398.0[ M + H-100 ]]+.
To a solution of tert-butyl 4- (((2- (2, 6-dioxopiperidin-3-yl) -6-fluoro-1-oxoisoindolin-4-yl) oxy) methyl) benzylcarbamate (80mg,0.161mmol) in DCM (4mL) at RT was added TFA (1 mL). The reaction was stirred for 1 hour. The solvent was evaporated and the residue was dried to give the amine TFA salt as a yellow gum.
The amine TFA salt was dissolved in DMA (1mL) and 2- ((3- (4- ((4- ((3- (N- (tert-butyl) sulfamoyl) phenyl) amino) -5-methylpyrimidin-2-yl) amino) phenoxy) propyl) amino) acetic acid (109mg,0.161mmol) was added followed by HOBt (32.6mg,0.242mmol), EDAC-HCl (46.5mg,0.242mmol) and DIEA (41.5mg,0.322mmol) and the mixture was stirred at RT for 10 h. The solvent was evaporated and the residue was purified by prep-HPLC as described before to give compound 25 as a white solid (23.9mg, 16% yield). MS (ESI) M/z 922.3[ M + H ]]+.1H NMR(400MHz,DMSO-d6)δ10.96(s,1H),8.75(s,1H),8.52(s,1H),8.29(t,J=6.4Hz,1H),8.14-8.11(m,2H),7.88(s,1H),7.55-7.23(m,10H),7.10-7.08(m,1H),6.77(d,J=5.2Hz,2H),5.19(s,2H),5.08(dd,J=8.4,13.6Hz,1H),4.37-4.18(m,4H),3.95(t,J=6.4Hz,1H),3.16(s,2H),2.93-2.83(m,1H),2.66-2.57(m,3H),2.11(s,3H),2.02-1.93(m,1H),1.86-1.79(m,3H),1.12(s,9H).
Example 27
Compound 26: (S) -3- (4- {2- [ p- (morpholinylmethyl) phenyl)]Ethoxy } -2-isoindolinoyl) -2,
7-azacycloheptanediones
Lithium aluminum hydride (1M in THF, 36mL) was added dropwise to a solution of methyl 4- (2-methoxy-2-oxoethyl) benzoate (5g,0.24mol) in THF (25mL) at 0 deg.C. The mixture was stirred at 0 ℃ for 2 hours and then Na was added2SO4The reaction was quenched with decahydrate, diluted with EtOAc and filtered. The filtrate was washed with brine and dried over anhydrous Na2SO4Drying, filtration and concentration gave 2- (4- (hydroxymethyl) phenyl) ethanol (3g, crude) as a yellow oil.1H NMR(400MHz,DMSO-d6)δ7.13-7.23(m,4H),5.08(t,J=5.6Hz,1H),4.61(t,J=5.2,8.4Hz,1H),4.44(d,J=7.0Hz,2H),3.54-3.59(m,2H),2.69(t,J=7.2Hz,2H).
To a stirred solution of 2- (4- (hydroxymethyl) phenyl) ethanol (3g, crude, 19.7mmol) in chloroform (30mL) was added manganese dioxide (6.9g,79 mmol). The mixture was stirred at 70 ℃ overnight and then filteredFiltered and concentrated. The residue was purified by silica gel chromatography (petrol/EtOAc, 5: 1) to give 4- (2-hydroxyethyl) benzaldehyde (1.3g, 38% after 2 steps) as a yellow oil.1H NMR(300MHz,CDCl3)δ9.90(s,1H),7.76(d,J=8.0Hz,2H),7.34(d,J=8.0Hz,2H),3.84(t,J=6.4Hz,2H),2.88(t,J=6.4Hz,2H).
To a stirred solution of 4- (2-hydroxyethyl) benzaldehyde (1.3g,8.67mmol) in DCM (20mL) was added tosyl chloride (2.5g,13mmol) and TEA (4.8 mL). The mixture was stirred at RT overnight, then evaporated and purified by silica gel chromatography (petrol/EtOAc, 5: 1) to give 4-formylphenethyl 4-methylbenzenesulfonate (2g, 77% yield) as a white solid.
To a stirred solution of (S) -4-hydroxy-2- (2-oxoazepan-3-yl) isoindolin-1-one (250mg,0.96mmol) and 4-formylphenethyl 4-methylbenzenesulfonate (392mg,1.15mmol) in ACN (5mL) at RT was added K2CO3(400mg,2.88 mmol). After stirring at 80 ℃ overnight, the mixture was concentrated and the residue was purified by silica gel chromatography (DCM/MeOH, 50: 1) to give (S) -4- (2- ((1-oxo-2- (2-oxoazepan-3-yl) isoindolin-4-yl) oxy) ethyl) benzaldehyde (100mg, 27% yield) as a colorless oil. MS (ESI) M/z 393.1[ M + H ]]+.
Dess-Martin reagent (530mg,1.25mol) was added to a solution of (S) -4- (2- ((1-oxo-2- (2-oxoazepan-3-yl) isoindolin-4-yl) oxy) ethyl) benzaldehyde (100mg,0.25mmol) in 1, 2-dichloroethane (6mL) and DMSO (1mL) at RT. The mixture was stirred at 80 ℃ overnight, then cooled to RT and filtered. The filtrate was quenched with saturated sodium thiosulfate solution and extracted with DCM. Work-up and purification by preparative-TLC (EtOAc) gave (S) -4- (2- ((2- (2, 7-dioxoazepan-3-yl) -1-oxoisoindolin-4-yl) oxy) ethyl) benzaldehyde (40mg, 38% yield) as a white solid. MS (ESI) M/z 407.0[ M + H ]]+.
To a solution of (S) -4- (2- ((2- (2, 7-dioxoazepan-3-yl) -1-oxoisoindolin-4-yl) oxy) ethyl) benzaldehyde (40mg,0.1mmol) and morpholine (26mg,0.3mmol) in DCM (5mL) at RT was added sodium triacetoxyborohydride (106mg,0.5 mmol).The mixture was stirred overnight and then concentrated. The residue was purified by prep-HPLC as described previously to give compound 26 as a white solid (18mg, 38% yield). MS (ESI) M/z 478.1[ M + H ]]+.1H NMR(400MHz,DMSO-d6)δ10.72(s,1H),7.45(t,J=8.0Hz,1H),7.23-7.30(m,6H),5.22(dd,J=4.8,12.4Hz,1H),4.36(s,2H),4.32(t,J=6.8Hz,2H),3.55(t,J=4.4Hz,4H),3.41(s,2H),3.03-3.08(m,3H),2.59-2.60(m,1H),2.29-2.32(m,5H),1.99-2.10(m,2H),1.74-1.84(m,1H).
Example 28
Compound 27: (S) -3- [5- ({3- [3- (p- { 5-methyl-4- [ m- (tert-butylaminosulfonyl) phenylamino ] amino
Base of]-2-pyrimidinylamino } phenoxy) propyl]Ureido methyl) -4- { [ p- (morpholinylmethyl) phenyl]Methoxy } -2-iso
Indolinyl radical]-2, 7-azacycloheptanedione
To a solution of (S) -3- (5- (aminomethyl) -4- ((4- (morpholinomethyl) benzyl) oxy) -1-oxoisoindolin-2-yl) azepan-2, 7-dione (50mg,0.084mmol) in THF (5mL) at RT was added TEA (68mg,0.672mmol) followed by a suspension of 4-nitrophenyl (3- (4- ((4- ((3- (N- (tert-butyl) sulfamoyl) phenyl) amino) -5-methylpyrimidin-2-yl) amino) phenoxy) propyl) carbamate (54mg,0.084mmol) in THF (1 mL). The mixture was stirred for 3 hours. The solvent was evaporated and the residue was purified by silica gel chromatography, eluting with DCM/MeOH (0% to 10%) to give the crude product as a white gum (70mg), which was further purified by prep-HPLC as described previously to give compound 27 as a white solid (27.7mg, 33% yield)]+.1H NMR(400MHz,DMSO-d6)δ10.70(s,1H),8.76(s,1H),8.53(s,1H),8.13(s,1H),7.90(s,1H),7.59-7.38(m,9H),7.34(d,J=8.0Hz,2H),6.79(d,J=8.8Hz,2H),6.34(t,J=6.0Hz,1H),6.13(t,J=5.6Hz,1H),5.23(dd,J=4.8,12.0Hz,1H),5.18(s,2H),4.65(s,2H),4.33(d,J=5.2Hz,2H),3.92(t,J=6.0Hz,2H),3.58-3.55(m,4H),3.47(s,2H),3.20-3.15(m,2H),3.12-3.04(m,1H),2.60-2.56(m,1H),2.35-2.31(m,5H),2.12(s,3H),2.08-1.99(m,1H),1.86-1.78(m,4H),1.12(s,9H).
PBMC assay
Frozen Primary Blood Mononuclear Cells (PBMCs) were purchased from AllCells. Cells were thawed quickly and washed once with RPMI-1640/10% FBS.
Cells were pretreated with DMSO or Compound 1 alone for 1 hour, then induced with 100ng/mL Lipopolysaccharide (LPS) for 18-24 hours according to the manufacturer's protocol, IL-1 β, IL-6 and TNF α in the supernatant were analyzed using the Meso Scale assay, negative control wells were treated with DMSO.
For IL-2 analysis, a 96-well plate was pre-coated with 1. mu.g/mL anti-human CD3 antibody (OKT3, eBioscience Inc.). After washing with PBS, compound 1(50 μ L/well) was added followed by PBMC diluted at 3-4 million cells/mL (150 μ L/well). Plates were incubated for 24 hours and supernatants were collected for mesoscale el-2 analysis.
The activity of the compound was measured as fold difference from the DMSO control IL-1 β activity is shown in figure 1, IL-6 activity is shown in figure 2, TNF α activity is shown in figure 3, IL-2 activity is shown in figure 4.10 μ M additional data for the compound (shown as percent inhibition) is shown in table 1,1 μ M additional data for the compound is shown in table 2, and 0.1 μ M additional data for the compound is shown in table 3 additional data for IL-activity (measured as fold change in activity) is shown in tables 4-6.
TABLE 1
TABLE 2
TABLE 3
TABLE 4
TABLE 5
TABLE 6
Western blot analysis
Western blot protocol: jurkat cells were grown in RPMI 1640 supplemented with streptomycin, penicillin and 10% fetal bovine serum.
At about 106cells/mL Jurkat cells were cultured, DMSO or the indicated compound at the indicated concentration was added to the cells, and allowed to incubate for the indicated time. Whole cell extracts were prepared using RIPA reagent according to the manufacturer's protocol (Pierce). Briefly, wash in PBS-5X 106Once per cell, the cell pellet was resuspended in RIPA solution and allowed to incubate for 10min at room temperature. Cell debris was removed by centrifugation and the cleared whole cell lysate was transferred to a new tube for further analysis.
For western blot analysis, whole cell extracts were separated on 4-12% SDS-polyacrylamide gels, transferred to nitrocellulose and probed with the indicated primary antibody. The membrane was then washed and probed with a suitable horseradish peroxidase (HRP) conjugated secondary antibody. Signals were detected using the WesternBright Tianlang red reagent (Advansta). The results are shown in fig. 5A and 5B.
The following antibodies were used in these studies:
β -actin mouse anti-b-actin was obtained from Cell Signaling (8H10D10).
CK1 α goat polyclonal antibody Santa Cruz Biotechnology, sc-6477(Santa Cruz, CA)
Ikaros rabbit monoclonal antibody: cell Signaling, #9034, D10E5(Danver, MA)
Donkey anti-goat IgG-HRP: santa Cruz Biotechnology, sc-2056(Santa Cruz, CA)
Goat anti-rabbit IgG-HRP: cell Signaling, #7074(Danver, MA)
Goat anti-mouse IgG-HRP: sigma, A4416(St. Louis, MO)
Cell viability assay
Molm-13 and MV-4-11 cells were cultured in RPMI-1640 (10% FBS/1% penicillin-streptomycin) and seeded at 20,000 cells/well in white-walled 96-well plates.
Cells were treated with the indicated concentrations of compound or DMSO (control) and cultures were incubated at 37 ℃ and 5% CO2Incubate for 3 days. After the incubation period, 100. mu.L of CellTiterGlow (CTG) reagent was added to each wellLuminocyte viability assay, Promega (Madison, WI)). After incubation for 10min with shaking, luminescence was measured using a Victor Wallac luminometer.
The proliferation activity of the Molm-13 cells is shown in tables 7 to 9. MV-4-11 cell proliferation activity is shown in tables 10 and 11.
TABLE 7
TABLE 8
TABLE 9
Watch 10
TABLE 11
While the application has been illustrated and described in detail in the drawings and foregoing description, such illustration and description are to be considered illustrative or exemplary and not restrictive. The present application is not limited to the disclosed embodiments. Variations to the disclosed embodiments can be understood and effected by those skilled in the art in practicing the claimed disclosure, from a study of the drawings, the disclosure, and the appended claims.
All references cited herein are incorporated by reference herein in their entirety. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and/or take precedence over any such contradictory material.
Unless otherwise defined, all terms (including technical and scientific terms) are to be given their ordinary and customary meaning to those of ordinary skill in the art, and are not to be limited to specific or custom meanings unless expressly so defined herein. It should be noted that the use of particular terminology when describing certain features or aspects of the application should not be taken to imply that the terminology is being redefined herein to be restricted to including any specific characteristics of the features or aspects of the application with which that terminology is associated.
Where numerical ranges are provided, it is understood that the upper and lower limits of the ranges and each value between the upper and lower limits are included in the embodiments.
Terms and phrases used in this application, and variations thereof, especially in the appended claims, should be construed as open ended as opposed to limiting unless expressly stated otherwise. As examples of the foregoing, the term "including" should be read to mean "including, but not limited to," "including but not limited to," and the like; the term "comprising" as used herein is synonymous with "including," "containing," or "characterized by," and is inclusive or open-ended and does not exclude additional unrecited elements or method steps; the term "having" should be read as "having at least"; the term "including" should be read as "including but not limited to"; the term "example" is used to provide exemplary instances of the items in discussion, rather than an exhaustive or limiting list thereof; adjectives such as "known," "normal," "standard," and terms of similar meaning should not be construed as limiting the item described to a given time period or to an item available as of a given time, but rather should be read to encompass normal or standard technologies that may be available or known now or at any time in the future; and the use of terms such as "preferably," "preferred," "desired," or "desirable" and words of similar import should not be construed as indicating any critical, required, or essential features of the structure or function of the invention, but merely as providing prominent alternative or additional features that may or may not be utilized in a particular embodiment of the invention. In addition, the term "comprising" should be understood to be the same as the phrase "including at least" or "including at least". When used in the context of a method, the term "comprising" means that the method includes at least the recited steps, but may include additional steps. The term "comprising" when used in the context of a compound or composition means that the compound or composition includes at least the recited features or components, but may also include additional features or components. Also, a group of items linked with the conjunction "and" should not be read as requiring that each and every one of those items be present in the group, but rather should be read as "and/or" unless expressly stated otherwise. Similarly, a group of items linked with the conjunction "or" should not be read as requiring exclusivity among the group, but rather should be read as "and/or" unless expressly stated otherwise.
With respect to the use of substantially any plural and/or singular terms herein, those having skill in the art can translate from the plural to the singular and/or from the singular to the plural as is appropriate to the context and/or application. For clarity reasons, a number of singular/plural permutations may be specifically listed herein. The indefinite article "a" or "an" does not exclude a plurality. A single processor (processor) or other unit may fulfill the functions of several items recited in the claims. The mere fact that certain measures are recited in mutually different dependent claims does not indicate that a combination of these measures cannot be used to advantage. Any reference signs in the claims (preferencesign) shall not be construed as limiting the scope thereof.
It will be further understood by those within the art that if a specific number of an introduced claim recitation is intended, such an intent will be explicitly recited in the claim, and in the absence of such recitation no such intent is present. For example, as an aid to understanding, the following appended claims may contain usage of the introductory phrases "at least one" and "one or more" to introduce claim recitations. However, the use of such phrases should not be construed to imply that the introduction of a claim recitation by the indefinite articles "a" or "an" limits any particular claim containing such introduced claim recitation to embodiments containing only one such recitation, even when the same claim includes the introductory phrases "one or more" or "at least one" and indefinite articles such as "a" or "an" (e.g., "a" and/or "an" should typically be interpreted to mean "at least one" or "one or more" and the use of definite articles to introduce a claim recitation. The direct recitation of "two recitations," without other modifiers, typically means at least two recitations, or two or more recitations). Further, in those instances where a convention analogous to "at least one of A, B and C, etc." is used, in general such a construction is intended to mean that one of ordinary skill in the art would understand the meaning of the convention (e.g., "a system having at least one of A, B and C" would include, but not be limited to, systems that have a alone, B alone, C alone, a and B together, a and C together, B and C together, and/or A, B and C together, etc.). In those instances where a convention analogous to "A, B or at least one of C, etc." is used, in general such a construction is intended that one skilled in the art will understand the meaning of the convention (e.g., "a system having at least one of A, B and C" will include, but not be limited to, systems that have a alone, B alone, C alone, a and B together, a and C together, B and C together, and/or A, B and C together, etc.). It will be further understood by those within the art that virtually any alternative words and/or phrases presenting two or more alternative terms, whether in the specification, claims, or drawings, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase "a or B" will be understood to include the possibility of "a" or "B" or "a and B".
All numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification are to be understood as being modified in all instances by the term "about". Accordingly, unless indicated to the contrary, the numerical parameters set forth herein are approximations that may vary depending upon the desired properties to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of any claims in any application claiming priority to the present application, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.
Claims (94)
1. A compound of the general formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
Q1is CH2、O、NR2S or a bond;
Q2is CH2Or a bond;
x is CH2Or C ═ O;
X1is hydrogen, deuterium, methyl or fluorine;
Each R1Independently is deuterium, hydroxy, halogen, nitro, substituted or unsubstituted amino, substituted or unsubstituted C1-C6Alkoxy, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C2-C6Alkenyl, substituted or unsubstituted C3-C8Cycloalkyl, substituted or unsubstituted 3 to 10 membered heterocyclyl,Substituted or unsubstituted C6-C10Aryl, substituted or unsubstituted 5 to 10 membered heteroaryl or L-Y;
R2is hydrogen, deuterium, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C2-C6Alkenyl, acyl or- (SO)2)-C1-C6An alkyl group;
each R3A、R3B、R3C、R3DAnd R3EIndependently hydrogen, deuterium, hydroxyl, halogen, nitro, substituted or unsubstituted amino, substituted or unsubstituted C1-C6Alkoxy, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C2-C6Alkenyl, substituted or unsubstituted C3-C8Cycloalkyl, substituted or unsubstituted 3 to 10 membered heterocyclyl, substituted or unsubstituted alkoxyalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted heteroaralkyl or L-Y;
m is 0, 1,2 or 3;
n is 1,2 or 3;
l is-Z1-(R4)t-Z2–;–Z1-(R4-O-R4)t-Z2–;–Z1(R4-NH-R4)t-Z2–;–Z1-(R4-(NHCO)-R4)t-Z2–;–Z1-(R4-(NHC(O)NH)-R4)t-Z2-; or-Z1-(R4-(CONH)-R4)t-Z2–;
Z1And Z2Independently selected from-NH-; -O-; -CH2–;–NH(CO)–;–(CO)NH–;–CH2NH–;–NHCH2–;–(CO)NHCH2–;–CH2CH2NH–;–CH2NH (CO) -; or-NHCH2CH2–;
Each R4Independently is unsubstituted C1-C6An alkylene group;
t is 1,2,3, 4,5 or 6; and
Wherein Y is derivatized to link to L; and
wherein Y is1、Y2、Y3、Y4And Y5At least one of which is R respectively3A、R3B、R3C、R3DOr R3E;
When Q is1Is CH2Or when a bond is present, then R3A、R3B、R3C、R3DOr R3EIs not hydrogen;
when R is1When L-Y is present, R3A、R3B、R3C、R3DAnd R3EEach of which is not L-Y; and
when Q is2Is a bond, Q1Is a bond or CH2(ii) a And
when Q is1Is a bond, X1Is hydrogen or methyl and Q2Is CH2(ii) a Then m is not 0; or
When Q is1Is a bond, X1Is hydrogen or methyl and Q2Is CH2(ii) a Then R is1、R3A、R3B、R3C、R3DAnd R3EOne of them is L-Y.
2. A compound of the general formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
Q1is CH2、O、NR2S or a bond;
Q2is CH2Or a bond;
x is CH2Or C ═ O;
X1is hydrogen, deuterium or fluorine;
Each R1Independently is deuterium, hydroxy, halogen, nitro, substituted or unsubstituted amino, substituted or unsubstituted C1To C6Haloalkyl, substituted or unsubstituted C1-C6Alkoxy, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C2-C6Alkenyl, substituted or unsubstituted C3-C8Cycloalkyl, substituted or unsubstituted 3 to 10 membered heterocyclyl, substituted or unsubstituted C6-C10Aryl, substituted or unsubstituted 5 to 10 membered heteroaryl or L-Y;
R2is hydrogen, deuterium, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C2-C6Alkenyl, acyl or- (SO)2)-C1-C6An alkyl group;
each R3A、R3B、R3C、R3DAnd R3EIndependently hydrogen, deuterium, hydroxyl, halogen, nitro, substituted or unsubstituted amino, substituted or unsubstituted C1To C6Haloalkyl, substituted or unsubstituted C1-C6Alkoxy, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C2-C6Alkenyl, substituted or unsubstituted C3-C8Cycloalkyl, substituted or unsubstituted 3 to 10 membered heterocyclyl, substituted or unsubstituted alkoxyalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted heterocyclylAlkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted heteroaralkyl or L-Y;
m is 0, 1,2 or 3;
n is 1 or 2;
l is-Z1-(R4-O-R4)t-Z2–;–Z1(R4-NH-R4)t-Z2–;–Z1-(R4-(NHCO)-R4)t-Z2-; or-Z1-(R4-(CONH)-R4)t-Z2–;
Z1is-NH-; -O-; -CH2–;–NH(CO)–;–(CO)NH–;–CH2NH–;–NHCH2–;–CH2NH (CO) -or-NHCH2CH2–;
Z2is-NH-; -O-; -CH2-; -nh (co) -; or- (CO) NH-; -CH2NH–;–NHCH2-; or-NHCH2CH2–;
Each R4Independently is unsubstituted C1-C6An alkylene group;
t is 1,2,3, 4,5 or 6; and
Wherein Y is derivatized to link to L; and
wherein Y is1、Y2、Y3、Y4And Y5At least one of which is CR3;
When Q is1Is CH2Or when a bond is present, then R3A、R3B、R3C、R3DOr R3EIs not hydrogen;
when R is1Is L-Y, R3A、R3B、R3C、R3DAnd R3EEach of which is not L-Y; and
when Q is1In the case of a key, the key is,then m is not 0.
3. The compound of claim 1 or 2, wherein X is CH2。
4. A compound according to claim 1 or 2, wherein X is C ═ O.
5. The compound of any one of claims 1-4, wherein X1Is hydrogen.
6. The compound of any one of claims 1-4, wherein X1Is fluorine.
7. The compound of any one of claims 1-5, wherein Q1Is NR2。
8. The compound of any one of claims 1-7, wherein R2Is hydrogen.
9. The compound of any one of claims 1-7, wherein R2Is substituted or unsubstituted C1-C6An alkyl group.
10. The compound of any one of claims 1-7, wherein R2Is unsubstituted C1-C6An alkyl group.
11. The compound of any one of claims 1-7, wherein R2Is an acyl group.
12. The compound of any one of claims 1-7, wherein R2Is- (SO)2)-C1-C6An alkyl group.
13. The compound of any one of claims 1-7, wherein R2Is methyl.
14. The compound of any one of claims 1-6, wherein Q1Is CH2。
15. The compound of any one of claims 1-6, wherein Q1Is O.
16. The compound of any one of claims 1-6, wherein Q1Is S.
17. The compound of any one of claims 1-6, wherein Q1Is a bond.
18. The compound of any one of claims 1-17, wherein Q2Is CH2。
19. The compound of any one of claims 1-17, wherein Q2Is a bond.
20. The compound of any one of claims 1-19, wherein n is 1.
21. The compound of any one of claims 1-19, wherein n is 2.
22. The compound of any one of claims 1-21, wherein m is 1.
23. The compound of any one of claims 1-21, wherein m is 2.
24. The compound of any one of claims 1-21, wherein m is 3.
25. The compound of any one of claims 1-18 or 20-21, wherein m is 0.
26. The compound of any one of claims 1-25, wherein each R1Independently is halogen, substituted or unsubstituted amino, substituted or unsubstituted C1-C6Alkoxy, substituted or unsubstituted C3-C8Cycloalkyl or substituted or unsubstituted C1-C6An alkyl group.
27. The compound of any one of claims 1-25, wherein each R1Independently halogen, substituted or unsubstituted amino, unsubstituted C1-C6Haloalkyl, unsubstituted C1-C6Alkoxy, unsubstituted C3-C8Cycloalkyl or unsubstituted C1-C6An alkyl group.
28. The compound of any one of claims 26-27, wherein each R1Independently of one another, fluorine, chlorine, -NH2、-NH(CH3)、-N(CH3)2、-CF3、-OCH3、-OCH2CH3、-OCH(CH3)2、-CH3、-CH2CH3、–CH(CH3)2Unsubstituted cyclopropyl, unsubstituted cyclobutyl, or unsubstituted cyclopentyl.
30. the compound of any one of claims 1-29, wherein R3A、R3B、R3C、R3DAnd R3EIn (1)Each is independently hydrogen, deuterium, hydroxy, halogen, nitro, substituted or unsubstituted amino, substituted or unsubstituted C1-C6Alkoxy, substituted or unsubstituted C1-C6Alkyl, substituted or unsubstituted C2-C6Alkenyl, substituted or unsubstituted C3-C8A cycloalkyl group, a substituted or unsubstituted 3 to 10 membered heterocyclyl group, a substituted or unsubstituted alkoxyalkyl group, a substituted or unsubstituted cycloalkylalkyl group, a substituted or unsubstituted heterocyclylalkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted heteroaralkyl group.
31. The compound of any one of claims 1-29, wherein R3A、R3B、R3C、R3DAnd R3EEach of which is independently hydrogen, hydroxy, halogen, nitro, unsubstituted amino, unsubstituted C1-C6Haloalkyl, unsubstituted C1-C6Alkoxy, unsubstituted C1-C6Alkyl, substituted or unsubstituted C3-C8A cycloalkyl group, a substituted or unsubstituted 3 to 10 membered heterocyclyl group, a substituted or unsubstituted alkoxyalkyl group, a substituted or unsubstituted cycloalkylalkyl group, a substituted or unsubstituted heterocyclylalkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted heteroaralkyl group.
32. The compound of any one of claims 1-29, wherein R3A、R3B、R3C、R3DAnd R3EEach of which is independently hydrogen, hydroxy, halogen, nitro, unsubstituted amino, unsubstituted C1-C6Haloalkyl, unsubstituted C1-C6Alkoxy, unsubstituted C1-C6Alkyl, unsubstituted C3-C8Cycloalkyl, unsubstituted 3 to 10 membered heterocyclyl, unsubstituted cycloalkylalkyl, unsubstituted 3 to 10 membered heterocyclylalkyl, unsubstituted aralkyl, or unsubstituted 5 to 10 membered heteroaralkyl.
33. The compound of any one of claims 1-32, wherein R3A、R3B、R3C、R3DAnd R3EEach of which is independently hydrogen, halogen, unsubstituted C1-C6Haloalkyl, unsubstituted C1-C6Alkoxy, unsubstituted C1-C6An alkyl group, an unsubstituted 3 to 10 membered heterocyclyl group or an unsubstituted 3 to 10 membered heterocyclylalkyl group.
34. The compound of any one of claims 1-33, wherein R3A、R3B、R3C、R3DAnd R3EOne of them is halogen, unsubstituted C1-C6Haloalkyl, unsubstituted C1-C6Alkoxy, unsubstituted C1-C6An alkyl group, an unsubstituted 3 to 10 membered heterocyclyl group or an unsubstituted 3 to 10 membered heterocyclylalkyl group, and R3A、R3B、R3C、R3DAnd R3EThe others in (a) are hydrogen.
35. The compound of any one of claims 1-34, wherein R3A、R3B、R3C、R3DAnd R3EOne of them is fluorine, chlorine, -CF3、-OCH3Unsubstituted C1-C6An alkyl group, an unsubstituted 3 to 10 membered heterocyclyl group or an unsubstituted 3 to 10 membered heterocyclylalkyl group, and R3A、R3B、R3C、R3DAnd R3EThe other of the groups is hydrogen.
37. The compound of any one of claims 1-24, wherein one R1Is L-Y.
38. The compound of any one of claims 1-28, wherein R3A、R3B、R3C、R3DAnd R3EOne of them is L-Y.
39. The compound of claim 38, wherein Y3Is C-L-Y.
40. The compound of any one of claims 1-24 or 37-39, wherein L is-Z1-(R4-O-R4)t-Z2–。
41. The compound of any one of claims 1-24 or 37-39, wherein L is-Z1(R4-NH-R4)t-Z2–。
42. The compound of any one of claims 1-24 or 37-39, wherein L is Z1-(R4-(NHCO)-R4)t-Z2-or-Z1-(R4-(NHC(O)NH)-R4)t-Z2–。
43. The compound of any one of claims 1-24 or 37-39, wherein L is-Z1-(R4-(CONH)-R4)t-Z2–。
44. The method of any one of claims 1-24 and 40-43A compound wherein Z1is-NH-.
45. The compound of any one of claims 1-24 and 40-43, wherein Z1is-O-.
46. The compound of any one of claims 1-24 and 40-43, wherein Z1is-CH2–。
47. The compound of any one of claims 1-24 and 40-43, wherein Z1is-NH (CO) -, - (CO) NH-or-CH2NH(CO)–。
48. The compound of any one of claims 1-24 and 40-43, wherein Z1is-CH2NH–。
49. The compound of any one of claims 1-24 and 40-43, wherein Z1is-NHCH2-or-NHCH2CH2–。
50. The compound of any one of claims 1-24 and 40-49, wherein Z2is-NH-.
51. The compound of any one of claims 1-24 and 40-49, wherein Z2is-O-.
52. The compound of any one of claims 1-24 and 40-49, wherein Z2is-CH2–。
53. The compound of any one of claims 1-24 and 40-49, wherein Z2is-NH (CO) -or- (CO) NH-.
54. The compound of any one of claims 1-24 and 40-49, wherein Z2Is- (CO) NH–。
55. The compound of any one of claims 1-24 and 40-49, wherein Z2is-CH2NH–。
56. The compound of any one of claims 1-24 and 40-49, wherein Z2is-NHCH2-or-NHCH2CH2–。
57. The compound of any one of claims 1-24 and 40-56, wherein each R4Independently is unsubstituted C1-C4An alkylene group.
58. The compound of claim 57, wherein each R4Independently is unsubstituted C1-C2An alkylene group.
59. The compound of any one of claims 1-24 and 40-58, wherein t is 1.
60. The compound of any one of claims 1-24 and 40-58, wherein t is 2.
61. The compound of any one of claims 1-24 and 40-58, wherein t is 3.
62. The compound of any one of claims 1-24 and 40-58, wherein t is 4.
63. The compound of any one of claims 1-24 and 40-58, wherein t is 5.
64. The compound of any one of claims 1-24 and 40-58, wherein t is 6.
66. A pharmaceutical composition comprising a compound of any one of claims 1-65, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
67. A method of inhibiting cytokine activity, comprising contacting a cell with an effective amount of a compound of any one of claims 1-65, or a pharmaceutically acceptable salt thereof.
68. The method of claim 67, wherein the cytokine is selected from the group consisting of IL-1 β, IL-2, IL-6, and TNF α.
69. The method of any one of claims 67-68, wherein the cytokine is TNF α.
70. A method of inhibiting aiolos activity, comprising contacting a cell with an effective amount of a compound of any one of claims 1-65, or a pharmaceutically acceptable salt thereof.
71. A method of inhibiting ikaros activity comprising contacting a cell with an effective amount of a compound of any one of claims 1-65, or a pharmaceutically acceptable salt thereof.
72. A method of inhibiting hellios activity comprising contacting a cell with an effective amount of a compound of any one of claims 1-65, or a pharmaceutically acceptable salt thereof.
73. A method of inhibiting CK-1 α activity comprising contacting a cell with an effective amount of a compound of any one of claims 1-65, or a pharmaceutically acceptable salt thereof.
74. The method of any one of claims 67-73, wherein the cell is a cancer cell.
75. The method of any one of claims 67-74, wherein the cell is a small cell lung cancer cell, a non-small cell lung cancer cell, a breast cancer cell, a prostate cancer cell, a head and neck cancer cell, a pancreatic cancer cell, a colon cancer cell, a rectal cancer cell, a teratoma cell, an ovarian cancer cell, an endometrial cancer cell, a brain cancer cell, a retinoblastoma cell, a leukemia cell, a skin cancer cell, a melanoma cell, a squamous cell carcinoma cell, an liposarcoma cell, a lymphoma cell, a multiple myeloma cell, a testicular cancer cell, a liver cancer cell, an esophageal cancer cell, a renal cancer cell, an astrocyte proliferating cell, a relapsed/refractory multiple myeloma cell, or a neuroblastoma cell.
76. A method of treating, ameliorating, or preventing a disease, disorder, or condition associated with a protein selected from the group consisting of cytokines, aiolos, ikaros, helios, CK1 α, and a combination of any of the foregoing in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-65, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 66.
77. The method of claim 76, wherein the disease, disorder, or condition is a cancer selected from a hematologic malignancy and a solid tumor.
78. The method of any one of claims 76-77, wherein the disease, disorder, or condition is a cancer selected from small cell lung cancer, non-small cell lung cancer, breast cancer, prostate cancer, head and neck cancer, pancreatic cancer, colon cancer, rectal cancer, teratomas, ovarian cancer, endometrial cancer, brain cancer, retinoblastoma, leukemia, skin cancer, melanoma, squamous cell carcinoma, liposarcoma, lymphoma, multiple myeloma, testicular cancer, liver cancer, esophageal cancer, kidney cancer, astrocytosis, relapsed/refractory multiple myeloma, and neuroblastoma.
79. The method of claim 76, wherein the disease, disorder, or condition is selected from inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung disease, chronic obstructive pulmonary disease, and Alzheimer's disease.
80. The method of claim 79, wherein the disease, disorder, or condition is selected from fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
81. The method of any one of claims 76-80, wherein the protein is a cytokine.
82. The method of any one of claims 76-81, wherein the protein is selected from the group consisting of IL-1 β, IL-2, IL-6, and TNF α.
83. The method of any one of claims 76-82, wherein the protein is IL-1 β.
84. The method of any one of claims 76-82, wherein the protein is IL-2.
85. The method of any one of claims 76-82, wherein the protein is IL-6.
86. The method of any one of claims 76-82, wherein the protein is TNF α.
87. The method of any one of claims 76-80, wherein the protein is aiolos.
88. The method of any one of claims 76-80, wherein the protein is ikaros.
89. The method of any one of claims 76-80, wherein the protein is helios.
90. The method of any one of claims 76-80, wherein the protein is CK1 α.
91. The method of any one of claims 76-80, wherein the protein is two of IL-1 β, IL-2, IL-6, TNF α, aiolos, ikaros, helios, and CK1 α.
92. The method of any one of claims 76-91, wherein the protein is overexpressed.
93. The method of any one of claims 76-92, wherein the protein is wild-type.
94. The method of any one of claims 76-92, wherein the protein is a mutant form of a protein.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762550489P | 2017-08-25 | 2017-08-25 | |
US62/550,489 | 2017-08-25 | ||
PCT/US2018/045626 WO2019040274A1 (en) | 2017-08-25 | 2018-08-07 | Ether compounds and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111247138A true CN111247138A (en) | 2020-06-05 |
Family
ID=63350615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880067990.7A Pending CN111247138A (en) | 2017-08-25 | 2018-08-07 | Ether compound and use thereof |
Country Status (8)
Country | Link |
---|---|
US (2) | US10513515B2 (en) |
EP (1) | EP3672955A1 (en) |
JP (1) | JP2020531481A (en) |
CN (1) | CN111247138A (en) |
AU (1) | AU2018321567A1 (en) |
CA (1) | CA3072543A1 (en) |
TW (2) | TW202222794A (en) |
WO (1) | WO2019040274A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022007659A1 (en) * | 2020-07-06 | 2022-01-13 | 北京诺诚健华医药科技有限公司 | Heterocyclic immunomodulator |
CN115677667A (en) * | 2021-07-30 | 2023-02-03 | 海创药业股份有限公司 | Bifunctional chimera heterocyclic compound and application thereof as androgen receptor degrading agent |
WO2023025136A1 (en) * | 2021-08-27 | 2023-03-02 | 杭州格博生物医药有限公司 | Isoindolinone compound and use thereof |
WO2024051766A1 (en) * | 2022-09-08 | 2024-03-14 | 标新生物医药科技(上海)有限公司 | Molecular glue compound based on cereblon protein design and use thereof |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019014100A1 (en) | 2017-07-10 | 2019-01-17 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
AU2019309894A1 (en) | 2018-07-27 | 2021-01-28 | Biotheryx, Inc. | Bifunctional compounds as CDK modulators |
CN113710661B (en) * | 2019-04-02 | 2022-11-22 | 上海睿跃生物科技有限公司 | Compounds and methods for treating cancer |
US11897930B2 (en) | 2020-04-28 | 2024-02-13 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
WO2022012622A1 (en) * | 2020-07-16 | 2022-01-20 | Beigene, Ltd. | Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use |
BR112023000817A2 (en) | 2020-07-20 | 2023-02-07 | Jiangsu Hengrui Pharmaceuticals Co Ltd | ISOINDOLINE DERIVATIVE CONTAINING SULFUR, AND METHOD OF PREPARATION OF THE SAME AND MEDICAL USE OF THE SAME |
TW202227427A (en) | 2020-09-16 | 2022-07-16 | 美商拜歐斯瑞克斯公司 | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
TW202231269A (en) | 2020-10-23 | 2022-08-16 | 美商拜歐斯瑞克斯公司 | Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
US20240124418A1 (en) | 2020-12-14 | 2024-04-18 | Biotheryx, Inc. | Pde4 degraders, pharmaceutical compositions, and therapeutic applications |
WO2022251588A1 (en) * | 2021-05-27 | 2022-12-01 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
WO2024064358A1 (en) | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102822165A (en) * | 2010-02-11 | 2012-12-12 | 细胞基因公司 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
WO2014116573A1 (en) * | 2013-01-22 | 2014-07-31 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
CN105566290A (en) * | 2014-10-30 | 2016-05-11 | 康朴生物医药技术(上海)有限公司 | Isoindoline derivative and intermediate, preparation method, pharmaceutical composition and application thereof |
WO2016191178A1 (en) * | 2015-05-22 | 2016-12-01 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
WO2017024318A1 (en) * | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
WO2017201069A1 (en) * | 2016-05-18 | 2017-11-23 | Biotheryx, Inc. | Oxoindoline derivatives as protein function modulators |
TW201837031A (en) * | 2017-03-14 | 2018-10-16 | 美商拜歐斯瑞克斯公司 | Compounds targeting proteins, compositions, methods, and uses thereof |
US20200361896A1 (en) * | 2017-08-15 | 2020-11-19 | Global Blood Therapeutics, Inc. | Tricyclic compounds as histone methyltransferase inhibitors |
CN112601751A (en) * | 2018-06-13 | 2021-04-02 | 拜欧斯瑞克斯公司 | Fused thiophene compounds |
CN114502543A (en) * | 2019-05-24 | 2022-05-13 | 拜欧斯瑞克斯公司 | Targeted protein compounds, pharmaceutical compositions and therapeutic applications thereof |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA793864A (en) | 1968-09-03 | G. Bassiri Taghi | Epsilon-caprolactams | |
DE292451C (en) | ||||
US3331835A (en) | 1965-01-07 | 1967-07-18 | Allied Chem | Novel epsilon-caprolactams |
BE793517A (en) | 1972-01-03 | 1973-06-29 | Bayer Ag | ANTHRAQUINONIC DYES |
US4339600A (en) | 1976-05-10 | 1982-07-13 | E. R. Squibb & Sons, Inc. | Compounds for alleviating angiotensin related hypertension |
US4415496A (en) | 1981-03-23 | 1983-11-15 | Merck & Co., Inc. | Bicyclic lactams |
US4644069A (en) | 1984-08-15 | 1987-02-17 | Ciba-Geigy Corporation | Process for the preparation of dimethylmaleic anhydride |
DE3833892A1 (en) | 1988-10-05 | 1990-04-12 | Bayer Ag | BASIC 4-ARYL-DHP AMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICINAL PRODUCTS |
SU1708812A1 (en) | 1989-10-03 | 1992-01-30 | Отдел Тонкого Органического Синтеза Института Химии Башкирского Научного Центра Уральского Отделения Ан Ссср | @,@-phthalimido-@-caprolactam as intermediate products for the synthesis of n@-methyl-@-lysine hydrochloride |
EP0446899A1 (en) | 1990-03-16 | 1991-09-18 | Konica Corporation | Silver halide photographic material |
DE4125292A1 (en) | 1991-07-31 | 1993-02-04 | Kali Chemie Pharma Gmbh | 6-OXO-AZEPINOINDOL COMPOUNDS AND METHODS AND INTERMEDIATE PRODUCTS FOR THEIR MANUFACTURE AND MEDICAMENTS CONTAINING SUCH COMPOUNDS |
US5272158A (en) | 1991-10-29 | 1993-12-21 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5504080A (en) | 1992-10-28 | 1996-04-02 | Bristol-Myers Squibb Co. | Benzo-fused lactams |
EP0669936B1 (en) | 1992-10-30 | 2000-11-22 | Merrell Pharmaceuticals Inc. | Mercaptoacetylamide bicyclic lactam derivatives useful as inhibitors of enkephalinase and ace |
WO1994015995A1 (en) | 1993-01-11 | 1994-07-21 | The Trustees Of The University Of Pennsylvania | Polycyclic aromatic compounds having nonlinear optical properties |
US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
US5631280A (en) | 1995-03-29 | 1997-05-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5932582A (en) | 1996-06-28 | 1999-08-03 | Merck & Co., Inc. | Fibrinogen receptor antagonist prodrugs |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
US6429212B1 (en) | 1996-08-16 | 2002-08-06 | Ishihara Sangyo Kaisha Ltd. | Medicinal composition |
DE69734290T2 (en) | 1996-11-05 | 2006-07-06 | The Children's Medical Center Corp., Boston | MEANS FOR INHIBITING ANGIOGENESIS-CONTAINING THALODOMIDE AND A NSAID |
US5977134A (en) | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
ATE283270T1 (en) | 1997-04-25 | 2004-12-15 | Takeda Chemical Industries Ltd | CONDENSED PYRIDAZINE DERIVATIVES, THEIR PREPARATION AND USE |
EP0927992A4 (en) | 1997-07-17 | 1999-09-15 | Sony Corp | Magnetic recording medium and magnetic recorder/reproducer comprising the same |
ATE266636T1 (en) | 1997-09-09 | 2004-05-15 | Bristol Myers Squibb Pharma Co | BENZIMIDAZOLINONE, BENZOXAZOLINONE, BENZOPIPERAZINONE, INDANONE AND THEIR DERIVATIVES AS FACTOR XA INHIBITORS |
JP2000159761A (en) | 1998-11-30 | 2000-06-13 | Yoshio Takeuchi | Fluorothalidomide |
US6284755B1 (en) | 1998-12-08 | 2001-09-04 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
AU4485400A (en) | 1999-04-26 | 2000-11-10 | Advanced Life Sciences Inc. | Synthetic indolocarbazole regioisomers and uses thereof |
US6492380B1 (en) | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
AU5737900A (en) | 1999-06-15 | 2001-01-02 | Du Pont Pharmaceuticals Company | Substituted heterocycle fused gamma-carbolines |
FR2800739B1 (en) | 1999-11-04 | 2002-10-11 | Corning Sa | NAPHTOPYRANS WITH A HETEROCYCLE IN POSITION 5,6, PREPARATION AND COMPOSITIONS AND (CO) POLYMERIC MATRICES CONTAINING THEM |
FR2801054B1 (en) | 1999-11-17 | 2003-06-13 | Adir | NOVEL DERIVATIVES OF 12,13- (PYRANOSYL) -INDOLO [2,3-A] PYRROLO [3,4-C] CARBAZOLE AND 12,13- (PYRANOSYL) -FURO [3,4-C] INDOLO [2,3 -A] CARBAZOLE, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US6388090B2 (en) | 2000-01-14 | 2002-05-14 | Orion Corporation | Imidazole derivatives |
US6686477B2 (en) | 2000-09-29 | 2004-02-03 | Eastman Chemical Company | Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same |
US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
AU2002254375A1 (en) | 2001-03-30 | 2002-10-15 | Merck And Co., Inc. | Inhibitors of prenyl-protein transferase |
US20030114448A1 (en) | 2001-05-31 | 2003-06-19 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
DE10137163A1 (en) | 2001-07-30 | 2003-02-13 | Bayer Ag | New thiophenecarboxamido-substituted isoindole derivatives, useful as Factor XIa inhibitors for treatment or prophylaxis of, e.g. thromboembolic diseases, atherosclerosis, arthritis, Alzheimer's disease or cancer |
AU2002340059A1 (en) | 2001-09-27 | 2003-04-07 | Linden Technologies, Inc. | Protected linker compounds |
US20040110757A1 (en) | 2002-03-21 | 2004-06-10 | Thomas Arrhenius | Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis |
US7342007B2 (en) | 2003-03-14 | 2008-03-11 | Astrazeneca Ab | Lactams and uses thereof |
WO2004087153A2 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
DE10317817A1 (en) | 2003-04-16 | 2004-11-04 | Chromeon Gmbh | Pyrrolopyrrole as a fluorescent marker for biomolecules and spherical particles |
CA2522990A1 (en) | 2003-04-28 | 2004-11-11 | Tibotec Pharmaceuticals Ltd. | Hiv integrase inhibitors |
WO2005016326A2 (en) | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
US7569580B2 (en) | 2004-06-03 | 2009-08-04 | Rigel Pharmaceuticals, Inc. | Heterotricyclic compounds for use as HCV inhibitors |
EA200700712A1 (en) | 2004-09-21 | 2008-02-28 | Эсерсис, Инк. | Indoleacetic acid with DERIVATIVES, METHOD FOR PRODUCING SUCH DERIVATIVES (OPTIONS) PHARMACEUTICAL COMPOSITION, KIT BASED THEREON, METHOD FOR INHIBITING ENDOGENOUS LIGAND BINDING AND METHOD FOR TREATING DISEASES AND DISORDERS, susceptibility to inhibition of binding of endogenous ligands to the receptor CRTH-2 |
US20080318998A1 (en) | 2005-02-09 | 2008-12-25 | Coley Pharmaceutical Group, Inc. | Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines |
JP2008535892A (en) | 2005-04-11 | 2008-09-04 | プロビオドルグ エージー | Inhibitors of prolyl endopeptidase |
AR056968A1 (en) | 2005-04-11 | 2007-11-07 | Xenon Pharmaceuticals Inc | ESPIRO-OXINDOL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS |
WO2007000337A1 (en) | 2005-06-29 | 2007-01-04 | Palau Pharma, S.A. | Bicyclic derivatives as p38 kinase inhibitors |
BRPI0613958A2 (en) | 2005-06-29 | 2011-02-22 | Palau Pharma Sa | bicyclic compound, its use as a p38 inhibitor and pharmaceutical composition containing the same |
TW200728277A (en) | 2005-06-29 | 2007-08-01 | Palau Pharma Sa | Bicyclic derivatives as P38 inhibitors |
WO2007028789A1 (en) | 2005-09-07 | 2007-03-15 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Quinazoline derivatives as antiviral agents |
EP2012810A2 (en) | 2006-03-24 | 2009-01-14 | Archemix Corp. | Solid support reagents for synthesis |
WO2007117394A2 (en) | 2006-03-31 | 2007-10-18 | Dynamis Therapeutics, Inc. | Compositions and methods related to fructosamine-3-kinase inhibitors |
US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
WO2008037266A1 (en) | 2006-09-25 | 2008-04-03 | Universite Libre De Bruxelles | Inhibitors of conventional protein kinase c isozymes and use thereof for treating inflammatory diseases |
US8143284B2 (en) | 2006-10-05 | 2012-03-27 | Abbott Laboratories | Poly(ADP-ribose)polymerase inhibitors |
AR063311A1 (en) | 2006-10-18 | 2009-01-21 | Novartis Ag | ORGANIC COMPOUNDS |
JP2009023986A (en) | 2006-11-08 | 2009-02-05 | Pharma Ip | Biaryl derivative as anticancer agent |
CN101186611B (en) | 2006-11-15 | 2011-05-18 | 天津和美生物技术有限公司 | Pyrroline-2-one derivative capable of inhibiting cell to release tumor necrotic factor and its preparation and application |
BRPI0720023A2 (en) | 2006-12-11 | 2018-09-04 | Novartis Ag | method for preventing or treating myocardial ischemia by inhibiting dgat1 enzyme with a dgat1 inhibitor |
JP2010515684A (en) | 2007-01-08 | 2010-05-13 | ポリエラ コーポレイション | Method for preparing arene-bis (dicarboximide) based semiconductor materials and related intermediates for preparing the same |
GB0707051D0 (en) | 2007-04-12 | 2007-05-30 | Istituto Di Ricerche D Biolog | Antiviral agents |
US20090082368A1 (en) | 2007-09-24 | 2009-03-26 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
KR101124350B1 (en) | 2007-10-17 | 2012-03-15 | 한국화학연구원 | Phenanthrene lactam derivatives having anticancer activity, method for preparing same and pharmaceutical composition containing same |
WO2009070533A1 (en) | 2007-11-29 | 2009-06-04 | Complegen, Inc. | Methods of inhibiting steroyl coa desaturase |
WO2009072581A1 (en) | 2007-12-05 | 2009-06-11 | Aska Pharmaceutical Co., Ltd. | Lactam compound or salt thereof, and ppar activator |
EP2072506A1 (en) | 2007-12-21 | 2009-06-24 | Bayer CropScience AG | Thiazolyloxyphenylamidine or thiadiazolyloxyphenylamidine und its use as fungicide |
RU2544856C2 (en) | 2008-01-25 | 2015-03-20 | Сергей Олегович Бачурин | NEW 2,3,4,5-TETRAHYDRO-1-PYRIDO[4,3-b]INDOLE DERIVATIVES AND METHODS FOR USING THEM |
US9446995B2 (en) | 2012-05-21 | 2016-09-20 | Illinois Institute Of Technology | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions |
WO2009112445A1 (en) | 2008-03-10 | 2009-09-17 | Novartis Ag | Method of increasing cellular phosphatidyl choline by dgat1 inhibition |
JP5628145B2 (en) | 2008-03-19 | 2014-11-19 | ケムブリッジ・コーポレーション | Novel tyrosine kinase inhibitor |
US8822500B2 (en) | 2008-03-19 | 2014-09-02 | Chembridge Corporation | Tyrosine kinase inhibitors |
AU2009262515A1 (en) | 2008-06-27 | 2009-12-30 | Bayer Cropscience Ag | Thiadiazolyloxyphenylamidines and use thereof as fungicides |
WO2010011924A2 (en) | 2008-07-24 | 2010-01-28 | Draths Corporation | Monomers derived from alpha-or beta-amino-e-caprolactam and polymers made therefrom |
AU2009333543A1 (en) | 2008-12-08 | 2011-07-07 | Sirtris Pharmaceuticals, Inc. | Isoindolinone and related analogs as sirtuin modulators |
CA2774871C (en) | 2009-10-20 | 2018-05-29 | Tokyo Institute Of Technology | Screening method utilizing thalidomide-targeting factor |
JP5734570B2 (en) | 2010-01-28 | 2015-06-17 | 富士フイルム株式会社 | Method for producing pigment fine particles |
KR20110119282A (en) | 2010-04-27 | 2011-11-02 | 다우어드밴스드디스플레이머티리얼 유한회사 | Novel organic electroluminescent compounds and organic electroluminescent device using the same |
US8697690B2 (en) | 2010-07-01 | 2014-04-15 | Merck Sharp & Dohme Corp. | Isoindolone M1 receptor positive allosteric modulators |
US8742097B2 (en) | 2010-11-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Triazole compounds I |
TWI445696B (en) | 2010-11-29 | 2014-07-21 | Univ Nat Yang Ming | Targeting human thymidylate kinase induces dna repair toxicity in malignant tumor cells |
JP5728921B2 (en) | 2010-12-10 | 2015-06-03 | コニカミノルタ株式会社 | Optical film, polarizing plate using the same, and liquid crystal display device |
WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
US9206200B2 (en) | 2011-05-17 | 2015-12-08 | Merck Sharp & Dohme Corp. | N-linked lactam M1 receptor positive allosteric mogulators |
CA2835014A1 (en) | 2011-05-27 | 2012-12-06 | Probiodrug Ag | Radiolabelled glutaminyl cyclase inhibitors |
WO2013010218A1 (en) | 2011-07-15 | 2013-01-24 | Freie Universität Berlin | Inhibition of clathrin |
CN104080784B (en) | 2012-01-10 | 2017-07-18 | 默克专利有限公司 | Heterocyclic carbamate derivatives as follicular stimulating hormone conditioning agent |
KR20130131663A (en) | 2012-05-24 | 2013-12-04 | 코오롱생명과학 주식회사 | Benzylidene phthalimide monomer, method for preparing the same, polymer comprising the same, liquid crystal alignment film comprising the same and retarder film comprising the same |
KR101592628B1 (en) | 2012-09-20 | 2016-02-11 | 주식회사 엘지화학 | Imidazole compound and organic electronic device using the same |
AR092742A1 (en) | 2012-10-02 | 2015-04-29 | Intermune Inc | ANTIFIBROTIC PYRIDINONES |
WO2014055634A1 (en) | 2012-10-02 | 2014-04-10 | Yale University | Identification of small molecule inhibitors of jumonji at-rich interactive domain 1a (jarid1a) and 1b (jarid1b) histone demethylase |
WO2014106019A2 (en) | 2012-12-27 | 2014-07-03 | Philadelphia Health & Education Corporation, D/B/A Drexel | Novel antiviral agents against hbv infection |
US20140213538A1 (en) | 2013-01-15 | 2014-07-31 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
KR20140103447A (en) | 2013-02-18 | 2014-08-27 | 코오롱생명과학 주식회사 | Benzylidene phthalimide monomer, method for preparing the same, polymer comprising the same, photoalignment film comprising the same and retardation film comprising the same |
CN104004122B (en) | 2014-05-08 | 2016-05-11 | 中国科学院长春应用化学研究所 | Novel temperature-sensitive polymer and prepare the method for Novel temperature-sensitive polymer with renewable resource 1B |
WO2017185023A1 (en) | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 9 (cdk9) by conjugation of cdk9 inhibitors with e3 ligase ligand and methods of use |
-
2018
- 2018-08-06 US US16/056,163 patent/US10513515B2/en active Active
- 2018-08-07 JP JP2020509482A patent/JP2020531481A/en active Pending
- 2018-08-07 AU AU2018321567A patent/AU2018321567A1/en not_active Abandoned
- 2018-08-07 EP EP18759219.1A patent/EP3672955A1/en not_active Withdrawn
- 2018-08-07 WO PCT/US2018/045626 patent/WO2019040274A1/en active Search and Examination
- 2018-08-07 CA CA3072543A patent/CA3072543A1/en active Pending
- 2018-08-07 CN CN201880067990.7A patent/CN111247138A/en active Pending
- 2018-08-21 TW TW110132428A patent/TW202222794A/en unknown
- 2018-08-21 TW TW107129086A patent/TWI742303B/en active
-
2019
- 2019-12-18 US US16/719,805 patent/US10927104B2/en active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102822165A (en) * | 2010-02-11 | 2012-12-12 | 细胞基因公司 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
WO2014116573A1 (en) * | 2013-01-22 | 2014-07-31 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
CN105566290A (en) * | 2014-10-30 | 2016-05-11 | 康朴生物医药技术(上海)有限公司 | Isoindoline derivative and intermediate, preparation method, pharmaceutical composition and application thereof |
WO2016191178A1 (en) * | 2015-05-22 | 2016-12-01 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
WO2017024318A1 (en) * | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
WO2017201069A1 (en) * | 2016-05-18 | 2017-11-23 | Biotheryx, Inc. | Oxoindoline derivatives as protein function modulators |
US20170333443A1 (en) * | 2016-05-18 | 2017-11-23 | Biotheryx, Inc. | Chimeric compounds targeting proteins, compositions, methods, and uses thereof |
TW201837031A (en) * | 2017-03-14 | 2018-10-16 | 美商拜歐斯瑞克斯公司 | Compounds targeting proteins, compositions, methods, and uses thereof |
US20200361896A1 (en) * | 2017-08-15 | 2020-11-19 | Global Blood Therapeutics, Inc. | Tricyclic compounds as histone methyltransferase inhibitors |
CN112601751A (en) * | 2018-06-13 | 2021-04-02 | 拜欧斯瑞克斯公司 | Fused thiophene compounds |
CN114502543A (en) * | 2019-05-24 | 2022-05-13 | 拜欧斯瑞克斯公司 | Targeted protein compounds, pharmaceutical compositions and therapeutic applications thereof |
Non-Patent Citations (1)
Title |
---|
MICHAEL GÜTSCHOW,等: "Aza analogues of thalidomide: synthesis and evaluation as inhibitors of tumor necrosisfactor-α production in vitro", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 09, no. 04, 1 April 2001 (2001-04-01), pages 1061 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022007659A1 (en) * | 2020-07-06 | 2022-01-13 | 北京诺诚健华医药科技有限公司 | Heterocyclic immunomodulator |
CN115677667A (en) * | 2021-07-30 | 2023-02-03 | 海创药业股份有限公司 | Bifunctional chimera heterocyclic compound and application thereof as androgen receptor degrading agent |
WO2023025136A1 (en) * | 2021-08-27 | 2023-03-02 | 杭州格博生物医药有限公司 | Isoindolinone compound and use thereof |
WO2024051766A1 (en) * | 2022-09-08 | 2024-03-14 | 标新生物医药科技(上海)有限公司 | Molecular glue compound based on cereblon protein design and use thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2020531481A (en) | 2020-11-05 |
EP3672955A1 (en) | 2020-07-01 |
US20190062320A1 (en) | 2019-02-28 |
TW202222794A (en) | 2022-06-16 |
US10513515B2 (en) | 2019-12-24 |
US10927104B2 (en) | 2021-02-23 |
TW201919639A (en) | 2019-06-01 |
AU2018321567A1 (en) | 2020-03-19 |
TWI742303B (en) | 2021-10-11 |
WO2019040274A1 (en) | 2019-02-28 |
CA3072543A1 (en) | 2019-02-28 |
US20200231582A1 (en) | 2020-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI742303B (en) | Ether compounds and uses thereof | |
CN108699035B (en) | Novel compounds | |
CN109071546B (en) | Pyrazolo [1,5-A ] pyrazin-4-yl derivatives as JAK inhibitors | |
CN107592861B (en) | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof | |
US10968219B2 (en) | 3-substituted propionic acids as αV integrin inhibitors | |
TWI605040B (en) | Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators, compositions, and their use | |
CN110225911B (en) | Oxadiazolone transient receptor potential channel inhibitors | |
KR102336371B1 (en) | Tetrazolone-substituted dihydropyridinone mgat2 inhibitors | |
CN112601751A (en) | Fused thiophene compounds | |
BRPI0708264A2 (en) | piperidinylpyrrolidines melanocortin type 4 receptor agonists | |
US11286252B2 (en) | Alkene spirocyclic compounds as farnesoid X receptor modulators | |
CN101528225A (en) | 2-aminobenzoxazole carboxamides as 5HT3 modulators | |
CN109476628B (en) | Sulfonylcycloalkylamide compounds as TRPA1 modulators | |
JP2016504282A (en) | Dihydropyrazole GPR40 modulator | |
CN102256944A (en) | Sphingosine-1-phosphate receptor antagonists | |
EP3680237A1 (en) | Process for preparing substituted 2,3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | |
US10265310B2 (en) | 6-membered cyclic amines or lactames substituted with urea and phenyl | |
CN114710956A (en) | Perk-inhibiting pyrrolopyrimidine compounds | |
CN113149996B (en) | Polycyclic amide derivative as CDK9 inhibitor, and preparation method and application thereof | |
TWI724995B (en) | Serine derivatives as ghrelin receptor agonists | |
CN114585606A (en) | PERK inhibiting compounds | |
US20230373919A1 (en) | At2r antagonists and uses thereof | |
WO2021129629A1 (en) | Zeste enhancer homologue 2 inhibitor and use thereof | |
KR20200125967A (en) | Receptor inhibitor, pharmaceutical composition comprising same, and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |